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ABSTRACT 
Background: UC781, a tight-binding non-nucleotide reverse transcriptase inhibitor (NNRTI) 
of HIV-1, is a thiocarboxanilide that has been identified as a potential microbicide agent. UC781 
prevents HIV-1 infection by potently inhibiting HIV-1 replication (EC50≈8nM) with a broad 
therapeutic index (>62,000). However, its extremely poor water solubility leads to a great 
challenge for its formulation development. A β-cyclodextrin (βCD) based drug delivery system 
was developed for UC781 to overcome this issue. 
Method: The complex of UC781: βCD was assessed with UV, FTIR, DSC, and NMR. An 
HPLC method was used to investigate the thermodynamic behavior of the UC781 complex.  
Complexation of UC781 with either hydroxypropyl β-Cyclodextrin (HPβCD) or methyl β-
Cyclodextrin (MβCD) was optimized by evaluation of four processing methods (autoclave, 
lyophilization, shaking, and kneading), incorporation of four water-soluble polymers (HPMC, 
HEC, PVA, and PVP K30), and utilization of three buffering systems (pH 7.0, 9.0 and 11.0).  
Finally, three formulations—methylcellulose (MC) gel, hydroxyethylcellulose (HEC) gel, 
and polyvinyl alcohol (PVA) film—were developed for UC781. The physical properties, toxicity, 
and anti-HIV activity of UC781 containing formulations were evaluated with in vitro and ex vivo 
models.  
Results: Complexation of UC781 with CDs was confirmed and characterized with UV, FTIR, 
DSC, and NMR. UC781’s complexation was found to be an enthalpy driven process. The 
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 viii 
solubility of UC781 was increased from almost none to 35 μg/ml in 15% HPβCD and 180 μg/ml 
in 15% MβCD solutions after optimization. 
Complexation technique significantly improved the release of UC781 from all three 
formulations. The complexation of UC781 with HPβCD or MβCD greatly increased the 
osmolality and decreased the viscosity of MC and HEC gel; shortened the disintegration time of 
PVA film; and reduced IC50 for UC781 in all three formulations. No observed toxicity was found 
in all complexed UC781 containing formulations. 
Conclusion: βCD complexation technique provided an effective method to overcome the 
aqueous solubility challenge for UC781. UC781 complexation can be used as a safe and 
effective drug delivery system for UC781. Of the formulations tested, PVA film with complexed 
UC781 provided the most promising option for microbicide product development.  
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1.0  INTRODUCTION OF HIV INFECTION AND PREVENTION 
STRATEGIES  
1.1 HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 AND AIDS 
1.1.1 History of HIV and AIDS Discovery  
A report on Kaposi's sarcoma in young homosexual men roused the beginning of early 
general awareness of acquired immunodeficiency syndrome (AIDS) (Hymes et al.,1981). On 
June 5, 1981, a report of five cases of Pneumocystis carinii pneumonia (PCP), a  fungal infection 
of the lungs,  among previously healthy young men in Los Angeles was published by Morbidity 
and Mortality Weekly Report (MMWR) (Angeles,1981). This report was commonly referred to 
as the “First Report on AIDS” in the USA (CDC,2001).   
On April 22, 1984, Dr. James O. Mason, head of the Federal Centers for Disease Control, 
believed a lymphadenopathy-associated virus (LAV) discovered in France was the cause of 
AIDS (Altman,1984). One day later, Margaret Heckler from United States Health and Human 
Services announced that AIDS is caused by Human T-lymphotropic Virus-III (HTLV-III), which 
had been isolated by Dr. Robert Gallo of the National Cancer Institute(AVERT,1984). LAV and 
HTLV-III were quickly proven to be the same virus: Human Immunodeficiency Virus (HIV) 
(Marx,1986; Ratner et al.,1985).  In 1986, both viruses were given the same name, HIV-1. Ten 
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years later, another member of the HIV family, HIV-2 was first reported in Egypt (Hassan et 
al.,1996). These two viruses are different in both origination and clinical behavour. HIV-1 is 
thought to have originated from Chimpanzees with higher virulence and transmittability (Gao et 
al.,1999) which accounts for the epidemic of HIV transmission. In contrast, HIV-2 which 
originated from the Sooty Mangabey with less virulence and transmittability and is primarily 
found in West Africa (Gao et al.,1992; Hirsch et al.,1989).  
1.1.2 The AIDS Epidemic and Pathogenesis 
AIDS is now a pandemic (Kallings,2008).  The prevalence of AIDS is one of the most 
serious challenges of infectious disease to public health all over the world.  In 2007, AIDS killed 
2.1 million people worldwide, including 330,000 children, and led to 33.2 million people living 
with the disease (UNAIDS.,2007).  An estimated 2.5 million persons were newly infected in 
2007, including 420,000 children (UNAIDS.,2007).  Every day, over 6,800 persons become 
infected with HIV and over 5,700 persons die from AIDS, mostly due to inadequate access to 
HIV prevention and treatment services.  
AIDS is defined as a clinical condition in humans in which the immune system begins to 
fail, leading to life-threatening opportunistic infections. HIV infects several cell types: CD4+  T 
cells, macrophages, and dendritic cells (DCs)(Miceli and Parnes,1993; Mohan,2005). This 
infection directly and indirectly destroys CD4+ T cells (Alimonti et al.,2003).  As CD4+ T cells 
are required for the proper functioning of the immune system, AIDS happens when no sufficient 
CD4+ T cells can be maintained for normal immune response. Clinically, CD4 count is used to 
assess immune status, susceptibility to opportunistic infections, and for defining AIDS (CD4 
<200). 
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Due to the loss of CD4+ cells by HIV infection, the major health issues faced by AIDS 
patients are certain opportunistic infections. These infections or cancers include the following 
diseases:  Pneumocystis pneumonia (PCP), a lung infection; Kaposi's sarcoma (KS), a skin 
cancer; Cytomegalovirus (CMV), an infection that usually affects the eyes; and Candida, a 
fungal infection that can cause thrush (a white film in mouth) or infections in the throat or vagina 
et al (Casabona et al.,1993; Stein et al.,1992). These infections do not normally develop in 
individuals with healthy immune systems and are caused by bacteria, viruses, fungi and parasites 
(Holmes et al.,2003; Holmes et al.,2006). AIDS related death is highly related to the latest CD4 
cells count (Margolis,2005).  A lower CD4 cell counts lead to a greater risk for particular AIDS 
conditions due to the weakened immune function, such as PCP et al (Kumar and Krieger,1998). 
As a consequence, the leading cause of death in AIDS patients is infection without effective 
treatment, with 30% of these infections being bacteria, and 25% being other opportunistic 
organisms (Stein et al.,1992). 
1.1.3 Molecular Biology of HIV-1    
1.1.3.1 Virion Classification and Tropism of HIV 
HIV is a member of the genus Lentivirus belonging to the family of Retroviridae, which 
have genes composed of ribonucleic acid (RNA) molecules. Generally, retrovirus converts its 
RNA into a DNA intermediate with its reverse transcriptase. The newly formed viral DNA is 
then permanently integrated the host cell chromosome DNA (Tang et al.,1999).   
Like HIV-1 cause immunodeficiency syndrome in human, other members of this family 
cause an immunodeficiency syndrome in mammals, such as monkeys (Daniel et al.,1985), cats 
(Yamamoto et al.,1986 ), and cattle (Wang et al.,1999).  These viruses share many similar 
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physical and biochemical properties with HIV-1 and HIV-2. Therefore, they were designated as 
simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), and bovine 
immunodeficiency-like virus (BIV), respectively. 
Two species of HIV have thus far been found that infect humans: HIV-1 and HIV-2 (Gao 
et al.,1999). HIV-1, HIV-2, and SIV comprise the subgenus “primate lentiviruses.” The genomic 
organization of these viruses is also very similar (Reeves and Doms,2002). HIV-2 shares 
approximately 60% nucleotide sequence similarity with HIV-1 (Figure 1-1).   
 
Figure 1-1.  Genes laid out in HIV RNA. 
Schemetic presentation shows genes of HIV-1 and HIV-2 genes on their RNA. These genes 
code out proteins with similar function with approximately 60% nucleotide sequence 
similarity between HIV-1 and HIV-2. 
 
This diagram is based on a map of the HIV-1, HIV-2, and SIV genomes, available at 
hiv-web.lanl.gov/content/immunology/pdf/2000/intro/GenomeMaps.pdf 
 
CD4 protein is the main receptor on host cells for HIV to recognize and bind to during 
HIV entry (Moore,1990; Sattentau et al.,1989). The affinity for CD4 of HIV-1 gp120 is 25 times 
higher than that for HIV-2 gp120 (Sattentau and Moore,1993). This may help to explain the 
lower virulence of HIV-2 than of HIV-1.   
Furthermore, HIV-1 shows specificity of entering into different target cell types in 
transmission, which are classified as T-cell-tropic (T-Tropic) virus (also called syncytium-
inducing (SI) strains) and Macrophage-tropic (M-Tropic) virus (called nonsyncytium-inducing 
 5 
(NSI) strains).  Syncytium is defined as a large cell-like structure formed by the joining together 
of two or more cells (National Cancer Institute). It was reported that reported that patients 
infected with syncytium-inducing phenotype HIV-1 strains were more likely to progress to the 
AIDS than patients with non-syncytium-inducing strains (Koot et al.,1993). This HIV-1 tropism 
phenomenon suggests the existence of co-receptors in HIV-1 infection. Two co-receptors were 
identified as involved in the HIV-1 infection in vivo- CCR5 and CXCR4 (Berger et al.,1999; 
Choe et al.,1996; Dragic et al.,1996).    
The M-Tropic virus utilizes the β-chemokine receptors CCR5 (sometimes the CCR3 co-
receptor (Choe et al.,1996)), which are associated with mucosal and intravenous transmission of 
HIV infection. On the other hand, T-Tropic virus utilizes the α-chemokine receptor, CXCR4 
(Power et al.,1995), as a co-receptor  (Berger et al.,1999; Moore,1997). HIV that use only the 
CCR5 receptor are termed R5 virus, those that use only CXCR4 are termed X4 virus, and those 
that use both, X4R5 virus. In summary, both M-Tropic viruses and T-Tropic viruses bind to the 
CD4 receptor; however, they utilize different co-receptors in order to enter the host cells.   
1.1.3.2 Virion Structure and Genomic Organization of HIV 
The HIV virus particle is roughly spherical in shape with a diameter  from 110 to 128 nm 
in its mature form and 132 to 146 nm in its immature form (Gentile et al.,1994). Typically, HIV-
1 has a high-density core encircled with an envelope in the transmission electron micrograph 
(Kumar et al.,2008; Salahuddin et al.,2007).  The structure of the HIV particle is shown in Figure 
1-2. .  
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Figure 1-2.   Structure of HIV Virus 
HIV particles compose of outer coat and core. The outer coat contains gp120 and 
gp41 proteins complex as spike to recognize host cells, biomembrane as envolope, 
and matrix protein. The core of HIV composes of two single strand of RNA and 
enzymes surrounded by capsid protein. 
 
The outer coating of the virus, known as the viral envelope, is composed of two layers of 
phospholipids, which come from the membrane of host cells when newly formed virus bud from 
the cell. 72 copies (on average) of the complex HIV proteins are embedded in the viral envelope 
(National Institute of Allergy and Infectious Diseases,2004). This complex, also called “spikes”, 
is composed of three glycoprotein 120 (gp120) as cap and three glycoprotein 41 (gp 41) as stem. 
A layer of a matrix protein composed of the viral protein p17 lines the inner surface of the 
membrane of HIV to keep the integrity of the virus  (Wang et al.,1999). 2,000 copies of the viral 
protein p24  form a conical capsid (Folkers,1996) of HIV which contains the HIV gene in the 
core.  
The core of HIV contains two copies of positive single-stranded RNA, reverse 
transcriptase, integrase, protease, and NucleoCapsid (p7) (National Institute of Allergy and 
Infectious Diseases,2004).   
The HIV-1 genome codes for the viruses’ nine genes: gag, pol, env, tat, rev, nef, vif, vpr, 
and vpu. The virus RNA is flanked by two long-terminal-repeats (LTRs or LTR) as shown in 
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Figure 1-3. Three of these genes, gag, pol, and env, contain information needed to produce 
structural proteins for new virus particles. The gag codes structural proteins MA (matrix), CA 
(capsid), NC (nucleocapsid), p6; The pol enzymes PR (protease), RT (reverse transcriptase), and 
IN (integrase). Six regulatory genes, tat, rev, nef, vif, vpr, and vpu, contain the information 
necessary for HIV replication (HIV Databases). The gene regulatory proteins are coded by tat 
and rev; and the accessory proteins are coded by nef, vif, vpr, and vpu. The LTR acts as a switch 
to control the production of new viruses and can be triggered by proteins from either HIV or the 
host cell (Reed-Inderbitzina and Maury,2003). The 5’ LTR contains the promoter sequence that 
controls viral expression, while the 3’-LTR is involved in polyadenylation. 
 
Figure 1-3.  HIV-1 Organization of the HIV-1 genome and virion 
The genes of HIV and their corresponding products were shown Figure 1-3.  Three 
genes, gag, pol, and env, code for structural proteins for HIV particles. Six 
regulatory genes, tat, rev, nef, vif, vpr, and vpu, contain the proteins necessary for 
HIV replication. 
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1.1.3.3 Life Cycle of HIV  
Generally,  HIV infection is recognized as having  four steps (Figure 1-4): 1 Virus entry 
(attachment and fusion): HIV uses its membrane proteins to find and bind to CD4 receptors on 
target cells and transfer its genome into host cells; 2 Reverse transcription and integration of 
virus genes: viral gene on the HIV RNA is converted into viral DNA and integrated into the host 
cells’ DNA; 3  Transcription/translation: after the integration of virus DNA into the host cells’ 
genome DNA, the components of the HIV begin to be manufactured from target  cells; 4 Virus 
particle  release: The HIV virus components are assembled and released in a "bud" form to 
become a new born HIV virus. 
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Figure 1-4.  HIV life cycle and anti-HIV drug target 
The HIV life cycle is shown in the figure above. The figure illustrates the different 
stages of infection: attachment and fusion; reverse transcription and integration; 
replication; budding; and release.  
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 1 Virus entry : In order to infect its target cells, HIV must transfer its genome into these 
host cells, crossing both the viral and cell bilayer membranes  (Doms and Trono,2000).   The 
virus entry events initiate from the contact and recognition between proteins from both virus 
membrane and cell membrane (Blobel et al.,1992; Hernandez et al.,1996). With the help of 
receptors and co-receptors for the host cell, a portal of entry is provided for virus penetration 
allowing membrane fusion to occur.    
The process of HIV entry involves fusion of the viral envelope with the host cell 
membrane, which requires the specific interaction of the envelope “spike” from HIV with 
specific cell surface receptors-CD4. The spike is a complex comprised of three functional units 
of gp120 molecules as a cap and functional units of gp41 molecules as a stick inserted into the 
viral lipid membrane.  The binding of gp120 to CD4 on the surface of the target cell induces a 
conformational change of gp120 leading to a further binding of co-receptors and the fusion 
process.  
The binding of gp120 to CD4 by itself does not trigger membrane fusion (Ashorn et 
al.,1990; Clapham et al.,1991). Therefore, chemokine co-receptors are necessary for HIV-1 
fusion. The conformation change of the V3 and V2 regions of gp120 after binding to CD4 enable 
it to interact with CCR5 or CXCR4, chemokine co-receptors that facilitate HIV entry into 
macrophage and T cells in vivo, respectively. This interaction triggers the fusion of HIV-1 to 
host cells by exposing the hidden gp41 to the target cell membrane through the formation of a 
triple-stranded coiled-coil (Pierson and Doms,2003), leading to fusion of the  virus and cell 
membrane. The content of HIV-1 is then transfered into the host cell for replication. 
In addition, both CD4, chemokine co-receptors for HIV-1 entry and budding process are 
found to be associated with the lipid rafts domains in the cell membrane (Kozak et al.,2002; 
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Popik et al.,2002). These cholesterol- and sphingolipid-enriched microdomains provide the 
platform for the interaction between HIV-1 and target cells. Decreasing cholesterol concentration 
in virion and target cell membrane will greatly decrease the infectivity of HIV-1. Therefore, the 
cholesterol-depleting modulators might be a viable strategy to prevent HIV-1 transmission at 
mucosal surfaces such as βCD. 
2 Reverse Transcription and integration of virus genes: Once the viral capsid enters 
the cell, HIV-1 genome is quickly reverse-transcribed into a double stranded viral DNA 
intermediate (vDNA) by the reverse transcriptase (RT), which contains RNA- and DNA-
templated polymerase and RNase H activities. This vDNA then forms a nucleoprotein complex 
called the pre-integration complex (PIC) and is transported to the nucleus by nuclear localization 
sequences (NLS) (Bouyac-Bertoia et al.,2001). After nuclear import, integrase (IN) recognizes 
and inserts the vDNA into the cellular DNA of the host cell in the nucleus. The vDNA remains 
permanently associated with the host cellular DNA for the lifetime of the cells. The 
understanding of infection steps is highly correlated with the prevention concept and methods of 
HIV-1 infection. Ideally, an effective prophylactic method should block the HIV infection before 
vDNA is integrated into the host cell genome.  
3 Transcription/translation:  The integrated vDNA serves as the template for the 
synthesis of newly generated HIV-1 mRNAs transcripts, which are transported out of the nucleus 
for translation in the cytoplasm, and then form the infectious virion particles. The polyproteins 
Gag and Gag-Pol for viral matrix and capsid are localized at the lipid raft domains of the cell 
membrane (Halwani et al.,2003; Leung et al.,2008). The Env precursor protein gp160 (gp120 
and gp41) is synthesized by the endoplasmatic reticulum (ER) using Env mRNA as template 
(Fenouillet and Jones,1995).   
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4 Virus particles release: Once all components of HIV are assembled at the inner 
surface of the cell membrane, the viral particles begin to bud from the cell surface to form new 
born immature viral particles. These noninfectious particles are then released and undergo a 
maturation process involving processing of Gag and Gag-Pol by HIV protease and assembly of 
the core particle (Freed,1998). Protease digests the polyproteins into Matrix (p17), Capsid (CA), 
NucleoCapsid (NC), Protease (PR), Reverse Transcriptase (RT), and Integrase (IN). This mature 
HIV virion is now ready to start another replication cycle by infecting next host cell (Kohl et 
al.,1988).  
1.1.3.4 Classification of Anti-HIV Drugs   
Generally, most anti-HIV compounds are desigend to interfere with different stages of 
the HIV life cycle. Therefore, they can be classified according to the stages of the HIV life cycle. 
A number of anti-HIV drugs have been approved by the FDA for HIV treatment and are listed in 
Table 1-1.  
Table 1-1. FDA approved Anti-HIV drugs 
Reverse Transcriptase Inhibitors 
Entry and Fusion inhibitors 
NNRTIs NRTIs 
Integrase  
Inhibitors 
Protease 
Inhibitors 
Fuzeon 
Selzentry (CCR-5 inhibitor) 
Intelence 
Rescriptor 
Sustiva  
Viramune 
Combivir 
Emtriva 
Epivir 
Epzicom 
Retrovir 
Trizivir 
Videx 
Truvada 
Viread 
Ziagen 
Zerit 
Raltegravir 
(Isentress) 
Atazanavir 
Agenerase 
Aptivus 
Crixivan 
Invirase 
Kaletra 
Lexiva 
Norvir 
Prezista 
Reyataz 
Viracept 
Table 1-1 shows FDA approved anti-HIV drugs listed by brand name. Drug information 
was obtained from aidsinfor.nih.gov.  
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Entry inhibitors (or fusion inhibitors): interfere with binding, fusion, and entry of HIV-
1 into the host cell by interfering with HIV gp120 or blocking receptors or coreceptors on target 
cells surface such as CD4, CXCR4 or CCR5. Fuzeon and Selzentry are the two currently 
available drugs in this class. 
 Reverse transcriptase inhibitors: can be classified into two categories—nucleoside 
reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) according to the different mechanism their RT inhibition.  
NRTIs inhibit reverse transcription by being incorporated into the newly synthesized 
viral DNA and preventing its further elongation. NRTIs are analogues of the naturally occurring 
deoxynucleotides necessary for synthesizing the viral DNA, and they compete with the natural 
deoxynucleotides for incorporation into the growing viral DNA chain. Due to their lack of a 3'-
hydroxyl group on the deoxyribose moiety in their structure, NRTIs act as chain terminators for 
viral DNA synthesis. In that a 5'-3' phosphodiester bond with the next incoming deoxynucleotide 
needed to extend the DNA chain cannot be formed resulting in the halt of viral DNA synthesis. 
All NRTIs are classified as chain terminators and competitive substrate inhibitors. 
NNRTIs inhibit reverse transcriptase directly by binding to the enzyme and interfering 
with its function. Instead of competing with natural deoxynucleotides as NRTIs, all NNRTIs 
bind tightly to the allosteric hydrophobic site with a common binding mode (Ren et al.,1995). 
This NNRTI binding pocket is located between two beta sheets of the p66 subunit of RT, 
approximately 10 Angstroms away from the polymerase active site of the RT (Ding et al.,1995).  
NNRTIs inhibit HIV-1 RT allosterically by displacing the catalytic aspartate residues relative to 
the polymerase binding site. NNRTIs are non-competitive (or mixed-type) inhibitors with respect 
to substrate and non-competitive or uncompetitive inhibitors with respect to template/primer. 
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Integrase inhibitors inhibit the enzymatic activity of HIV integrase, which is responsible 
for integration of viral DNA into the DNA of the infected cell.  
Protease inhibitors (PIs) target viral assembly by inhibiting the activity of protease, an 
enzyme used by HIV to cleave nascent proteins for final assembly of new virions.  
Other anti-HIV compounds can inhibit or interfere with the HIV life cycle at stages 
other than those mentioned above. With the development of understanding and research on HIV, 
more and more compounds are under investigation for the treatment of HIV infection focusing 
on new targets directed toward different viral or cellular components of the life cycle of HIV 
replication. Compounds in this category can inhibit or interfere with viral maturation, viral 
packaging, polyamine biosynthesis in host cells, or RNA interference (RNAi) to silence the RNA 
of HIV.  A high occurrence of HIV resistance development with anti-HIV drugs and the adverse 
effects associated with early regimens of HAART led to increases in the failure rate associated 
with anti-HIV treatment (Recsky et al.,2004).  However, newer combination drug strategies look 
promising.  The development of these new anti-HIV molecules provides strategies toward new 
anti-HIV targets which may potentially improve the effectiveness and efficacy of AIDS therapy 
in the future. 
1.1.4 Prevention and Treatment of HIV/AIDS 
1.1.4.1 HIV Transmission and Its Prevention  
HIV is transmitted through three main routes: sexual contact (anal or vaginal), exposure 
to infected body fluids or tissues (including the sharing of contaminated needles/syringes; blood 
transfusion), and from mother to fetus or child during pregnancy, childbirth, and breastfeeding 
(CDC,1999).  Although HIV can also be found in the saliva, tears, and sweat of HIV positive 
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patients, no recorded cases of infection by contact with these secretions has been shown to result 
in transmission of HIV (CDC,1999). 
 Unprotected sexual contact is one of the primary modes of HIV infection worldwide 
(Johnson and Laga,1988).  The utilization of male or female condoms can reduce the chances of 
infection with HIV. Consistent condom use results in 80% reduction in HIV incidence (Davis 
and Weller,1999; Weller and Davis,2001).  
Injecting drug users (IDUs) have been among the high-risk groups affected by HIV and 
AIDS (23.8% (Gomma et al.,1993)). Syringe sharing has made HIV, as well as other blood-
borne pathogens, spread rapidly through intravenous drug users’ population. Harm reduction 
strategies such as needle-exchange programs are used in attempt to reduce the infections caused 
by drug abuse (Kerr et al.,2007; Rhodes et al.,2006).  
Occupational HIV infection is mostly caused by exposure to HIV-infected blood via a 
percutaneous injury (i.e. from needles, blades, instruments, etc.). The average risk for HIV 
transmission after percutaneous exposure to HIV infected blood is not high, only about three per 
1,000 injuries (Wilks et al.,2003), this is still a considerable concern for many health care 
workers. Precautions should be taken to reduce the exposure to HIV. These precautions include 
barriers such as gloves, masks, and protective goggles or shields, which prevent exposure of the 
skin or mucous membranes to blood-borne pathogens. Additionally, post-exposure prophylaxis 
(PEP) is used in cases in which there was a failure to avoid virus exposure.  This post-exposure 
prophylaxis is an antiretroviral treatment administered directly after a highly significant exposure 
to HIV (CDC,2005; Hamlyn and Easterbrook,2007). However, the effectiveness of PEP is still 
under investigation.  Another approach called pre-exposure prophylaxis ( PrEP) is also under 
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clinical evaluation for efficacy as a female-controlled prevention method for women worldwide 
(CDC,2008a).   
As for mother-to-child transmission of HIV (1% worldwide in 2007, (UNAIDS.,2007)), 
using anti-HIV drugs prophylaxis in late pregnancy with no breast-feeding can greatly reduce the 
infection of HIV from 27% to 9% in infants (Steel-Duncan et al.,2004). Currently, WHO 
recommends that long term breast-feeding of infants should be avoided by HIV positive mothers.  
(WHO and CDC,2008). 
1.1.4.2 Treatment of HIV/AIDS with Highly Active Antiretroviral Agents 
Due to the lack of vaccine or cure for AIDS, current antiviral treatments of HIV consist 
of a highly active antiretroviral therapy (HAART) in current clinical practice.  HAART has been 
highly beneficial to many HIV-infected individuals since its introduction in 1996 when the 
protease inhibitor-based HAART initially became available (Melroe et al.,1999; Vandamme et 
al.,1998) .  
The key in the HAART is to disrupt HIV at different stages in its replication. HAART is 
a combination (or "cocktail") of drugs belonging to at least two types, or "classes," of 
antiretroviral agents targeting different HIV replication stages. Typical regimens consist of two 
nucleoside reverse transcriptase inhibitors (NRTIs) plus either a protease inhibitor (PI) or a non-
nucleoside reverse transcriptase inhibitor (NNRTI). It is reported that NNRTI-based HAART 
was more effective than PI-based HAART for virus suppression and was similar to PI-based 
HAART for clinical outcomes of death, disease progression, and withdrawals (Chou et al.,2006). 
HAART is a very effective regimen for AIDS treatment and has saved thousand of lives 
since it was introduced in 1995 (Ho et al.,1995). HAART had been designed to treat AIDS by 
suppressing HIV replication and reconstituting the patient’s immune system (Flint et al.,2006).  
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In the absence of HAART, the median survival time for patients after developing AIDS is 
only 9.2 months (Morgan et al.,2002).  Fortunately, HAART therapy increases survival time by 
between 4 and 12 years (King et al.,2003; Tassie et al.,2002).  Furthermore, with the application 
of powerful HAART therapy, the AIDS death rate in the U.S has been greatly decreased since 
1995 for the first time as shown in Figure 1-5.   
However, HAART treatment has significant drawbacks: it cannot completely suppress 
the HIV-1 replication and long-term therapy carries a risk of toxicity.   Selection of (multi) drug-
resistant viral variants or adverse effect from HAART drug components are the primary reason 
for failure of this regimen (Day,2003; Vandamme et al.,1998). 
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Figure 1-5.  Yearly AIDS deaths in US since 1981 
Figure 1-5 shows the yearly number of AIDS deaths in the United States since 
1981. The death rate of AIDS patients increased yearly after HIV was discovered 
in 1981 until the clinical implementation of HAART in 1995. With the appearance 
of HAART the number of deaths dropped. The number of deaths of HIV patients 
in 1997 dropped to approximately half of that in 1995 and has been maintained at 
that level. 
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Due to the success of current therapies in HIV-positive individuals, these drugs have also 
been investigated as a means to prevent HIV infection.  It was reported that male HIV positive 
patients treated with AZT were 50% less likely to transmit HIV to their female partners than 
were untreated patients, due to reduction in the viral load in biofluid (Musicco et al.,1994).  In a 
study evaluating the potential use of HAART as a prevention strategy it was estimated that 
HAART could reduce the yearly rate of HIV incidence by as much as 50% in Canada (Montaner 
et al.,2006).  
However, the effect of HAART on HIV prevention is still in dispute (Anema et al.,2008). 
There is no direct evidence to support the use of a combination of multi-drug regimen following 
occupational exposure to HIV (Young et al.,2007). Furthermore, cost is also a critical issue in 
applying HAART to prevent HIV transmission. For example, using generic Lamivudine 
(Epivir®, or 3TC) to avoid HIV infection, the cost will be $6,625 per infection avoided 
(Derdelinckx et al.,2006). Therefore, cost-effective methods must be developed for the 
prevention of HIV transmission, especially for developing countries.  Microbicides may 
represent a safe, effective, and cost-saving method for HIV prevention under development.  
1.2 MICROBICIDES: A FEMALE CONTROLLED METHOD OF PROTECTION 
AGAINST HIV INFECTION  
1.2.1 HIV/AIDS and Women  
HIV infection or AIDS has reached pandemic levels and poses one of the greatest 
challenges to global public health.  Although HIV/AIDS was originally thought to be associated 
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with sexual practices of male homosexuals, women are more easily to be infected by HIV than 
men. The number of infected women has significantly increased since HIV/AIDS was first 
identified. At the end of 2007, UNAIDS estimated that out of the 33.0 million people worldwide 
living with HIV, nearly half are women (15.5 million) (UNAIDS.,2007).  Young women age 
between 15 and 24 years old are at least three times more likely to be infected than young men in 
South Africa, Zambia, and Zimbabwe (Quinn and Overbaugh,2005).  
Heterosexual transmission and drug abuse are the two most common routes of HIV 
infection in women. One of the first studies in Zaire revealed  a strong relationship between HIV 
infection and heterosexual intercourse in the 80’s (Piot et al.,1984).   Heterosexual transmission 
accounts for the fastest growing risk group in the United States. AIDS cases attributed to 
heterosexual transmission increased from 3% of all cumulative AIDS cases among women from 
1983 to 1984 to 64% from 1999 to 2002 (CDC,2004). More than 80% of  newly diagnosed 
infections in the U.S are the result from heterosexual intercourse, and AIDS is the fifth leading 
cause of death for American women from ages 25 to 44, according to the newest CDC report 
(CDC,2008b)..   
Women are more vulnerable to HIV infection than their male counterparts due to their 
anatomical and biological differences. These differences include greater area of mucous 
membrane exposure to virus during intercourse in women than in men, larger quantity of body 
fluids transferred from men to women, the higher viral content of male sexual fluids, and 
microtears in the cervix and vaginal epithelium that commonly occur during sexual intercourse. 
These properties facilitate HIV crossing the reproductive tract and enter the bloodstream.  
The risk of male-to-female HIV transmission has been reported in several studies. 
Females were shown to be up to 20 times more likely to be infected than their male counterparts 
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in these studies (Nicolosi et al.,1994; Padian et al.,1991; Padian et al.,1997). This risk can also be 
greatly amplified with non-consensual sex, sex without condom use, and high-risk behaviors of 
their partners (Cameron et al.,1989; Fowler et al.,1997). Furthermore, women are 4 to 13 times 
more vulnerable to acquiring other sexually transmitted infections (STIs) (UNAIDS.,26 February 
- 9 March 2007). These STDs and some other genital tract diseases, such as HSV infection and 
ulcers, are also cofactors to enhance HIV infection in women (Corey et al.,2004). Moreover, 
social, cultural, economic, and legal discrimination or inequities also greatly affect the behavior 
of women in heterosexual transmission of HIV.  
In addition to the direct effects from HIV infection, millions of women have been 
indirectly affected by the HIV/AIDS epidemic. To women, the impact of HIV/AIDS is not 
limited only to the disease itself. AIDS disproportionately affects women in many other ways. 
Pregnancy and childbearing may lead to mother-to-child transmission of HIV in HIV positive 
women. The responsibility of caring for AIDS patients and orphans in the family may affect 
women more strongly than men. AIDS also has a huge economic impact on HIV positive 
patients, especially women. The average cost of HAART therapy is $10,500 per HIV positive 
patient per annum (Chen et al.,2006). For the prevention of mother-to-child transmission of HIV, 
the treatment costs are about $104,502 for 100 HIV-positive pregnant women and their newborns 
(Mauskopf et al.,1996). These costs are not considering the impact of resistance to antiretroviral 
therapy, the effect of metabolic abnormalities, and toxicities.  Therefore, the responses for 
solutions to the problem of HIV/AIDS are particularly urgent for the female population. 
Effective prophylactic methods must be developed for the prevention of HIV in sexual 
transmission for women. 
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1.2.2 Microbicides as an effective prevention method against HIV/AIDS transmission in 
Women  
1.2.2.1 HIV-1 Invading the Female Genital Tract   
The vagina has several innate factors which serve as a protective barrier to infection, such 
as its acidic pH (4.2), and peroxides produced by vaginal lactobacilli (Schwebke,1966). However, 
pre-exiting inflammatory conditions, such as sexually transmitted diseases, ulcers, or bacterial 
vaginosis; and menstrual cycle may greatly reduce the innate barrier function and  thus increase 
the likeliness of HIV transmission (Martin et al.,1999).  
For heterosexual transmission, HIV-1 has to cross the mucosal barrier of the genital tract 
before it can infect CD4+ T cells or macrophage cells. In women, the morphology of the 
epithelium changes from the squamous epithelium of the vagina and ectocervix to the single-
layer columnar epithelium of the endocervix. It may be easier for HIV-1 to cross the single layer 
of endocervical  epithelium in comparison with the multilayer squamous epithelium of the 
ectocervical and vaginal mucosa (Moss et al.,1991). However, with more than 15 times the 
surface area as compared with that of endocervix, the vaginal wall and ectocervix may provide 
potential access sites for HIV invasion, particularly when breaches or damages occur in the 
epithelial layer (Hladik and McElrath,2008). HIV-1 can invade mucosal barriers as either a cell-
free or cell-associated virus. It is then available to infect local leukocytes or  to be captured by 
Langerhans cells for further systemic infection as shown in Figure 1-6 (Bass,2004; Boggiano and 
Littman,2007).   
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Figure 1-6.  Potential pathway for HIV-1 crossing mucosal barriers. 
HIV can cross the vaginal epithelia through physical abrasion or upon interaction with 
cells in the epithelium (DCs, T cells, epithelial cells). HIV infected cells or HIV-
carrying cells can then migrate to the lymph nodes via the afferent lymphatics 
resulting in virus dissemination to and amplification in resident CD4+  T cells. 
 
Importantly, heterosexual transmission is strain dependent. M-tropic HIV-1 strains (using 
the CCR5 co-receptor) are implicated in about 90% of sexual transmissions of HIV; CXCR4-
using (T-tropic) strains are comparatively rare in sexual transmission (Moore,1997). It was 
reported that epithelial cells account for this preferential transmission of the R5 HIV-1 strain due 
to their selection of capturing R5 HIV-1 and then transferring the infection to CCR5-expressing 
target cells underneath the epithelia (Meng et al.,2002; Saïdi et al.,2007).  
HIV-1 can invade mucosal barriers as either a cell-free or a cell-associated virus. For 
cell-free viral entry, HIV-1 virus has to cross the primary genital epithelial layer using 
unconventional mechanisms due to the natural barrier against pathogens invasion of vaginal 
epithelium.  HIV may directly cross the epithelium through the ruptures in the epithelial surface 
and then infect target cells. Another route for HIV transfer across the epithelium layer is through 
the transcytotic pathway, a vesicular pathway which is hypothesized as one by which HIV-1 
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could cross an intact barrier to infect susceptible host cells in the underlying tissues 
(Bomsel,1997; Schacker et al.,1996). Fortunately, this route can be neutralized with secretory 
antibodies (Bélec et al.,2001; Bomsel et al.,1998). Furthermore, the efficiency of transcytosis is 
also extremely poor (less than 0.02% of the initial inoculums) (Bobardt et al.,2007).  
HIV-1 can also enter DCs through the endocytosis using Dendritic Cell-Specific 
Intercellular Adhesion Molecule Grabbing Nonintegrin (DC-SIGN) receptors resulting in HIV-1 
entry through the mucosal route (Geijtenbeek et al.,2000). However,  about 90% of HIV-1 will 
be destroyed by this route in DCs (Arrighi et al.,2000). This interaction of HIV-DC-SIGN can be 
affected by environmental  pH change (Davis et al.,2003).  
For cell-associated virus transmission, DCs are currently thought to play an important 
role by trafficking HIV to T cells once DCs have captured HIV in the mucosa.  In the vagina, 
HIV-1 can  be captured by DCs  and then presented to T-cells, resulting in a more efficient virus 
infection due to “trans transfer” through the formation of a 'viral synapse' (DC–T cell receptor–
mediated binding) (Arrighi et al.,2000; Geijtenbeek et al.,2000). Thus, these virus-carrying DCs 
disseminate HIV infection to other CD4+ T cells, resulting in amplifying the infection. 
Moreover, they will further disseminate the infection to induce an immune response by carrying 
out their normal function of conveying and presenting pathogens or antigens to draining 
lymphatic tissues.  
After crossing the epithelial barrier, HIV-1 can infect CCR5-expressing DCs, 
macrophages, and T cells underneath mucosal tissues to initiate its local propagation. Dendritic 
cells are widely found in skin and mucosal tissue. They capture microorganisms that enter 
peripheral mucosal tissues and then migrate to secondary lymphoid organs. DCs and CD4+ T 
lymphocytes are the predominant cell populations targeted by HIV-1 in both intraepithelial and 
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submucosal tissues. However, the exact role of cell-free vs. cell-associated virus in mucosal 
transmission remains unresolved. More research is still necessary to further understand mucosal 
transmission of HIV.  
1.2.2.2 Microbicides for Prevention of Heterosexual Transmission of HIV-1 
Numerous efforts have been applied in attempt to bring the HIV/AIDS epidemic into 
control.  An effective vaccine could be the eventual solution—preventing HIV transmission and 
saving the lives of millions. Even a 50% effective vaccine could  reduce HIV infections by more 
than half in 15 years in developing countries (IAVI,November, 2006). However, the 
development of an HIV vaccine has been elusive. Therefore, other methods must be developed 
for prevention of HIV sexual transmission.  
A male-controlled method, the male condom, is quite effective in preventing HIV and 
other STIs. However, the male condoms usage rate is still not very high. In low-income drug 
abusing populations, condom use is only 19% (Malow et al.,2000).  In addition to condom 
slippage and breakage during intercourse accounting for a 1.9% failure rate (Grady and 
Tanfer,1994), social and culture barriers hindering the use of condoms may put people, 
particularly women, at high risk of HIV infection in some regions(Mahoney,2000; Trussell et 
al.,1992).  The female condom has also been applied for the prevention of HIV transmission. 
However, the female condom is less accepted; it was reported that most women (87%) and their 
partners (91%) disliked using the female condom (Andrzej et al.,2007). Thus, other effective, 
female-controlled methods need to be developed to prevent heterosexual HIV transmission.  For 
all these reasons, microbicide represents the best near-term solution for protecting not only 
women, but also men from heterosexual transmission of HIV. Researchers are investigating 
the use of antiretroviral drugs as microbicide for pre-exposure prophylaxis (PrEP) to prevent 
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HIV infection in women (Mauck et al.,1997; Roddy et al.,1998). It was estimated that even a 
partially effective microbicide could prevent 2.5 million cases of HIV infection in three years in 
low-income countries (Katz,2007).  Microbicide products are estimated much cheaper than 
regular HAART as mentioned previously. It only costs from $1 to $8 per daily dose (Klasse et 
al.,2006), a price that will make it accessible to a larger population, including low-income 
populations.  
Microbicides, defined as antiviral products that can be applied topically for the 
prevention of STIs, particularly for HIV, may offer an alternative to condoms as the most 
feasible method for primary prevention of HIV infection. Unlike male or female condoms, 
microbicides are a potentially preventive option that women can easily control which do not 
require the cooperation, consent, or even knowledge of the partner. A successful microbicide 
product can offer a number of advantages and conveniences for female use(National Institute of 
Allergy and Infectious Diseases,2003).  These advantages include that they can be fast-acting, 
long-lasting, and non-irritating; effective against multiple STDs, including HIV/AIDS; low cost 
and safe to use more than once a day and for long periods of time without affecting the vagina’s 
physiological barrier and its natural flora; colorless, odorless and undetectable to a sexual partner.  
Microbicides can be developed with various mechanisms of action as shown in Figure 
1-7. These products are generally divided into two categorises, non-specific and specific (Table 
1-2), according to their strategies for targeting more generalized features of the virus  or  
blocking the viral replication cycle at a specific step (Balzarini and Damme,2005; Bass,2004). 
Non-specific microbicides consist of buffering agents, detergents, or surfactants, and a variety of 
anionic substances that target the adsorption and fusion process of the virus. Buffer agents can 
maintain the normal vaginal acidic pH, which results in inactivation of the pathogenic 
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microorganisms and viruses. Detergents, such as C31G and Nonoxynol-9 (N9), destroy the 
biomembrane of HIV-1 to disrupt and destroy the virus; Anionic substances target the adsorption 
and fusion process of the virus by coating the viral envelope through their negative charges and 
then blocking its cell entry. Pro2000, which is a sulfonated polyanion, significantly impairs virus 
capture by monocyte-derived Dendritic Cells (MDCCs) and envelope-mediated cell-cell fusion 
for both R5 and X4 HIV-1 virus (Teleshova et al.,2008).   
 
 
Figure 1-7.  Potential anti-HIV mechanisms of microbicide compounds. 
There are several mechanisms by which microbicids can provide protection as shown in 
Figure 1-7. Microbicide products are designed to provide a physical and/or chemical 
barrier against HIV-1 infection. They can act as a lubricant by coating the epithelial 
surface providing a physical barrier to entry.  Some microbicide drug candidates act by 
lysing the HIV virus in the vaginal lumen prior to its entry.  Other microbicide drug 
candidates offer a chemical barrier to protect target cells against HIV infection by 
interfering with virus adsorption and fusion or interfering with virus reverse 
transcription or integration into the host cell genome. 
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Table 1-2. Microbicide candidates in development for HIV prevention 
Detergents or surfactants 
•Nonionic compounds (e.g., nonoxynol-9, chlorhexidine) 
• Anionic compounds (e.g., SLS, SDS, monocaprin) 
•Cationic compounds (e.g., benzalkonium chloride,GEDA Plus) 
• Amphoteric compounds(e.g,  C31G ) 
Buffering agents •BufferGel; •ACIDFORM 
Non-specific 
microbicides 
Anionic polymers •Sulfated polysaccharides (e.g., dextrin sulfate, heparin, carrageenan) •Sulfonated polymers (e.g., PRO-2000, PAVAS, PVAS) 
•Polycarboxylatesr† 
Entry inhibitors 
• Soluble CD4 (e.g., soluble CD4-IgG) 
• CXCR4 antagonists (e.g., SFD-1, bicyclams) 
• CCR5 antagonists (e.g., RANTES derivatives, ) 
• Glycoprotein 120 (gp120)-recognizing agents (e.g., neutralizing antibodies,  )
• gp41-interacting agents (i.e., T-20 [enfuvirtide]) 
Reverse transcriptase 
inhibitors 
• NRTIs (e.g., [R]-PMPA [tenofovir]) 
• NNRTIs (e.g., UC781, TMC-120 [dapivirine]) 
Specific anti-HIV 
microbicides 
Integrase inhibitors • Variety of compounds    S-1360;    C-731, 
 
HIV-specific drug candidates should effectively block the viral replication cycle at a step 
before integration of the HIV genome into the target cell. Several steps of the viral life cycle 
(attachment, fusion, reverse transcription, and integration) can be a target for microbicidal 
intervention. A combination of several drugs, which target different steps in the virus infection 
cycle, may provide the advantage of decreasing their dosing level and toxicity, less viral 
resistance development, and more anti-HIV efficacy. Although microbicides provide a very 
promising strategy for HIV-1 prevention, there are still many challenges before a safe, cheap and 
effective microbicide product becomes commercially available.  
1.2.2.3 NNRTIs: Optimal Drug Candidates for Microbicide Products  
In order to develop a safe and effective microbicide product, only those compounds that 
have the ability to neutralize  HIV virus,  block HIV attachment/fusion, or prevent intracellular 
HIV replication will be considered acceptable drug candidates for microbicide products 
(Stone,2002). Various compounds, such as Cellulose sulfate (CS) , Vivigel®, PRO 2000®, and 
Cyanoviran® have been considered as microbicides for preventing heterosexual transmission of 
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HIV attachment/fusion intervention strategies (Pauwels and De Clercq,1996; Shattock and 
Moore,2003).  
NNRTIs provide unique benefit in AIDS therapy. NNRTIs specifically bind to the 
“NNRTI binding pocket” in HIV-1 RT and inhibit the RT function as non-competitive inhibitors 
(De Clercq,1998). RT itself does not exist in host cells. The inhibition of RT by NNRTI will 
have less interference with the host cell, which leads to its unique property to be a good target for 
a microbicide. NNRTIs can prevent intracellular HIV replication at an early stage of HIV 
infection and do not require intracellular metabolic activation as do protease inhibitors (PIs). In 
addition to their high potency, they can effectively suppress HIV infection when used in 
combination with other anti-HIV agents (Drake,2000; Robbins et al.,2003; Staszewski et 
al.,1999). NNRTIs based regimens have also been reported to be better than PI based regimens 
for better tolerance and less risk for metabolic disorders (Chou et al.,2006; De Clercq,2004). 
Importantly, NNRTIs (such as UC781) can directly inactivate the reverse transcriptase in the 
virus particle (Balzarini and Van Damme,2005; Hossain and Parniak,2006; Stone,2002), create a 
local chemical barrier (Borkow et al.,1997), and provid extended protection due to "memory 
effect" (Barnard et al.,1997; Borkow et al.,1997). NNRTIs are promising candidates for the 
prevention of HIV infection as microbicide products due to their extremely potent antiretroviral 
activity and unique specificity for HIV-1 (Ren et al.,2002).  
  A limitation for NNRTIs in HIV treatment is that a single mutation in the RT enzyme 
NNRTI-binding pocket may confer high-level resistance to one or all of the available NNRTIs in 
long-term treatment of AIDS. However, the resistance development of HIV-1 to NNRTIs would 
not be a major issue for the use of  NNRTIs  as topical microbicide products (De Clercq,2004).  
NNRTIs can still effectively inhibit NNRTI-resistant virus  at a high concentration without 
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toxicity due to their wide therapeutic windows (Balzarini and Van Damme,2005; Buckheit et 
al.,1997b).  
In summary, NNRTIs are very promising candidates for the development of anti-HIV 
microbicide products. They can be used either as a single agent or in combination products. They 
provide many desired anti-HIV properties with high potency and better tolerance than PIs. Three 
NNRTIs, nevirapine, delavirdine, and efavirenz, are approved for clinical use by the FDA. Three 
others, etravirine, dapivirine and rilpivirine are subjects of clinical phase I/II studies currently, 
either for potential microbicide use (dapivirine) or for systemic (etravirine) therapy of HIV-1. 
1.2.3 Formulation Development of Microbicide Products  
Microbicides are a new class of drug products being developed in the form of gels, 
creams, tablets, films, or rings to help prevent sexually transmitted infections of HIV/AIDS. 
With the steadily growing incidence of AIDS infections globally, microbicides offer the most 
promising method for the prevention of sexually transmitted infections (STIs), including HIV. 
Many dosage forms had been investigated as vaginal drug delivery systems for 
microbicide products (Bader et al.,1991; Balzarini et al.,1996b; Garg,2005; Mauck et al.,1997; 
Roddy et al.,1998).  However, only gels and vaginal rings have entered clinical trials as of yet.  
Each dosage form has it own advantages and disadvantages. Economical situation, social 
conditions, age, and consumer/patient preferences can greatly interfere with the products’ 
acceptability and consequently, with the effectiveness of microbicides. Several clinical studies 
on the acceptability of vaginal formulation were conducted in several different countries (Table 
1-3) 
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Table 1-3. Acceptability of vaginal formulations  
Products tested Countries (people) Preference of  Products Reference 
Film Kenya (75) Film, (86 %) (Steiner et al.,1995) 
Foaming tablet Dominican Republic (65) Film (52 %)  
 Mexico (60) Film (58 %)  
Film Cote D'Ivoire (31) Discomfort or Irritation rate (Coggins et al.,1998) 
Gel Zimbabwe (22) Film 4%  
 USA (31) Gel 20%  
 Thailand (rural, 36) Suppository 12%  
 Thailand (Urban, 25)   
Film Mexico (292) Film   (55%) Tablet (50% ) 
(Raymond et al.,1999) 
Foaming tablet Ecuador (226)   
 Guatemala (91)   
 Ghana (90)   
 USA ((66)   
Female condom Uganda (146) Sponge (25%) (Pool et al.,2000) 
Foaming tablets  Foaming tablets (23%)  
Sponge  Female condom (19%)  
Foam  Foam (16%)  
Film  Gel (9%)  
Gel  Film (7%)  
Film USA (1536) Film (41%) (Raymond et al.,2005) 
Gel (A,B,C)  Gel A, B, C (46, 49, 43 %)  
Suppository  Suppository (34%)  
 
Gel, tablet, suppository, sponge, and film are investigated for their acceptability in women 
over several countries. Compared with other formulations, film shows significant 
acceptability and lower rate of discomfort or irritation rate. 
 
Vaginal films in the recent decade have been investigated as contraceptives and more 
recently as microbicide formulations (Garg,2005; Mauck et al.,1997; Roddy et al.,1998). Vaginal 
films show combined advantages from both tablet and gel formulations. In addition to their 
superior pharmaceutical properties, such as extended retention time and increased drug stability, 
they are economic, easily applied, and acceptably to users.  
In acceptability studies conducted at the University of Alabama and at the University of 
Zambia (Elias and Coggins,2001), it was shown that film formulations are more likely to be 
accepted by women than are other vaginal formulations, such as gels, foams, or suppositories. 
Vaginal films are easier for women to use without the help of applicators, and are light and 
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convenient to be carried. The small package of film makes it easy to store and inexpensive per 
dose. More advantages and disadvantages of film formulation are identified in following lists. 
Advantages of Vaginal film 
• Convenient for women to use without applicator.  
• Inexpensive manufacturing cost per dose.  
• Lighter and easier to carry. 
• Not as messy as other current vaginal gel products. 
• Can in some cases increase the stability of the drug. 
• Can be formulated with a combination of different drugs. 
Disadvantages Vaginal film  
• Microbicide effectiveness is diminished if the film does not completely dissolve.  
• Some individuals may have an allergic reaction to vaginal film.  
• For some drugs this dosage form may require coitally dependent use. 
1.3 DEVELOPMENT OF CYCLODEXTRIN BASED DRUG DELIVERY SYSTEMS  
1.3.1 History of Cyclodextrins  
Cyclodextrins have long history of application. Cyclodextrins (CDs) were first described 
by Villiers in 1891 (Villiers,1891). However, they did not come into wide use until after the 
1950’s, when  French and coworkers modified the chemical process for the production of CDs  
(French,1957). CDs are obtained from the enzymatic digestion of starch by cyclodextrin 
glycosyltransferase (CGTase) (Biwer et al.,2002; Freitas et al.,2004; Larsen et al.,1998). But the 
availability of cyclodextrins and high production costs greatly limited their research and 
application until the 1970’s (Horikoshi,1971; Horikoshi,1979). The advancement of 
biotechnology has resulted in dramatic improvements in cyclodextrin production, which has 
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lowered their production costs, leading to the availability of highly purified cyclodextrins and 
cyclodextrin derivatives (Astakhova and Demina,2004) at relatively inexpensive cost.  
Today, more than 30 different pharmaceutical products containing cyclodextrins are on 
the market worldwide (Table 1-4). More and more cyclodextrin based dosage forms are under 
development. 
Table 1-4. βCD containing pharmaceutical products on the Market 
1.3.2 Chemical Structure of Cyclodextrins and Complexation Phenomenon  
The family of cyclodextrins (CDs) comprises of a series of cyclic oligosaccharides 
compounds, and several members of this family are used industrially in pharmaceutical, 
chemical, and food science applications. CDs are generally crystalline, water-soluble, cyclic, 
Brand  name Drug / Cyclodextrin Formulation Company  
Prostarmon E PGE2/βCD  Sublingual tablet Ono ( Japan) 
Caverject Dual Alprostadil/ αCD i.v. solution Pfizer (USA) 
Aerodiol 17-β-Estradiol / MβCD Nasal spray Servier ( France) 
Cetirizin Cetirizine/ βCD Chewable Tablet Losan Pharma (Switzerland) UCB Pharma (USA) 
Fluner Flunarizine/ βCD Tablet Geno Pharmaceuticals ) 
Vitaseptol Thiomersal/ βCD Eye drop Europhta (Monaco) 
Mobitil Meloxicam/ βCD Tablet, suppository Medical Union Pharmaceuticals (Egypt) 
Abilify Aripiprazole/ sulfobutyl-βCD i. m. solution Bristol-Myers Squibb (USA) Otsuka Pharm. (Japan, USA) 
Cerenia Maropitant/ sulfobutyl-βCD Parental solution Pfizer Animal Health (USA) 
Dexocort Hydrocortisone/ HPβCD Solution Actavis (EU) 
Nicorette Nicotine / βCD Subligual tablet Pfizer (USA)  
Vfend Voriconazole/  sulfobutyl ether -βCD i.v. solution Pfizer (USA) 
MitoExtra Mitomycin / HPβCD i.v. Infusion Novartis ( Switzerland ) 
Voltaren 
OPHTHA Diclofenac (INN) sodium  / HPβCD Eye drop Novartis ( Switzerland ) 
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homogeneous, non-reducing, oligosaccharides built up from glucopyranose (Glc) units. The 
three commonly used CDs are α-cyclodextrin comprised of six glucopyranose units, βCD 
comprised of seven units and γCD comprised of eight such units (Figure 1-8). Larger CDs, 
containing more than eight glucopyranose units in the molecule, have also been studied for their 
complexation phenomenon (Maestre et al.,2007).   
 
 
 
 
 
 
αCD      βCD     γCD 
Figure 1-8.  Chemical Structure of CDs 
Structures of αCD, βCD, and γCD are shown in Figure 1-8 (from left to right). Chair 
conformation of glucopyranose units is presented. The number of glucopyranose units is six 
for αCD, seven for βCD, and eight for γCD resulting in a size different in three CDs. 
 
The most important property of CDs is their ability of “entrapping” hydrophobic guest 
molecules into their cavity in the aqueous phase as shown in Figure 1-9. This complexation 
ability is due to their chemical structure and the glucopyranose units conformation. In 
cyclodextrin molecules, the glucopyranose units are present in the chair conformation. Therefore, 
the hydroxyl functional groups are orientated to the cone exterior with the primary hydroxyl 
groups of the sugar residues at the narrow and wider edges, which gives it a hydrophilic outer 
surface. The central cavity is formed by the skeletal carbons and ethereal oxygens of glucose 
residues, which gives the CD molecule a comparatively hydrophobic inner cavity. The polarity 
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of this cavity has been estimated to be similar to that of an aqueous ethanolic or methanolic 
solution (Connors,1997; Groom et al.,2003).   
 
Figure 1-9.  Complexation process of CDs with drugs 
Schematic presentation of the process of complex formation. Small circles represent water 
molecules, red ellipses represent drug mulecules. Water molecules are repulsed both by 
thehydrophobic drug molecules and the hydrophobic cavity of the truncated CD cylinder.  The 
main driving force for inclusion is mainly the substitution of the polar–apolar interactions 
(between the apolar CD cavity and polar water ) for apolar–apolar interactions (between the drug 
and the CD cavity). 
 
The main driving force for complex formation is thought to be the release of enthalpy-
rich water from the cavity due to the entrapping of guest molecules of CDs (Guo et al.,1998; 
Loftsson and Brewster,1996; Loftsson and Masson,2001). Weak Van der Waals forces, hydrogen 
bonds, and hydrophobic interactions keep the complex together.  No covalent bonds are formed 
or broken during drug-CD complex formation. Therefore, the complexation process can be 
considered as a replacement of water molecules with drug molecules.  
Generally, in an aqueous solution, the cyclodextrin cavity (slightly apolar) is occupied by 
water molecules, which is thermodynamically unfavorable (polar-apolar interaction). Therefore, 
the water molecules inside the cavity have less tendency to form hydrogen bonds in the same 
way as in solution and result in a higher enthalpy and higher energy. When hydrophobic guest 
molecules are incorporated into this system, the energy of the system is lowered by substituting 
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these enthalpy-rich water molecules with those hydrophobic guest molecules to form the 
complex of CDs and “guest molecules”. 
In aqueous solution, an equilibrium is reached with the formation of a complex of the 
drug and CD and with the dissociation of the complexes. Therefore, the complexation can be 
studied with methods as chemical reactions.  Most frequently, the complexation happens 
between one cyclodextrin and one guest (1:1 ratio) molecule. However, 2:1, 1:2, 2:2, and higher 
order complex equilibria always exist simultaneously in the system. Phase solubility diagrams 
are normally used to analyze the complexation stoichiometry.  
In addition, the complexation is determined both by the CDs’ inner cavity size and by the 
appropriate size of those organic compounds or guest molecules (Szejtli,1998b).  Only those 
guest molecules with suitable shape and size can be incorporated into the CDs’ inner cavity to 
form inclusion complexes. The cavity size of CDs is dependent on the number of glucose in the 
molecule as shown in Figure 1-10 and Table 1-5.  The cavity size of αCD is the smallest of the 
three CDs and insufficient for many drugs. γCD has the largest cavity size of all three CDs. 
However, it is much more expensive than the other CDs. Therefore, βCD is most widely used in 
research and manufacturing due to its cost and suitable cavity size for most drug molecules.  
(Loftsson and Brewster,1996; Szejtli,1998a).   
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Figure 1-10.  Dimensions and hydrophilic/hydrophobic regions of the CD molecules. 
 
Table 1-5. Characteristics of α, β and γ-CDs 
 α β γ 
Number of Glucose units 6 7 8 
Molecular Weight 972 1135 1297 
H2O solubility [g/100mL] 14.5 1.85 23.2 
pKa 12.33 12.2 12.08 
Inner diameter [nm] 0.45-0.57 0.62-0.78 0.79-0.95 
Outer diameter [nm] 1.37 1.53 1.69 
Depth / Height [nm] 0.79 0.79 0.79 
Cavity volume [nm3] 0.174 0.262 0.472 
 
Parameters of three cyclodextrins were reported by Szjtli et al   (Szejtli,1998a) 
 
Due to the limitation of size and apolar character of the CD cavity, the complexation is 
obviously not suitable for all drugs. For example, inorganic salts such as KCl and NaCl are 
generally recognized as not suitable for CD complexation. Generally, with the consideration of 
CD molecule characteristics, drug molecules should fit the following requirements but not 
without exception to form an applicable complex with βCD.  
-  more than 5 atoms (C, P, S, and N) form the skeleton of the drug molecule; 
-  solubility in water of should be less than 10 mg/ml; 
-  melting point temperature is below 250 ºC; 
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-  the molecule consists of less than 5 condensed rings;  
-  a molecular weight between 100 and 400; 
This solubilization strategy using cyclodextrin complexation is not suitable for very small 
compounds, or compounds that are too large such as peptides, proteins, enzymes, sugars, 
polysaccharides. However, the side chain in macromolecules may contain suitable groups which 
can react with CDs in aqueous solutions and form a partial complexes with CDs such as insulin 
(Lovatt et al.,1996).  
 
Figure 1-11. Application of βCD in Pharmaceutics 
Schematic representation of the application of βCD in pharmaceutical industries for 
improving the drug performance in formulations. βCD complexation can improve 
bioavailability, reduce irritation, improve patient compliance, stabilize actives, and simplify 
handling.  
 
1.3.3 Pharmaceutical Application of Cyclodextrins Complexation 
The formation of inclusion complexes provides numerous advantages in pharmaceutical 
formulation development (Figure 1-11).  βCD was reported to increase bioavailability of poorly 
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soluble drugs by increasing the drug solubility. (Barone et al.,1998; Nasongkla et al.,2003).   
Light, thermal and oxidative stability of drug molecules can be improved through the formation 
of cyclodextrin complexes (Cwiertnia et al.,1999; Tirucherai and Mitra,2003). Cyclodextrins 
have also been used to reduce dermal, gastrointestinal, or ocular irritation, mask unpleasant tastes 
or odors, and prevent adverse drug-ingredient interactions (Loftsson and Jarvinen,1999; Redenti 
et al.,2001). 
One major application of drug complexation with cyclodextrin is to increase the drug 
bioavailability in formulations. The solubility and permeability behavior of drug molecules has 
been extensively studied due to the significant impact on drug absorption.  FDA and other drug 
regulatory organizations have defined a Biopharmaceutical Classification System in which drugs 
are sorted into four Classes based on their solubility and permeability (Amidon et al.,1995; Chen 
et al.,2001) as shown in  Table 1-6.  Numerous drug candidates with great potency belong to 
Class II or Class III with significant difficulties in low solubility or permeability. βCD 
complexation is an important technology for increasing the bioavailability of compounds 
belonging to Class II and III (Loftsson,2002; Loftsson et al.,2004).  Drugs from Class II and 
Class III can be shifted to Class I by forming a complex with βCD(Loftsson,2002). This 
complexation can enhance the apparent water solubility and the permeability of these insoluble, 
hydrophobic drugs by increasing the amount of dissolved drug in bioliquid and biological 
membranes, leading to the increase of bioavailability.   
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Table 1-6. Effect of cyclodextrin complexation on the classification of drug substance. 
 
 
Class I 
 
High Permeability 
High Solubility 
 
 
Class II 
 
High Permeability 
Low Solubility 
 
 
 
Class III 
 
Low Permeability, High Solubility 
 
Class IV 
 
Low Permeability, Low Solubility 
 
 
βCD complexation process in Pharmaceutical industries for improving the performance of 
drug in formulations. βCD complexation can improve bioavailability, reduce irritation, 
improve patient compliance, stabilize actives, and simplify handling.  
 
UC781 is a very potent NNRTI and a promising microbicide candidate with extremely 
low water solubility. It is important to formulate UC781 into a suitable dosage form for vaginal 
delivery. One of the major challenges in the development of UC781 formulation is to increase its 
solubility. For these reasons, this complexation technique may provide a potential strategy for 
the development of UC781 as a microbicide product.  
1.4 HYPOTHESIS AND SPECIFIC AIMS  
Microbicides are topically used antiviral products for the prevention of sexually 
transmitted infections (STIs), including HIV infection. They may provide an alternative to 
condoms as the most feasible method for primary prevention of HIV infection, particularly for 
women. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are considered potential 
candidates for microbicide products.  
Cyclodextrin complexation increases solubility 
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UC781 is a NNRTI, which provides a chemical barrier against HIV-1 infection by 
inhibiting its (HIV-1) reverse transcriptase (RT) activity with marked potency in vitro. Although 
it shows good permeability in the intestinal model (Deferme et al.,2002), as a ClassⅡ drug, the 
extremely low water solubility (<29ng/ml, unpublished data) of the UC781 molecule poses a 
great challenge for its administration. Therefore, a suitable vaginal drug delivery system, which 
can increase the solubility of UC781, needs to be developed for formulation purposes.  
β-cyclodextrin (βCD) is a cyclic (α-1, 4)-linked oligosaccharide of α-D-glucopyranose 
containing a relatively hydrophobic central cavity and hydrophilic outer surface. Due to its 
molecular structure and shape, βCD possesses a unique ability to act as a molecular container by 
entrapping guest molecules in its internal cavity.  
Considering the highly hydrophobic nature of UC781 and βCD’s ability of entrapping 
guest molecules, we hypothesize that UC781 will be reversibly entrapped into the hydrophobic 
cavity of βCD due to its hydrophobic nature, and the formed UC781:βCD complex will not 
interfere with the interaction between UC781 and HIV-1 reverse transcriptase. Therefore, 
UC781 will be solubilized in the form of molecular complex with βCD in aqueous solution while 
maintaining its activity of RT inhibition, thus inhibiting HIV infection. 
Based on this hypothesis, we predict that (1) UC781 will form a complex with β-
cyclodextrin in both liquid and solid state; (2) UC781: βCD complex will enhance the solubility 
of UC781 in aqueous media. The complexation process of UC781: βCD can be optimized by 
modifying the preparation methods and complexation conditions; and (3) UC781: βCD complex 
will facilitate the release of UC781 from formulation, due to the solubility increase of UC781, 
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and will maintain the same potency against HIV in vitro as UC781 alone. The hypothesis was 
tested with the following three specific aims: 
 
Aim 1: Determine whether βCD can form an inclusion complex with UC781 and whether 
different cyclodextrins can affect the thermodynamic behavior of the complex (Chapter 2 
and Chapter 3) 
UC781: βCD complexes in the liquid and solid state were prepared respectively and 
evaluated using UV and NMR for the liquid state and Differential Scanning Calorimetry (DSC) 
and IR for the solid state. UC781 alone, βCD and UC781/βCD physical mixtures were also 
examined for comparison. The thermodynamic properties of UC781:βCD complexes were 
investigated with an HPLC method. Results obtained from these experiments provide evidence 
that UC781 and βCD can form inclusion complexes and elucidate the mechanism for the driving 
force for the reaction. 
Aim 2: Determine whether UC781: βCD complexes increase the aqueous solubility of 
UC781 and investigate the impact of different experimental conditions on complexation 
(Chapter 4) 
Solubility studies of the UC781: βCD complex were conducted using HPLC methods. 
Complexes were prepared using kneading, shaking, lyophilization, and autoclave methods. All 
samples were dissolved in Milli-Q water and filtered with a 0.45μm filter for quantitative HPLC 
assay. pH change as well as water-soluble polymer (HPMC, HEC, PVA, and PVP) incorporation 
were investigated as methods to enhance the solubility of UC781 in cyclodextrin solutions. 
Results obtained from these experiments revealed that the complexation of UC781 with βCD can 
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be enhanced using an autoclave method for manufacture, incorporation of water-soluble 
polymers during processing, or pH adjustment.   
 
Aim 3: Determine whether complexed UC781 is released faster than non-complexed UC781 
from formulations and whether the UC781: cyclodextrins complex maintains the same 
potency against HIV-1 in vitro as UC781 alone (Chapter 5) 
Three formulations were developed for complexed and non-complexed UC781. The 
release of UC781 in both the complexed and non-complexed form was evaluated using a 
dissolution apparatus. The amount of UC781 released was determined using a quantitative HPLC 
assay. Mean dissolution time was determined for comparison. The ability of formulated non-
complexed UC781 and complexed UC781 to maintain biological activity was also evaluated. 
Results showed that RT inhibition activity and virus replication inhibition can be maintained in 
the formulated state.  Furthermore, the incorporation of complexed UC781 in formulations 
results in significant  enhancement of UC781 release from the formulated product.    
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2.0  CHARACTERIZATION STUDIES FOR UC781: βCD COMPLEXES  
2.1 INTRODUCTION   
UC781, (N-[4-chloro-3-(3-methyl-2-butenyloxy) phenyl]-2-methyl-3-
furancarbothioamide) (Figure 2-1), is a tight-binding HIV-1 non-nucleoside reverse transcriptase 
(RT) inhibitor (NNRTI). UC781 has been identified as an extremely potent inhibitor of HIV-1 
replication in cell culture [50% effective concentration (EC50), approximately 3 ng/ml] (Balzarini 
et al.,1996b; Balzarini et al.,1998; Barnard et al.,1997). It belongs to the class of 
(thio)carboxanilide derivatives, the prototype of which (UC-84) was previously reported (Bader 
et al.,1991).  
 
 
 
 
 
Figure 2-1. Structure of UC781 
Structure of UC781: N-[4-chloro-3-(3-methyl-2-butenyloxy) 
phenyl]-2-methyl-3-furancarbothioamide (MW:335.48). Protons of 
UC-781 are shown for NMR purposes 
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UC781 can inhibit several laboratory and clinical strains of HIV-1 (Balzarini et 
al.,1996b), including both syncytium- and non syncytium-inducing phenotypes (Zussman et 
al.,2003). It has also been shown to inhibit HIV-1 strains which are resistant to nucleoside RT 
inhibitors with a potency similar to that for inhibition of wild-type virus (Borkow et al.,1999). 
Furthermore, UC781 targets HIV-1 RT and is effective against a variety of NNRTI resistant 
HIV-1 strains  (Balzarini et al.,1996a; Balzarini et al.,1996b) and restores the anti viral activity 
of AZT to AZT resistant HIV-1 strains (Borkow et al.,1999). Importantly, high resistance to 
UC781 is only obtained when more than one mutation occurs in the NNRTI binding pocket 
(Balzarini et al.,1996a; Hossain and Parniak,2006). Thus, with the broad therapeutic index 
(>62,000) (Buckheit et al.,1997b), UC781 can effectively inhibit NNRTI-resistant virus isolates 
at a high dosing level without any toxicity.  
UC781 is under consideration for use in microbicide formulations designed to minimize 
sexual transmission of HIV-1. This molecule exhibits a number of virologic  properties that are 
important for anti-HIV microbicides (Borkow et al.,1997) including inactivation of isolated HIV 
virions and prevention of cell-to-cell transmission of HIV (Hossain and Parniak,2006; Zussman 
et al.,2003).  Importantly, UC781 has two unique properties as a microbicide candidate. Firstly, 
UC781 takes effect very rapid. A very short tissue exposure to UC781 can offer enough 
protection against HIV-1 infection in cervical tissue models. Pretreatment of the cervical tissues 
with UC781 for 10 min at 10 μM offered complete protection from the HIV-1 containing semen 
(Zussman et al.,2003). These properties make UC781 an excellent candidate for a microbicide 
product. Secondly, it exhibits a “memory” effect in that pretreatment of uninfected cells renders 
the cells refractory to infection upon subsequent exposure to infectious HIV-1 despite the 
absence of exogenous drug (Borkow et al.,1997; Liu et al.,2005a). These results were confirmed 
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by Liu et al who also showed that the memory effect of UC781 was specific for drug-cell 
interaction and not to nonspecific binding of UC781 to the surfaces of culture plate wells (Liu et 
al.,2005a). This memory effect may result in the long cellular half life of UC781. The cellular 
half-life of UC781 in MT-2 cell line can reach 5.5 days (Borkow et al.,1997; Zussman et 
al.,2003). It was reported that HIV-1 virus still can be infective in the DC-SIGN-bound form for 
4 days after exposure in the vagina (Geijtenbeek et al.,2000), but free HIV lost its infectivity 
very quickly with pH decrease. The half life for virus infectivity decreased from more than 120 
min to 6 min at pH 4.5 and pH 3.5, respectively (Neurath et al.,2006; O'Connor et al.,1995). 
Therefore, UC781 will provide an effective protection window  against HIV infection.   
These properties of UC781 are likely related in part to the hydrophobicity of the 
compound. However, this hydrophobicity also poses great challenges in formulation and release 
of UC781 upon topical administration. UC781 is regarded as belonging to class II of the 
Biopharmaceutical Classification System (low solubility, high permeation across membranes) 
(Deferme et al.,2002). No aqueous parenteral formulation of UC781 is currently available for 
clinical use.  
The purpose of this research is to develop a beta-cyclodextrin  based drug delivery 
system for UC781 as an effective anti-HIV microbicide product. In this chapter, the ability of 
three different cyclodextrins, beta cyclodextrin (βCD), methyl-beta-cyclodextrin (MβCD) and 2-
hydroxylpropyl-beta-cyclodextrin (HPβCD), to enhance the aqueous solubility of UC781 using 
phase-solubility diagram technique is evaluated. Characterization of  these UC781-cyclodextrin 
complexes by a variety of physicochemical methods, including Ultraviolet (UV), Fourier 
Transform Infrared Spectroscopy (FTIR), and Differential Scanning Calorimetry (DSC) analysis 
is presented 
 45 
Additionally, Nuclear Magnetic Resonance (NMR) spectroscopic studies of UC781 
alone, βCD alone and UC781: CD complexes are presented to gain insight into interactions 
between UC781 and βCD in the complexed form.  Finally the bioactivity of the UC781: HPβCD 
complex is demonstrated using an in vitro reverse transcriptase inhibition assay. Results from 
these studies showed that cyclodextrins provide substantial increases both in aqueous solubility 
and in biological activity of UC781, suggesting that UC781-cyclodextrin inclusion complexes 
may be important in the development of appropriate formulations of UC781 for use as a topical 
microbicide to prevent sexual transmission of HIV.  
2.2 MATERIALS AND METHODS   
2.2.1 Materials   
UC781 for these studies was initially provided by Biosyn Co. Ltd. (Huntington, PA). 
However the licensing rights to this drug were transferred to CONRAD who provided 
subsequent supply as needed. βCD (MW 1134), MβCD (MW: Approx. 1320; Mean degree of 
substitution: 1.7-1.9), and HPβCD (MW: Approx. 1380 and Mean degree of substitution: 0.8) 
were purchased from Spectrum Chemical Company (Gardena, CA). Deuterated 
dimethylsulfoxide (DMSO-d6 99.6%) was obtained from Sigma Aldrich (St Louis, Missouri). 
All other reagents used were of reagent grade and all solvents were of HPLC grade. Milli-Q 
water was used to prepare buffer solutions and other aqueous solutions. 
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2.2.2 Methods 
2.2.2.1 Phase Solubility Studies of UC781 Complexation 
An excess amount of UC781 was added into a sealed 2 ml auto sampler screw-thread glass 
vial (Fisher Scientific, Hampton, NH) containing 1 ml distilled water with various concentrations 
of βCD, MβCD, and HPβCD (from 0 to 0.52 M). The vials were shaken on a horizontal rotary 
shaker at a speed of 50 rpm at ambient temperature (25 °C) for seven days. The solutions were 
then filtered through a 0.45 μm nylon disc filter (Millipore Co., Billerica, MA) to collect a clear 
solution. All samples were prepared in triplicate. The concentration of UC781 in the UC781: CD 
inclusion complex solution was determined using high performance liquid chromatography 
(HPLC). The assay used the following conditions: a Waters 510 pump and Waters 2487 dual 
wavelength absorbance detector at 275 nm; column ODS-C18 (4.6 × 250 mm, 5μm; Alltech, 
Columbia, MD); a mobile phase of acetonitrile/water (75:25 v/v); a flow rate of 1 ml/min. 
The complexation constant (K1:1), according to the hypothesis of 1:1 stoichiometric ratio of 
complexes, was calculated from phase-solubility diagrams (Higuchi and Connors,1965) using the 
following Equation (2-1).            
)slope1(S
slopeK
o
1:1 −=                  Equation 2-1                                               
In this equation, K1:1 is the complexation constant, So is the intrinsic solubility, and the 
slope is calculated from a graph of the dissolved drug concentration verses βCD concentration in 
the medium. The intrinsic solubility value (So) of UC781 in the absence of βCD was determined 
directly in aqueous media.  
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2.2.2.2 UV Absorption Spectrophotometry of UC781 and Its Complexes 
The effect of each βCD on the UV spectra of UC781 was studied using a NanoDrop®  ND-
1000 spectrophotometer (Nanodrop technologies Inc, Wilmington, DI). All measurements were 
performed at ambient temperature. Different amounts of MβCD (0 to 20%, w/v) and HPβCD (0 
to 20%, w/v) were added into a 50% (v/v) aqueous ethanol solution with a fixed UC781 
concentration (1×10-4M). UV absorption profiles for UC781 at different CD concentrations were 
obtained between wavelengths of 220 to 410 nm. A UC781 solution without cyclodextrin was 
used as a control for these studies. 
The stoichiometric proportion and complexation constant (K1:1) were evaluated using the 
Scott  Equation (2-2)  (Brandao et al.,2003):  
1:1781781
11
KC
C
CA
C
UC
CD
UC
CD
×Δ×+Δ×=Δ εε         2-2 
where CCD and CUC781 are the total molar concentrations of cyclodextrin and UC781, ΔA 
is the change in absorbance after complexation of cyclodextrin (ΔA=AUC781-ACD: UC781), K1:1 is 
the complexation constant and Δε is the difference of the molar absorptivities for free and 
complexed UC781. If the plot of CCD/ΔA against CCD yields a straight line, a 1:1 complex 
between UC781 and cyclodextrins is indicated.  Under this circumstance, Equation (2-2) can be 
simplified giving Equation (2-3) 
erceptCslope
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C
CD
CD int+•=Δ        2-3 
The complexation constant K1:1 (M-1) can be mathematically calculated from Equation 
(2-3) using Equation (2-4):  
K1:1= (slope/intercept) × 1000            2-4 
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2.2.2.3 2D 1H-1H Nuclear Magnetic Resonance ROESY of UC781: βCD Complex           
2D 1H-1H Rotating frame Overhause Effect Spectroscopy (ROESY) was carried out on a 
Varian Mercury 400 (400MHz) spectrometer (Varian Inc, Walnut Creek, CA) with a 5mm 
sample tube, operating at 400 MHz at 25°C. Typically, deuterated water is used as a solvent in 
this type of study.  However, given the poor aqueous solubility of UC781, DMSO-d6 was chosen 
as the solvent in these experiments. DMSO-d6 has a dielectric constant which is similar to that of 
water (Miyake et al.,1999).  Additionally, it offers acceptable solubilization for both UC781 and 
βCD moieties. No internal reference was used to avoid interference with the complexation 
between UC781 and cyclodextrins; therefore, the solvent signal (2.50 ppm) was used as an 
internal reference. 2D ROESY was performed in the phase-sensitive mode with a spin-lock 
mixing time of 500 ms. Complexes of UC781 with βCD were prepared by dissolving 1.0×10-2M 
of both UC781 and βCD in DMSO-d6 for the 2D 1H-1H ROESY experiment. UC781 and βCD 
were dissolved in DMSO-d6 separately (1.0×10-2M) as controls. The 1H-signals of βCD were 
assigned as described by Schneider et al (Schneider et al.,1998).  
2.2.2.4 Preparation of UC781: βCDs physical mixtures and the solid complexes 
Complexes of UC781 with each of βCD, MβCD, and HPβCD were prepared at a 1:3 molar 
ratio. The UC781 cyclodextrin mixture was added to a solution consisting of 1.5ml NH3⋅H2O and 
0.8ml EtOH to dissolve both the cyclodextrin and the UC781. The solution was shaken 
vigorously and then frozen using liquid nitrogen. The frozen solution was then freeze-dried with 
a Labconco Freezone 6 Freeze-Dryer system (Labconco Corporation, Kansas City, MO) for at 
least 48 hr. The freeze-dried samples were gently ground into a fine powder with a mortar and 
pestle. The powder was placed onto a filter paper and then rinsed with 1ml of 100% acetonitrile 
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(ACN) to remove non-complexed UC781.  The filter was then placed into a vacuum oven at 30 
oC for 30 minutes to remove any residual solvent.  
Physical mixtures of UC781 with three different β-cyclodextrin in 1:3 molar ratios were 
prepared by mixing freeze-dried UC781 powder with freeze-dried βCD, MβCD, or HPβCD for 2 
min on a Fisher Vortex Genie 2® Mixer (Fisher Scientific International Inc. Hampton, NH). 
2.2.2.5 Differential Scanning Calorimetry (DSC)  
DSC analysis was carried out for pure UC781, the three different pure cyclodextrins, 
physical mixtures of UC781 with each cyclodextrin at a 1:3 molar ratio, and complexes of 
UC781 with each of βCD, MβCD, and HPβCD. The DSC patterns were recorded on a Perkin-
Elmer DSC-7 (PerkinElmer. Inc, Boston, MA) equipped with a thermal analysis data station. 
Each sample (3 to 5 mg) was heated in crimped aluminum pans over a temperature range of 50 to 
200 °C at a constant scanning rate of 5 °C/m in nitrogen purging (20 ml/min). A blank aluminum 
pan was used as a reference. The heat of fusion was calibrated using an indium standard obtained 
from the PerkinElmer company (indium purity: 99.99 %, melting point: 157.07 °C, ΔH = 20.37 
J/g, heating rate: 5 °C/min). 
2.2.2.6 Fourier Transform Infrared Spectroscopy (FTIR) Studies 
The infrared spectra of UC781, and its complexes with the three different βCD in solid state 
were obtained using a Bio-Rad Excalibur series FTIR spectrometer FTS 3000MX (Bio-Rad 
Laboratories, Inc. Hercules, CA) equipped with a Digilab Merlin 3.3 workstation according to 
the thin solid film method described by Song et al.(Song and Wang,2003). A thin solid film of 
UC781, βCD, MβCD, HPβCD, physical mixtures of UC781 with each βCD at a 1:1 molar ratio, 
and complexes of UC781 with each of βCD, MβCD, and HPβCD were cast on a sodium chloride 
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(NaCl) plate from a solution of 70% ethyl alcohol. The selected wave-number range used in this 
study was from 500 to 4000 cm-1.  For comparison purposes, FTIR spectra was obtained for pure 
UC781, each βCD being studied, as well as physical mixtures of UC781 and each cyclodextrin. 
2.2.2.7 Determination of RNA-dependent DNA Polymerase Activity of HIV-1 Reverse 
Transcriptase 
HIV-1 RT DNA polymerase activity was determined by a fixed time assay, as previously 
described by Barnard et al  (Barnard et al.,1997).  Reaction mixtures (50μl total volume) 
contained 50 mM Tris-HCl (pH 7.8, 37ºC), 60mM KCl, 10mM MgCl2, 5 μg/ml of either 
poly(rA)-oligo(dT)12-18 or poly(rC)-oligo(dG)12-18, and either 20μM [3H]TTP or 10μM 
[3H]dGTP. Reactions were initiated by the addition of 50-80 ng of RT (9-12 nM final 
concentration). Reaction mixtures were incubated at 37ºC for 20 min and then quenched with 
250μl of ice-cold 10% trichloroacetic acid (TCA) containing 20 mM sodium pyrophosphate. 
Quenched samples were left on ice for 20 min, then filtered using 1.2 μm glass fiber Type C 
filter multi-well plates (Millipore), and washed sequentially with 10% TCA containing 20mM 
sodium pyrophosphate and with 100% ethanol. The extent of radionucleotide incorporation was 
determined by a Wallace 1450 Microbeta Jet liquid scintillation (Perkin Elmer, Waltham, MA) 
counting of the dried filters.  
2.2.2.8 Statistical Analysis  
IC50 values for UC781 in both the non-complexed and complexed forms were calculated 
using GraphPad Prism 4.0. Data was analyzed using one-way ANOVA analysis with Tukey 
comparison. P<0.05 represented significant differences.  
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2.3 RESULTS AND DISCUSSION   
2.3.1 Phase solubility Studies of UC781 Complexes 
The effect of cyclodextrin on the aqueous solubility of UC781 was evaluated using the phase 
solubility method. Figure 2-2 and Figure 2-3 show the phase diagrams for UC781 in the presence 
of the three different types of cyclodextrins in aqueous media. The intrinsic aqueous solubility of 
UC781 is almost negligible (<3×10-5 mg/ml).  The presence of βCD in the aqueous phase 
resulted in increased apparent aqueous solubility of UC781 regardless of the βCD type used.  
UC781 solubility was increased 20 fold in the presence of 1.8% w/v βCD (1.7×10-6 M ), nearly 
4000 fold in the presence of 40% w/v MβCD (3.2×10-4 M), and 500 fold in the presence 40 
%w/v HPβCD (4.1×10-5 M). The solubility of UC781 increased linearly as a function of βCD, 
MβCD, and HPβCD concentration under the experimental conditions. The phase solubility 
profiles show that complexation of UC781 with all three βCDs increases UC781 solubility  in a  
linear pattern, displaying type AL Phase diagrams according to the classification by 
Higuchi(Higuchi and Connors,1965). This indicates the formation of 1:1 inclusion complexes of 
UC781 with each of three cyclodextrins in solution. The correlation coefficient of the linear 
regression for each of the phase solubility curves was greater than 0.98, indicating a good fit for 
all regressions. The complexation constants (K1:1) of UC781 with each cyclodextrin are 1119.5 
M-1 for βCD, 2239.4 M-1 for HPβCD, and 13449.7 M-1 for MβCD using Equation 2-1. 
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Figure 2-2.  Phase-solubility diagram for UC781 with βCD in water 
 
 
 
 
 
 
 
 
 
Figure 2-3.  Phase-solubility diagrams for UC781: HPβCD and UC781: MβCD in water 
 
For MβCD, inclusion constants were additionally calculated for a 1:2-complex (K1:2) using 
Equation 2-5. This equation was derived by Lofftson et al (Loftsson et al.,2002).  
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In this equation, St and [CD] t correspond to total UC781 and MβCD concentration 
respectively, K1:1 and K1:2 represent the complexation constants for the 1:1 and 1:2 complexes 
respectively. The K1:1 value for the MβCD complex was calculated as 5597 M-1. This value was 
significantly higher than that calculated for K1:2 for this complex (4.2 M-1), and corresponds to 
the observed significant increase in aqueous solubility of UC781 in the presence of MβCD. The 
apparent low value of K1:2  with respect to K1:1 indicates that the 1:1 complex is the predominant 
form. 
Increases in UC781 solubility in aqueous cyclodextrin solutions are consistent with the 
formation of inclusion complexes between UC781 and cyclodextrin molecules. Generally, the 
main driving force for complex formation is the hydrophobic interaction between a poorly water-
soluble guest compound, such as UC781, and the apolar cavity of the cyclodextrin molecule. The 
hydrophobicity and geometry of the guest molecule as well as the cavity size and the derivative 
groups of the cyclodextrin are important for complex formation. In the current study, the 
enhancement of UC781 solubility is highly dependent on the type of cyclodextrin used. Based on 
the phase solubility diagrams, MβCD is more effective in solubilizing UC781 in aqueous media 
compare to HPβCD and βCD.  
The different complexation constants found for the different cyclodextrin molecules studied 
indicate that the derivative groups on the cyclodextrins appear to play an important role in the 
incorporation of UC781 into the cyclodextrin cavity, since much higher complexation constants 
were obtained for MβCD and HPβCD.  Specifically, physicochemical properties of cyclodextrins 
are greatly altered upon methylation. MβCD can be dissolved in both organic solvents and water 
with less hygroscopic and higher surface activity than underivatized cyclodextrins (Uekama and 
Otagiri,1987). Furthermore, the cyclodextrin cavity is lengthened upon for the methylation of the 
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OH (2) and OH (6) groups of the cyclodextrin rim without significant distortion of the ring, and 
this would enhance the complexation ability of MβCD (Sueishi et al.,2003; Suzuki et al.,1994). 
These properties lead to greater complexation ability for MβCD with UC781 than for βCD and 
HPβCD. Even though βCD is a good host molecule for UC781, the relatively poor aqueous 
solubility of βCD (16.3 mM) limits its utility for use in the enhancement of UC781 aqueous 
solubility. Our studies suggest that HPβCD and MβCD may be more appropriate candidates for 
the solubilization of UC781 for use in topical microbicide formulations. 
 
2.3.2 UV Studies of UC781 Complexes 
Ultraviolet spectroscopy was used to further confirm the complexation of UC781 with the 
three different cyclodextrins in solution. Figures 2-4 to 2-6 show the effect of βCD (Figure 2-4), 
HPβCD (Figure 2-5), and MβCD (Figure 2-6. ) on the UV spectrum of UC781. Maximum UV 
absorption for UC781 solubilization in an aqueous ethanol solution was observed at 300 nm.  
The obtained maximum absorption of UC781 was enhanced with the addition of βCD, HPβCD, 
and MβCD.  Results generated comparing varying concentrations of cyclodextrins showed that 
the most significant increase in enhancement of UC781 absorbance occurred at a concentration 
of 0.25% βCD, 2.5% HPβCD, and 10% MβCD. In addition, a broader UV peak and a slight blue 
shift (about 5 nm) was displayed in the UV absorption profile for UC781 under these conditions. 
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Figure 2-4.  Effect of βCD concentration on the UV absorbance of UC781 in aqueous solution 
 The βCD concentration was 0%, 0.125%, 0.25%, 0.5%, 0.75%, and 1.0%.  Solid diamond = 
UC781; blank square = UC781 with 0.125% βCD; black star=UC781 with 0.25% βCD; black 
dash=UC781 with 0.5% βCD; solid triangle = UC781 with 0.75% βCD; solid square= UC781 
with 1% βCD.  
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Figure 2-5. Effect of HPβCD concentration on the UV absorbance of UC781 in aqueous solution 
The HPβCD concentration was 0%, 2.5%, 5%, 10%, 15%, and 20%. Solid diamond = UC781; 
blank square = UC781 with 2.5% HPβCD; black star=UC781 with 5.0% HPβCD; black 
dash=UC781 with 10% HPβCD; solid triangle = UC781 with 15% HPβCD; solid square= 
UC781 with 20% HPβCD.  
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Figure 2-6.  Effect of MβCD concentration on the UV absorbance of UC781 in aqueous solution 
 The MβCD concentration was 0%, 2.5%, 5%, 10%, 15%, and 20%. Solid diamond = UC781; 
blank square = UC781 with 2.5% MβCD; black star=UC781 with 5.0% MβCD; black 
dash=UC781 with 10% MβCD; solid triangle = UC781 with 15% MβCD; solid square= UC781 
with 20% MβCD.  
 
UV results showed that the UC781 UV absorbance intensity increased in the presence of 
βCD, HPβCD, or MβCD.  No baseline absorption was observed for any of the cyclodextrins 
studied under these experiment conditions.  The baseline UV absorption profile for UC781 was 
modified in a concentration dependent manner upon addition of cyclodextrin.  A maximum in 
UV absorption was observed in the presence of low cyclodextrin concentrations (0.25% βCD, 
2.5% HPβCD and 10% MβCD). However, in the presence of higher cyclodextrin concentrations, 
no further increase in UV absorption was seen.  This variation in absorption intensity observed at 
varied concentration of cyclodextrins may be due to the high concentration of alcohol in the 
solvent system (50%).  Further studies are needed to clearly define this phenomenon.  
The change in UV absorption of UC781 in the presence of the cyclodextrins indicated the 
formation of inclusion complexes, and suggested that this complexation involves the UC781 
chromophore entering the cyclodextrin cavity (Chow and Karara,1986; Iglesias,2006; Liu et 
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al.,2006). A linear relationship of CCD/ΔA vs. CCD was observed indicating a 1:1 stoichiometric 
proportionality for the UC781: CD complexes (data not shown). The complexation constant 
values (K1:1) calculated from the Scott Equation were found to be 17, 7, and 10 M-1 for βCD, 
MβCD, and HPβCD, respectively. The value of K1:1 calculated from UV data was lower than 
that obtained from the phase-solubility data. This difference is most likely due to the presence of 
ethanol in the UV experiments. Ethanol was not present in the system for phase solubility 
studies.  
2.3.3 DSC Analysis of UC781 Complexes 
Differential scanning calorimetry (DSC) has been one of the most widely used calorimetric 
techniques for studies of the interactions between drugs and βCDs in the solid state (Ghorab and 
Adeyeye,2001). In this study, DSC was applied to evaluate the interaction between UC781 and 
each of the three different cyclodextrins in the solid state.  
DSC thermograms for each pure component, physical mixtures, and UC781: cyclodextrin 
complexes are shown in Figure 2-7 to Figure 2-9. The DSC isotherms of the pure components 
were characterized by a sharp endothermic peak for UC781 at 131℃. No endothermic peaks 
were observed for MβCD and HPβCD due to their amorphous nature. The βCD endothermic 
peak was not observed due to the freeze-dry preparation. The broadening of the UC781 
endothermic curve in DSC thermograms obtained for physical mixtures of either HPβCD or 
MβCD with UC781 may be due to carrier induced drug amorphorization. No characteristic 
UC781 endothermic curve was observed in DSC thermograms for solid complexes of UC781. 
This can be associated with the formation of UC781: βCD (Figure 2-7), UC781: HPβCD (Figure 
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2-8), and UC781: MβCD (Figure 2-9) inclusion complexes in the solid state. Although these 
results suggest complex formation, it is important to recognize that in these studies, 
uncomplexed UC781 in the amorphous state may also exist in this solid-state mixture. However, 
combined  results obtained from DSC studies with those obtained from phase solubility and UV 
studies show that the complexed form of UC781 is the major product in the solid-state mixture.  
8 8 1 1 0 1 3 2 1 5 4
T e m p e ra tu re  oC
 U C 7 8 1
 P h y s ic a l M ix tu re  o f  U C 7 8 1  w ith  β C D
 C o m p le x  o f  U C 7 8 1  w ith
 β C D
 β C D
 
Figure 2-7. DSC thermograms for UC781: βCD physical mixture, βCD, UC781, and UC781: βCD 
complex. 
Solid line = UC781; Dashed line =Physical Mixture of UC781 and βCD ; Dotted line =UC781 
complex with βCD; dot and dash line = βCD. 
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Figure 2-8. DSC thermograms for UC781, UC781: HPβCD physical mixture, UC781: HPβCD 
complex, and HPβCD. 
Solid line = UC781; Dashed line =Physical Mixture of UC781 and HPβCD; Dotted line =UC781 
complex with HPβCD; dot and dash line = HPβCD. 
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Figure 2-9. DSC thermograms for UC781: MβCD physical mixture, UC781: MβCD complex, MβCD, 
and UC781. 
Solid line = UC781; Dashed line =Physical Mixture of UC781 and MβCD; Dotted line 
=UC781 complex with MβCD; dot and dash line = MβCD. 
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2.3.4 FTIR Studies of UC781 Complexes 
Fourier Infrared spectrophotometry (FTIR) has been employed as a useful tool to identify 
drug excipient interactions (Hsiue et al.,1998; Sarisuta et al.,2006).  In these reports, the use of 
FTIR spectroscopy to provide important information regarding the confirmation of inclusion 
complex formation of βCDs with drug molecules is demonstrated.  Figure 2-10, Figure 2-11, and 
Figure 2-12 show the FTIR spectra of the three different UC781-βCD complexes as compared 
with spectra obtained for pure UC781, pure βCD, and a physical mixture of the two. In the FTIR 
spectrum for pure UC781, the absorption observed at 3437 cm-1 can be attributed to the 
stretching vibrations (v) of the N-H bond.  The peak observed in this spectrum at 1645 cm-1 
reflects N-H group bending vibrations (δ). FTIR spectrums for the complexed forms were shown 
to have a broadening in the v (N-H) and δ (N-H) bands obtained.  In addition, a slight red shift 
was observed for each of these bands in the spectrums obtained for the complexes. These studies 
revealed that the N-H group of UC781 is specifically involved in the interaction between UC781 
and each of the βCDs studied.  The FTIR spectrums for the complexes showed a substantial 
decrease in intensity for the two bands associated with the UC781 N-H group.  This result 
suggests the formation of new supramolecular compound.  Additionally, no new peaks were 
observed in the spectra of all UC781-βCD complex systems, indicating no chemical bonds were 
created in the complex formation. Thus, the FTIR spectra indicate that UC781 molecule is 
partially (NH group) included into the βCD cavity to form the inclusion complex. 
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Figure 2-10. FTIR spectra of UC781, βCD and their complex. 
Solid line = UC781; Dashed line =βCD; Dotted line = Physical Mixture of UC781 and βCD; 
Dot and dash line = UC781 complex with βCD  
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Figure 2-11. FTIR spectra of UC781, HPβCD and their complex. 
Solid line = UC781; Dashed line =HPβCD; Dotted line = Physical Mixture of UC781 and 
HPβCD; Dot and dash line = UC781 complex with HPβCD 
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Figure 2-12. FTIR spectra of UC781, MβCD and their complex. 
Solid line = UC781; Dashed line =MβCD; Dotted line = Physical Mixture of UC781 and 
MβCD; Dot and dash line = UC781 complex with MβCD 
2.3.5 2D ROESY NMR Spectra Studies of UC781 Complexes 
2D ROESY was conducted to predict the UC781: βCD complex structure in DMSO-d6. 
Figure 2-1 shows the numbered protons of the UC781 molecule. The entire NMR spectrum is 
shown in Figure 2-13.  Cross-peaks were observed between the 5,6,7 protons on the benzene ring 
of UC781 and the 3’,5’ protons of βCD (Figure 2-14) and between the N-H proton of UC781 and 
OH2, OH3 of βCD (Figure 2-15) indicating very close interaction of UC781 and βCD in the 
liquid state. This suggests that the complex formed between UC781 and βCD involves the 
aromatic ring and NH group of UC781 entering the βCD cavity. These cross-peaks were not 
observed in spectra obtained for pure UC781 or pure βCD. Figure 2-16 shows a molecular 
simulation of the association of UC781 and βCD in the complex form. 
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Figure 2-13. 2D ROESY spectrum of a mixture of 1.0×10-2M UC781 and βCD. 
Annotated cross-peaks indicate intermolecular interactions between UC781 and βCD. 
 
Figure 2-14. 2D ROESY spectrum of a mixture of 1.0×10-2M UC781 and βCD. 
Annotated cross-peaks indicate intermolecular interactions between benzene ring (H5, H6, H7) of 
UC781 and H3’, H5’ of βCD. 
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Figure 2-15. 2D ROESY spectrum of a mixture of 1.0×10-2M UC781 and βCD. 
Annotated cross-peaks indicate intermolecular interactions between NH of UC781 and OH2, OH3 of βCD. 
 
 
Figure 2-16. Molecular simulation of UC781:βCD complex created using CACHE docking software.  
Due to random substitution of the βCD derivatives MβCD and HPβCD, NMR studies were 
conducted for the UC781: βCD complex only. Given the extremely low solubility of UC781 in 
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D2O and the same for βCD in deuterated organic solvent, high-quality NMR spectra would not 
be possible using D2O or other deuterated co-solvent. Therefore the drug and βCD were 
dissolved in DMSO-d6, as both βCD and UC781 have a high degree of solubility in this solvent.  
In addition, the relative magnitude of the dielectric constants of DMSO and H2O (ε=46.8 and 80, 
respectively) are similar; therefore essential interactions of UC781 with βCD in DMSO should 
be similar to those in water (Matsui et al.,1994; Miyake et al.,1999).  Combinding results from 
2D ROESY, solubility, UV, IR spectroscopic, and DSC, it is showing that the benzyl ring of 
UC781 is included into the βCD cavity while the NH group of the drug interacts with OH2 and 
OH3 of βCD on the primary side as shown in Figure 2-16. This suggests that the molecule of 
UC781 enters cavity of beta-cyclodextrin when the inclusion complex is formed, hence 
demonstrating that UC781 has a preferred fixed orientation within the cyclodextrin cavity.  
2.3.6 HIV Reverse Transcriptase (RT) Inhibition Analysis of UC781: HPβCD Complex 
An in vitro HIV reverse transcriptase inhibition assay was used to study the anti-HIV 
activity of the complexed form of UC781 with HPβCD compared to the non-complexed form of 
UC781. These studies were conducted only for the UC781:HPβCD complex based on the cell 
toxicity observed for βCD and MβCD (Chapter 4 and 5).  In these studies, the UC781 
concentration in the complex was varied (1.5, 3.0, and 6.0μg/ml).  No RT inhibition activity was 
observed for either the control (phosphate buffered saline) or cyclodextrin alone (2% HPβCD).  
Figure 2-17 shows that the inhibition of RT by the UC781: HPβCD complex is dose-
dependent. Currently, a UC781-containing gel product (50 μg/ml of UC781 dispersed in an 
aqueous based gel matrix) developed by Biosyn, Inc is being evaluated as a microbicide product 
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in Phase 1 clinical trials overseen by CONRAD. We used this gel to compare inhibitory activity 
with three different UC781:HPβCD complexes (containing 1.5, 3.0 or 6.0 µg/ml UC781). The 
half maximal inhibitory potency (IC50) for each was calculated. As shown in Figure 2-18, the 
inhibitory activity of each of the UC781:HPβCD complexes was substantially better (up to 10-
fold) than that of the gel formulated drug (p<0.01). We hypothesize that this enhanced 
bioactivity is due to the increase in aqueous solubility of the UC781:HPβCD complexes as 
compared to that of the non-complexed UC781 in the aqueous based gel matrix.  
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Figure 2-17. The reverse transcriptase inhibition activity of non-complexed UC781 gel 
vs. UC781: HPβCD complex. 
                       
UC781 HEC gel 50.0 μg/ml (♦); UC781 complex 6.0 μg/ml (■); UC781 complex 3.0 μg/ml 
(▲); UC781 complex 1.5 μg/ml (∆)  
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Figure 2-18.  Calculated IC50 for UC781 in formulations and complex. 
 
Non-complexed UC781 Gel formulation (50.0 μg/ml UC781) (  ); 
UC781:HPβCD complex (6.0 μg/ml) ( ); UC781:HPβCD complex (3.0 
μg/ml) ( ); UC781:HPβCD complex (1.5 μg/ml) ( ).  ** p<0.01 
compared to Gel formulation of non-complexed UC781  
 
Ultimately, it is important to demonstrate that the complex of UC781 still maintains the 
bioactivity of UC781.  For this reason, a series of in vitro HIV reverse transcriptase inhibition 
studies were conducted.  These studies showed that the complexed UC781 can greatly enhance 
the RT inhibition of UC781 as compared with that of non-complexed UC781. This enhanced 
bioactivity is most probably associated with the enhanced water solubility of UC781 obtained by 
the complexed form.  
2.4 CONCLUSIONS   
This study shows that UC781 can form inclusion complexes with various cyclodextrins 
including βCD, HPβCD, and MβCD, and that these complexes provide substantial increases in 
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the aqueous solubility of the virtually water-insoluble drug. Phase solubility and 2D 1H NMR 
data suggest that the UC781: cyclodextrin interaction involves stable 1:1 stoichiometric 
complexes of the cyclodextrin and UC781. Importantly, the inhibitory potency of the 
cyclodextrin complexed form of UC781 was greatly increased in comparison to that of the non-
complexed form in the aqueous based gel formulation currently being evaluated in Phase 1 
clinical trials.   
Our data suggest that the cyclodextrin complexation has the potential to greatly reduce the 
amount of UC781 required in a formulated biologically active microbicide product without 
significant loss of biological activity, leading to reduced cost per dose of the microbicide 
product. Furthermore, the dramatic increases in aqueous solubility of UC781 afforded by the 
complexation approach will enable new formulation technologies to be tested in the development 
of new more effective anti-HIV microbicide products.   
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3.0  THERMODYNAMIC PROPERTIES OF UC781: βCD 
COMPLEXES  
3.1 INTRODUCTION 
3.1.1 Determination of Thermodynamic Properties of UC781:Cyclodextrins Complexes 
Using HPLC  
A β-cyclodextrin based drug delivery system was developed to enhance the aqueous 
solubility of UC781 was described in Chapter 2. We confirmed and characterized the formation 
of complexation of UC781 with βCD and its derivates. There are two questions which need to be 
addressed for the further development of this βCD based formulation: which cyclodextrin is the 
most efficient agent for the complexation of UC781? And, How can we maximize the solubility 
of UC781 using lower concentrations of cyclodextrin?  
The complexation of UC781 with βCD must be further investigated before we can 
answer the questions above.  As mentioned previously in Chapter 2, the main driving force for 
the complex formation is the replacement of water molecules in the cavity of CDs with drugs or 
guest molecules. This replacement process can be evaluated through thermodynamic parameters.  
Thermodynamic study of UC781: cyclodextrin complexation provides information needed to 
understand the behavior of complexation in the aqueous phase, optimize complexation 
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conditions, and choose the cyclodextrin with the best complexation efficiency.  Furthermore, the 
understanding of the thermodynamic properties and mechanism of UC781:cyclodextrin 
complexation is a the key factors for the complexation processing during formulation, from 
bench scale to scaled-up manufacture.  
The thermodynamic behavior of the βCD complexation with flavonoids using 
chromatographic methods had been previously reported. These studies used thin layer 
chromatography (Guo et al.,2004). The use of HPLC has been reported to study the lipophilicity 
of drugs directly (Cimpan et al.,2000; Liu et al.,2004; Musilek et al.,2008). Chapter 3 describes a 
newly developed high performance liquid chromatography (HPLC) method for the study of the 
thermodynamic properties of the complexation of UC781 with βCD and its derivatives. The 
primary advantage of the HPLC method is that it requires only small quantities of both drug and 
CDs. The secondary advantage is that thermodynamic assessment can be rapidly acquired. The 
complexation constants of UC781 with CDs were determined for comparison. The effect of βCD 
and its derivatives on lipophilicity change of UC781 was also investigated. These results 
facilitate comparison of the complexation ability of different CDs with UC781. The 
thermodynamic parameters of the complexation process were calculated and enthalpy-entropy 
(ΔH-ΔS) relationships were plotted. The results obtained for these thermodynamic studies 
provide a deeper understanding of the complexation of UC781 with βCD and its derivatives and 
offer information for the formulation development of βCD based drug delivery system for 
UC781. 
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3.1.2 HPLC Theory for The Complexation Study 
High-performance liquid chromatography (or High Pressure Liquid Chromatography, 
HPLC) is a separation technique using column chromatography to separate, identify, and 
quantify compounds. Retention time of drugs in HPLC varies depending on the interactions 
between the stationary phase, the molecules being analyzed, and the solvent(s) used. In a given 
HPLC system, retention time (tR) can be thought of as the character of the drug itself, reflecting 
the interaction between drug and the stationary phase. Retention time changes reflect differences 
in how  the drug interacts with the stationary phase.  
In addition to tR, another important parameter used in this study is "capacity factor" (Kc). 
Historically, a slightly different retention parameter, Kc was introduced by the analogy based on 
the liquid partitioning theory and is widely accepted in chromatographic practice. Kc is 
dimensionless and independent of any geometrical parameters of the column or HPLC system. It 
can be considered a thermodynamic characteristic of the solid phase-compound-mobile phase 
system (Kazakevitch and Eltekov,1988).  Kc is defined by Equation (3-1) (Swadesh,2000)  
m
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−==                          3-1 
Where s is the solid phase and m is the mobile phase; Ms is the mass of analyte in the 
solid phase, Mm is the mass of analyte in the mobile phase; t is the retention time of drug (tdrug) 
and mobile phase (tm).  
In a given mobile phase, the following equilibrium can be reached between drug and 
solid phase. The mass balance can be expressed as Equation (3-2) 
                                             [Drug]+[S] ⇔ [Drug-S]      
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Where S is the solid phase of column; K1 is the binding constant for drug and solid phase. 
When cyclodextrin is added into the mobile phase, another equilibrium can happen between drug 
and CD, expressed as Equation (3-3) 
                                        [Drug] + [CD] ⇔ [Drug-CD]    
                                         
]][[
][
1:1 CDDrug
DrugCDK −=                          3-3 
K1:1 is the complexation constant of drug and cyclodextrin; the total drug in the HPLC 
system can be given by Equation (3-4) 
[Drug] Total = [Drug-S] + [Drug]m+ [Drug-CD]               3-4 
Combining equation (3-4) and (3-1) obtains Equation (3-5) and (3-6) 
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The drug concentration and retention time are now correlated with each other through Kc. Re-
arranging the expression gives an Equation 3-7 and 3-8  
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Thus, plotting 
m
m
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−drugt
 vs. [CD] will results in a linear relationship between the 
retention time of Drug (
m
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−drugt
) and βCD concentration ([CD]) where the slope =
1
1:1
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⋅  
and intercept =
1][
1
KS ⋅ . K1:1 under the experimental conditions can be calculated using Equation 
(3-9) 
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3.2 MATERIALS AND METHODS 
3.2.1 Materials  
UC781 was provided by Biosyn Co. Ltd. (Huntington, PA). βCD (MW: 1134), MβCD 
(MW: Approx. 1320; Mean degree of substitution: 1.7-1.9) were purchased from Spectrum 
Chemical Company (Gardena, CA); HPβCD (MW: Approx. 1380 and Mean degree of 
substitution: 0.8) was obtained from Sigma Aldrich (St Louis, MO). All other reagents used were 
of reagent grade and all solvents were of HPLC grade. Milli-Q water was used to prepare buffer 
solutions and other aqueous solutions. 
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3.2.2 Methods  
HPLC analysis for UC781 was conducted using a  Waters HPLC system equipped with 
an auto injector model Waters 717, and a Waters 2487 dual wavelength (λ) absorbance detector 
at 300 nm  (Waters Corporation, Milford, MA). Separation of the compound in the experiment 
was achieved by using an Alltech ODS-C8 column (4.6 mm i.d ×7.5 mm, 5μm, Columbia, MD). 
A mobile phase of acetonitrile (ACN) / Milli-Q water (30:70 v/v) containing different CD 
concentrations at a flow rate of 1.0 ml/min was used. The column temperature was controlled 
using a water bath with a range of ± 0.1 oC. UC781 was dissolved in ACN at a concentration of 3 
μg/ml. A10 μl aliquot of UC781 ACN solution was injected for the thermodynamic study. The 
retention time of UC781 was recorded for calculation of the thermodynamic parameters 
calculation. 
3.3 RESULTS AND DISCUSSION  
3.3.1 Complexation Behavior of Cyclodextrins with UC781 
Effect of cyclodextrins concentration on the retention time values for UC781 is shown in 
Table 3-1. A measurable decrease in UC781 retention time was observed with increasing 
cyclodextrins concentration in mobile phase. This result showed that the interaction between 
UC781 and the solid phase of the HPLC column was interfered with due to the complexation of 
UC781 with all three cyclodextrins in mobile phase.  In addition, the retention time of UC781 
decreased more quickly in MβCD containing mobile phase than in HPβCD containing mobile 
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phase at the same cyclodextrins concentration. This result showed a stronger complexation 
ability of MβCD with UC781 than that of HPβCD. It has been shown that both HPβCD and 
MβCD exhibit better solubility properties than native βCD in mobile phase. The effect of βCD 
on retention time was not compared with MβCD and HPβCD due to its limited solubility in 
mobile phase. 
Table 3-1. Effect of CDs on the retention time of UC781 in HPLC 
  Concentration % 0.5 1 2 4 5 
MβCD 34.18 31.36 26.47 19.81 17.65 
HPβCD tR  (min) 32.89 31.49 30.62 28.52 27.25 
 Concentration % 0.1 0.2 0.3 0.4 0.5 
βCD tR (min) 36.99 34.67 33.68 31.84 32.20 
  
3.3.2 Effect of Cyclodextrins on The Lipophilicity of UC781  
In this chapter, a HPLC method for the determination of partition coefficient was used to 
evaluate the impact of different cyclodextrins on the lipophilicity of UC781. 
The partition coefficient is a parameter that is used to describe the degree of lipophilicity 
of a compound typically expressed as log P.  Specifically it is experimentally determined by 
evaluating the distribution of a compound between two immiscible phases (such as octanol and 
water).  Drug molecules with larger log P values are more lipophilic and tend to be less able to 
be dissolved into water. This parameter is useful in estimating distribution  and permeability of 
the drug within the body (Alhaique et al.,1977; Cross et al.,2003; Kretsos et al.,2004).  However, 
the traditional shake-flask method (Cripe et al.,1987; Unger et al.,1978), does not provide a rapid 
determination of lipophilicity.  In addition, this method requires a large amount of compound 
when the compound is very lipophilic.  A HPLC method was used to rapidly determine log P 
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from Kw (Ayouni et al.,2005; Musilek et al.,2008). Kw is the capacity factor when the mobile 
phase is pure water.  It has been demonstrated that the extrapolated logarithm of the capacity 
factor for a pure aqueous eluent (log kw) gives the best correlation with log P (Liu et al.,2005b). 
Moreover, logarithm of the capacity factor (log Kc) and log Kw can be expressed through 
equation (3-10) 
wc KAK log]C[log +⋅=     3-10 
Where A is the slope, C is the volume fraction of organic solvent  in mobile phase and 
log Kw the intercept of the regression curve. In these studies, the CD concentration change was 
used instead of the change in organic solvent for the calculation of log Kw since it was desired to 
determine the impact of CD on lipophilicity change of UC781.  The log Kw is a fixed value 
obtained from equation (3-10) in these studies. Therefore, the slope values obtained from linear 
regression can be compared to evaluate the complexation ability of the three cyclodextrins with 
UC781.  
Figure 3-1 represents the logarithm of the Kc of UC781 as a function of CD concentration 
in the mobile phase. In the presence of cyclodextrins in the mobile phase, log Kc of UC781 
decreased with increasing CD concentration. Linear relationships between log Kc and CD 
concentration in the mobile phase were observed, indicating that a classical reverse phase elution 
mechanism is operating (Clarot et al.,2000; Horvath et al.,1976).  The absolute value of slopes 
(Table 3-2) obtained in the linear regression treatment followed an order of MβCD > βCD 
>HPβCD, which also corresponds with the retention time changes shown in Table 3-1.   This 
phenomenon can be explained by the alteration of hydrophobic interaction between UC781 and 
the solid phase in the HPLC column, which is induced by the complexation of UC781 with CD 
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in the mobile phase. The results also indicate that MβCD has a better ability to form a complex 
with UC781 under these experimental conditions. 
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Figure 3-1.  Influence of CDs on the lipophilicity of UC781 at 30oC 
 
Table 3-2. Slopes, logKw, and correlation coefficients (r2) obtained for linear regression treatment of 
logKc for different CDs in the mobile phase. 
 slope log Kw r2 
βCD -0.066 2.01 0.96 
MβCD -0.057 2.01 0.99 
HPβCD -0.020 1.99 0.99 
 
3.3.3 Effect of Temperature on The Complexation of UC781 with Cyclodextrins  
The effect of temperature on the inclusion constants obtained for UC781 with different 
CDs is shown in Figure 3-2. The Gibbs free energy (ΔG) values were calculated from the 
inclusion constants Equation (3-11) and are shown in Figure 3-3.   
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1:1ln KRTG −=Δ          3-11 
Where R is the gas constant, and T is the temperature in Kelvin; K1:1 is the complexation 
constant of UC781 with βCD. K1:1 and absolute ΔG value decreased with increasing temperature. 
The results indicate that higher temperatures are unfavorable for the inclusion process. This can 
be explained by the increased movement of molecules at high temperatures, which leads to 
disassociation.  
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Figure 3-2.  K1:1 change of UC781 with CDs in HPLC at different temperature 
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Figure 3-3. Temperature vs. Gibbs free energy change on the complexation process of UC781 with 
three cyclodextrins 
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All ΔG values obtained for inclusion processes as shown in Figure 3-3 are negative. This 
suggests that the inclusion process proceeds spontaneously. From ΔG values, other 
thermodynamic parameters can be obtained using the Van’t Hoff Equation –(Equation (3-12)). 
Enthalpy (ΔH) and entropy (ΔS) changes for complexes can be calculated using this equation: 
SH
T
G Δ−Δ=Δ
T
1
        3-12 
From Equation (3-12), the slope and the intercept of the plot of ΔG/T vs. 1/T are −ΔS and 
ΔH, respectively. Figure 3-4 shows the plot of ΔG/T vs. 1/T for the three CDs studied. The ΔH 
and ΔS values obtained graphically are shown in Table 3-3. Negative values for ΔH mean that 
the inclusion process is exothermic; therefore, low temperatures are more suitable for the 
inclusion process. The absolute value of ΔH is much greater than ΔS, suggesting that the 
inclusion process of UC781 with CD is primarily an enthalpy driven process.  
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Figure 3-4.  Van’t Hoff equation for UC781 and CDs complex study 
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Table 3-3. Enthalpy-Entropy change of UC781 complex with CDs. 
 ΔH (J/mol) 
ΔS  
( J·mol-1·K-1) 
βCD -29.42 -0.072 
MβCD -11.02 -0.013 
HPβCD -20.64 -0.052 
The enthalpy-entropy compensation relationship has been observed in these host-guest 
combinations for βCD complex (Connors,1997). Enthalpy-entropy compensation is the 
phenomenon in which the change in enthalpy is offset by a corresponding change in entropy 
resulting in a smaller net free energy change, and it is believed to play an important role in the 
reactions in solution (Inoue et al.,1993a; Inoue et al.,1993b). The Enthalpy-entropy 
compensation is also attributed to the interactions with water molecules in the βCD cavity 
(Lemieux et al.,2007).  In this study, ΔH is plotted against ΔS to give a straight line (Figure 3-5). 
The slope is the compensation temperature, T=304 K. It demonstrates that the inclusion process 
also displays an enthalpy-entropy compensation effect (Luscher-Mattli,1982). 
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Figure 3-5.  Enthalpy-entropy plots of UC781-CD inclusion complexes 
 81 
3.4 CONCLUSIONS  
The complexation interaction between UC781 and three different cyclodextrins was 
investigated systematically using HPLC method. This method provides a rapid evaluation of the 
thermodynamics of inclusion and requires minimal drug substance. The inclusion ability and 
hydrophilicity enhancement effect of cyclodextrins on UC781 were found to follow the rank 
order of MβCD > βCD > HPβCD. The thermodynamic behavior of UC781 and all three 
cyclodextrins studied were shown to be enthalpy driven processes. Enthalpy-entropy 
compensation was also observed for complexation of UC781 with cyclodextrins indicating a 
replacement of water molecules in cyclodextrin cavities with UC781. These results provide a 
better understanding of the inclusion process of  UC781 with cyclodextrins. Additionally, the 
developed methods provide a novel means for evaluation of other hydrophobic drug candidates 
for their complexation ability with cyclodextrins.  
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4.0  EFFECT OF pH, POLYMERS, AND PREPARATION METHOD 
ON THE COMPLEXATION OF UC781  
4.1 INTRODUCTION 
As mentioned in Chapter 2 and Chapter 3, UC781 is a very hydrophobic compound 
belonging to Class II of the Biopharmaceutical Classification System (Deferme et al.,2002). Its 
intrinsic solubility is lower than 30 ng/ml. No aqueous parenteral formulation for UC781 is 
currently available for clinical use. Therefore, we are trying to develop a βCD based drug 
delivery system to enhance the solubility of UC781.  
Cyclodextrins (CDs) are widely used in the pharmaceutical industry for drug 
complexation. Complexation with CDs is reported to enhance drug aqueous solubility (Loftsson 
and Brewster,1996), permeability (Sigurðoardóttir and Loftsson,1995) , and stability (Kang et 
al.,2002). Cyclodextrin containing dosage forms may also increase drug concentration in plasma, 
increase bioavailability, and create formulations that offer more effective and less frequent 
treatment schedules for hydrophobic molecules.  
Although CDs can provide many benefits in the formulation development, there are some 
practical limitations on the application of CDs in formulations.  For example, in solid oral dosage 
froms, the total amount of CD in each dosage cannot be over 600 mg. Generally, the weight of 
an oral solid dosage form is considered not to exceed 800 mg (Loftsson and O'Fee,2003).  
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Therefore, if a drug: βCD complex has only a very low complexation constant, more βCD is 
needed to form a complex with the drug than in the case of a high complexation constant in the 
formulation. It will be very hard to design a formulation with a large dosage form with drug:βCD 
complex due to the mass limitations of traditional oral dosage.  
For vaginal formulations, mass limitation is more critical than in oral dosage due to the 
limitation of the vaginal cavity size and amount of bioliquid present. Too much cyclodextrin will 
not only cause difficulty in formulation design, but will also lead to toxicity and damage to the 
vaginal epithelium by depletion of cholesterol from cell membrane. Therefore, enhancement of 
the complexation capacity of the chosen CDs to reduce the amount of CDs in formulation is of 
practical importance. 
The objective of these studies reported in this chapter is to optimize the complexation 
process and obtain the most efficient complexation condition for further formulation 
development. UC781: βCD complexes were developed and evaluated in Chapter 2 and Chapter 
3. In this study, βCD and its derivatives (HPβCD and MβCD) were complexed with UC781 to 
increase the aqueous solubility of UC781. pH variation, complexation methods used, and  
incorporation water-soluble polymers on the complexation efficiency were investigated to 
optimize the complexation of UC781 with cyclodextrin. The in vitro RT inhibition activity of 
UC781: HPβCD and UC781: MβCD complexes was also determined to establish that formed 
complexes maintained bioactivity.   
 84 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
UC781 was provided by Biosyn Co. Ltd. (Huntington, PA). βCD (MW:1134), 
,MβCD(MW: 1320; Mean degree of substitution: 1.7-1.9) , HPβCD (MW: 1380 and mean 
degree of substitution: 0.8), hydroxypropyl methylcellulose (HPMC) (Mn: 10,000; viscosity: 
6,000 mPa.s 2 % w/w in water), hydroxyethyl cellulose (HEC) (1,500 mPa.s; 5% w/w in water), 
polyvinyl alcohol (PVA) (MW: 9,000-10,000, 80% hydrolyzed), polyvinylpyrrolidone K30 
(PVP K30) (MW: ~40,000), and PVP K90 (MW: ~360000) were purchased from Sigma Aldrich 
(St. Louis, MO). 2 ml autosampler screw-thread glass vials were obtained from FisherScientific 
Inc. (Waltham, MA). All other reagents used were of reagent grade and all solvents were of 
HPLC grade. Milli-Q water was used to prepare buffer solutions and other aqueous solutions. 
 
4.2.2 Methods 
4.2.2.1 High Performance Liquid Chromatography (HPLC) Analysis for UC781  
HPLC analysis for UC781 was conducted as follows: A Waters HPLC system equipped 
with an auto injector model Waters 717 and a Waters 2487 dual wavelength (λ) absorbance 
detector at 275 nm was used (Waters Corporation, Milford, MA). Separation of the compound in 
experiment was achieved by using an Alltech ODS-C18 column (4.6 mm i.d ×250 mm, 5μm, 
Columbia, MD). A mobile phase of acetonitrile/ Milli-Q water (75:25 v/v) at a flow rate of 1.0 
ml/min was used.  
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4.2.2.2 Methods for UC781: Cyclodextrins Complexation 
Most cyclodextrin complexes are formed in the presence of water. Through repulsive 
interactions, water provides the main driving force for complexation.  A secondary role for water 
is that it serves as a medium for dissolution of both the cyclodextrin and the drug molecule. A 
number of methods have been used for complex formation.  These include coprecipitation, slurry 
or paste formation (ex. kneading), and dry mixing methods (ex. spray drying or lyophilization) 
(Hedges,1998).  A heating method (autoclaving) has also been used for complex formation.  This 
method offers an enthalpy driven process of complexation (Hassan et al.,1990).  It has been 
previously shown that the choice of complexation method can impact complexation efficiency 
(Moyano et al.,1995).  For this reason, it is important to evaluate several methods for 
complexation optimization. 
In this chapter, four specific complexation methods were evaluated: kneading, shaking, 
autoclaving, and lyophilization.  In the kneading method, 300 μg UC781 was mixed with 15 mg 
βCD, or 150mg HPβCD or 150 mg MβCD in an agate mortar. 50 μl ethanol was added as a 
wetting agent to form a slurry.  The UC781 and βCD paste was then ground by pestle. 1 ml of 
Milli-Q water was added drop by drop while grinding until cyclodextrin was totally dissolved. 
The resulting solution was filtered with a 0.45 μm filter for HPLC analysis.  
In the shaking method, 300 μg UC781 was mixed with 15 mg βCD, or 150 mg HPβCD 
or 150 mg MβCD in a 2 ml glass vial. 1 ml Milli-Q water was added with 50 μl ethanol as a 
wetting agent. All vials were shaken for 72 h at room temperature on a vertical shaker at a speed 
of 50 rpm. Solutions were then filtered with a 0.45 μm nylon filter for HPLC analysis.   
In the autoclave method 300 μg UC781 was mixed with 15 mg βCD, or 150 mg HPβCD 
or 150 mg MβCD in a 2 ml glass vial. 1 ml Milli-Q water was added with 50 μl ethanol as a 
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wetting agent. All vials were autoclaved at 250 °F for 15 minutes followed by shaking for 24 h 
on a vertical shaker at a speed of 50 rpm. The solution was then filtered with a 0.45 μm nylon 
filter for HPLC analysis. 
The lyophilization method involved mixing 300 μg UC781 with 15 mg βCD, or 150 mg 
HPβCD or 150 mg MβCD in a 2 ml glass vial. 1 ml NH3⋅H2O was then added into the vial to 
dissolve cyclodextrin and 500 μl ethanol was added to dissolve the UC781. The resulting 
solution was then frozen at -80 °C for 6 h until totally frozen. All vials were lyophilized at -51 
°C using a Labconco Freezone 6 lyophilizer (Kansas City, Missouri) for 48 h until all moisture 
was removed. Lyophilized powder was re-constituted into 1ml Milli-Q water. The solution was 
then filtered with a 0.45 μm nylon filter for HPLC analysis. All samples were prepared in 
triplicate. Data were expressed as mean ± SD.  
4.2.2.3 Phase Solubility Studies of UC781 with Cyclodextrins 
300 μg UC781 was added to sealed HPLC glass vials containing 1.0 ml of 10mM buffer 
(PBS for pH 7.0, boric acid buffer for pH 9.0, and PBS for pH 11.0) or distilled water with 
various concentrations of βCD, MβCD, and HPβCD (from 0 to 0.11 M). All vials were 
autoclaved for 15 min at 250 °F. The vials were then shaken on a horizontal rotary shaker at a 
speed of 50 rpm at ambient temperature (25 °C) for 24 h avoiding light. The solutions were 
filtered through a 0.45 μm filter for HPLC assay. Given that high pH systems are used in this set 
of experiments, it was necessary to replace the water portion of the mobile phase with 5.0 mM 
PBS buffer (pH 7.0) HPLC assay to keep the pH of the mobile phase stable. All samples were 
prepared in triplicate.  
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The complexation constant (K1: 1), according to the hypothesis of 1:1 stoichiometric ratio 
of complexation, was calculated from phase-solubility diagrams (Higuchi and Connors,1965) 
using the following Equation. (4-1): 
)slope1(S
slopeK
0
1:1 −=             4-1 
In this equation K1:1 is the complexation constant, So is the intrinsic solubility, and the 
slope is calculated from a graph of the dissolved drug concentration versus CD concentration in 
the medium. The intrinsic solubility value (So) of UC781 in the absence of CD was determined 
directly in aqueous media. Data were expressed as mean ± SD. 
4.2.2.4 Polymer Effects on UC781 Solubility (in HPβCD and MβCD Solutions) 
300μg UC781 were added into 1ml of 15% HPβCD and 15% MβCD solution with 
various concentrations of HPMC, HEC, PVA, PVP K30 or PVP K90 (from 0 to 1.0 %). 50 μl 
ethanol was used as a wetting agent.  All vials were autoclaved at 121 oC (250 °F) for 15 min 
followed by shaking for 24 h at room temperature on a vertical shaker at a speed of 50 rpm. The 
solution was then filtered with a 0.45 μm filter for HPLC analysis. All samples were prepared in 
triplicate.   
4.2.2.5 HIV-1 RT inhibition Assay for UC781 and Its Complexes in The Liquid State 
HIV-1 RT activity was determined using a fixed time assay. HPβCD or MβCD was 
dissolved in 10 mM pH 7.2 PBS buffer to obtain a 15% w/w solution. To 1 ml of this solution, 
UC781 was added such that final concentration was either 5 or 10 μg/ml . The solution was then 
autoclaved at 250 °F for 15 min followed by rotation at 50 rpm overnight at room temperature to 
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form the UC781: HPβCD or UC781: MβCD complex at 5   or 10 μg/ml. UC781 was dissolved 
in DMSO and then quickly dispersed into 10 mM PBS buffer served as a positive control. PBS 
buffer was used as the negative control. Test samples were mixed with reaction solution (50 μl 
total volume) containing 50 mM Tris-HCl (pH 7.8, 37 ºC), 60 mM KCl, 10 mM MgCl2, 10 
UI/ml of either poly(rA)-oligo(dT)12-18 and 20 μM [3H]TTP.  Reactions were initiated by the 
addition of 50 ng of RT. Reaction mixtures were incubated at 37 ºC for 20 min and then 
quenched with 200 μl of ice-cold 10% trichloroacetic acid (TCA) containing 20 mM sodium 
pyrophosphate. Quenched samples were left on ice for 20 min, then filtered using 1.2 μM glass 
fiber Type C filter multi-well plates (Millipore) and with 100% ethanol wash. The extent of 
radionucleotide incorporation was determined by liquid scintillation spectrometry (Wallace 1450 
Microbeta Jet Liquid scintillation, Perkin Elmer, Waltham, MA) of the dried filters. All samples 
were prepared in triplicate. Data were expressed as mean ± SD for analysis 
4.2.2.6 Statistical Analysis 
The 50% inhibitory concentration (IC50) analysis was done using nonlinear regression 
analysis (GraphPad PRISM; GraphPad Software, Inc. La Jolla, CA). Data were expressed as 
mean ± sd and analyzed with one-way ANOVA using Tukey’s multiple comparison. 
 89 
4.3 RESULTS AND DISCUSSION  
4.3.1 UC781 Cyclodextrins Complexes Formation Efficiency is Impacted by Method of 
Preparation  
Our previous studies showed that the complexation of UC781 with CD is an enthalpy 
driven process. The complexation is more favorable at lower temperature. Therefore, a 
temperature-controlled method can be used to enhance the complexation of UC781 with CD.  In 
addition, very poor solubility of UC781 greatly limited the interaction of UC781 and βCD 
molecules in solution. Therefore, the autoclave method was developed to offer a temperature 
controlled environment to enhance the solubility of UC781 and the interaction of UC781 with 
βCD in solution. Lyophilization method was also developed to be compared with traditional 
shaking and kneading methods for complexation optimization.  
Autoclave, lyophilization, kneading, and shaking methods of preparation of UC781:βCD 
complexes with βCD, HPβCD or MβCD were investigated. Figure 4-1 shows that the processing 
method can greatly affect the aqueous solubility of UC781. An autoclave method was found to 
be the most efficient for UC781 complex preparation. It can increase UC781 solubility to 5 to10 
times higher than other methods tested for βCD, 1 to 6 times for HPβCD, and 1 to 2 times for 
MβCD. The order of UC781 solubility enhancement obtained using different methods was 
autoclave > kneading > shaking > lyophilization for 1.5% βCD solution, autoclave > shaking > 
kneading >lyophilization for 15% HPβCD solution, and autoclave > kneading > lyophilization > 
shaking for 15% MβCD solution.  
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Figure 4-1.  Methods of preparation for complexation of UC781 with cyclodextrins 
The autoclave method is the most efficient preparation method for the complexation of 
UC781 with βCD, HPβCD or MβCD.  The complexation of UC781 with βCD is an enthalpy-
driven process. In the autoclave method, the displacement of water molecules in the cyclodextrin 
cavity with UC781 is enhanced during the cooling process of complex formation. Additionally, 
the solubility of UC781 may be increased at higher temperature (121 °C) increasing the 
interaction between UC781 and βCD molecules. Complexation of UC781 in aqueous media is 
highly associated with the CD species used in the experiment. In our study, MβCD showed the 
highest solubility enhancement of UC781 as compared to βCD and HPβCD.  
With these studies, an autoclave method for complexation was successfully developed. 
This method was based on our previous studies on the thermodynamic properties of UC781 
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complexation with βCD. The autoclave method can dramatically enhance the formation of 
complexed UC781 with cyclodextrins over other methods tested. 
4.3.2 pH Effect on the Complexation of UC781 with Cyclodextrins (Phase-Solubility 
Studies) 
The ionized form of compounds dissolves more easily in aqueous media than non-ionized 
forms of compounds. Therefore, UC781 solubility may be increased due to an active proton in 
NH group in the molecular structure. This solubility increase will also enhance the interaction 
between UC781 and CDs to increase the complexation of UC781 with CDs. The ionization 
diagram of UC781 at different pH values was simulated with an online software-Marvin 
calculator as shown in Figure 4-2. The pKa of UC781 is 9.14 ± 0.66.  Based on the simulation, 
we can predict that pH value must be over 9.14 to ionize the majority of UC781 hence enhancing 
the solubility of UC781.  
Studies showed that solubility of UC781 is a function of pH (Figure 4-3). The solubility 
of UC781 was increased at high pH values. For this reason, studies were conducted to evaluate 
the impact of pH on the complexation of UC781 with cyclodextrins.  
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Figure 4-2.  Relative proportions of UC781 and ionized UC781as a function of pH 
Diamond line (◆) shows the change of non-ionized form of UC781 according to pH 
change in solution; square line (■) shows the change of ionized form of UC781 according 
to pH change in solution. 
 
 
 
 
 
 
 
 
 
 
Figure 4-3.  pH effect on UC781 solubility in water 
 
The interaction of UC781 with βCD, HPβCD or MβCD in water and at pH 7.0, 9.0 and 
11.0 were evaluated using phase-solubility analysis for βCD (Figure 4-4), HPβCD (Figure 4-5) 
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and MβCD (Figure 4-6).  Qualitative assessment of relationships at all pH values studied shows 
a linear dependence of solubility on cyclodextrin concentration, indicating a linear increase in 
UC781 solubility behavior for both βCD and HPβCD. A positive curvature line was obtained for 
MβCD (The phase solubility diagram is described in the Appendix).  This result suggests that 
first order cyclodextrin complexation occurs for βCD and HPβCD.  Moreover, a higher order 
cyclodextrin complexation was observed for UC781: MβCD when high concentrations of MβCD 
were used in the system.  In addition, higher pH values enhanced the complexation of UC781 
with βCD by increasing UC781 solubility.  
 
Figure 4-4.  Phase solubility of UC781 with BCD at different pH values 
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Figure 4-5.  Phase solubility of UC781 with HPBCD at different pH values 
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Figure 4-6.  Phase solubility of UC781 with MBCD at different pH values 
In the absence of cyclodextrin, the solubility of UC781 in water is almost negligible 
(<3×10-5 mg/ml). In the presence of cyclodextrins in pure water, UC781 solubility was increased 
over 50 fold with of 1.5% w/v βCD (1.58×10-3 mg/ml), nearly 874 fold with of 15% w/v MβCD 
(2.62×10-2 mg/ml), and 316 fold with 15% (w/v) HPβCD (9.48×10-3 mg/ml).  
UC781 solubility increases with increasing pH, such as at  pH 7, 9, and 11, 
concentrations of 1.14×10-3, 3.63×10-3, and 7.82×10-3 μg/ml in 1.5% βCD solution; 6.36×10-3, 
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11.19×10-3, and 24.7×10-3 μg/ml in 15% HPβCD solution; 38.67×10-3, 44.97×10-3, and 
50.30×10-3 μg/ml in 15% MβCD solution, respectively, were obtained.  
The inclusion constants (K1:1), calculated using Equation 4-1, which is described in the 
methods section of this Chapter, are reported in Table 4-1. 
Table 4-1. Calculated K1:1 values for UC781 complexes with CDs at different pH value 
 pH 7 pH 9 pH 11 
βCD  3388.25 ± 64.51 11364.34 ± 323.02 23499.42 ± 1121.37 
HPβCD  2308.26 ± 129.00 5623.39 ± 64.73 11177.92 ± 1118.9 
MβCD  4841.51±645.29 7859.42± 64.6 16028.15 ±646.58 
For MβCD, inclusion constants were additionally calculated for a 1:2-complex (K1:2) 
using Equation 4-2 (data shown in Table 4-2). This equation was derived by Loftson et al 
(Loftsson et al.,2002).  
   ]CD[SKK]CD[SKSS 202:11:101:10t ⋅⋅+⋅⋅+= 4-2 
      In this equation, St and [CD] t correspond to total UC781 and MβCD concentration 
respectively; K1:1 and K1:2 represent the inclusion constants for the 1:1 and 1:2 complexes 
respectively. The MβCD complex displays a very high K1:1 value compared with K1:2; this 
corresponds to the observed significant increase in aqueous solubility in the presence of MβCD. 
The apparent low value of K1:2 as compared with that of K1:1 indicates that the 1:1 complex is the 
predominant form in the solution. 
Table 4-2. Calculated K1:1 and K1:2 values for UC781:MβCD complex 
   pH 7 pH 9 pH 11 
1:1 ratio K1:1 4841.51±645.29 7859.42± 64.6 16028.15 ±646.58 
K1:1 2605.56 ±644.71 3387± 64.47 5955.56 ±1289.42 
1:2 ratio K1:2 41±7.09 39.25± 1.3 7.67 ±11.62 
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In the current study, the enhancement of UC781 solubility is highly dependent on the 
type of βCD molecule used and pH of the complexation environment shown in Table 4-2.  The 
different inclusion constants found for the different cyclodextrin molecules studied indicate that 
the derivative groups in the cyclodextrin play an important role in the complexation of UC781 
into the CD cavity. Therefore, MβCD and HPβCD appear to be better host molecules for UC781 
inclusion. Additionally, due to the extremely low intrinsic solubility of UC781, the K1:1 may be 
overestimated.  
UC781 shows weak acidic property in aqueous solution based on the ionizable nitrogen 
in its structure. In solution, at pH equal to the drug’s pKa, protonated forms of UC781 are 
present in equilibrium with nonprotonated forms.  The pKa of UC781 is 9.14 ± 0.66 at ambient 
conditions. Data for phase solubility at different pH also suggest that the complexation may 
change as a function of UC781 ionization. At pH 7, the compound is essentially in the unionized 
form; K1:1 is the smallest, exhibiting the lowest stability of the complex. The results from the 
phase solubility analysis indicate that the total drug solubility progressively increased with 
increasing pH. As expected, the K1:1 values also increased with increasing pH. This can be 
explained by the progressive increase of the amount of drug in ionized form, which leads to 
increased solubility of UC781. These data suggested that complexation in a high pH enviroment 
enhanced the efficiency of UC781:βCD complexation due to the increased degree of ionization 
of UC781 and the increased solubility of UC781 in aqueous solution at high pH. 
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4.3.3 Water-soluble Polymers Enhance The Solubility of UC781 in Cyclodextrins 
Solutions  
UC781 solubility was greater at extremely high pH values than lower pH. However, the 
high pH values required for enhancement are not suitable for vaginal formulations. Therefore, 
methods other than pH adjustment have to be investigated for enhancement of UC781:CD 
complexation. Polymers are widely used as excipients in most drug formulations. Therefore, it is 
worthy of interest to investigate the possible effect of polymer incorporation into the 
cyclodextrin complexation medium.  
HPβCD and MβCD were selected in these experiments for their good water solutility. 
Effect of HPMC, HEC, PVA, PVP K30 and PVP K90 on UC781’s solubility in cyclodextrin 
solutions were investigated with  autoclave method, and are shown in Figure 4-7 for HPβCD and 
Figure 4-8 for MβCD. Quantitative measurement of UC781 concentration in cyclodextrin 
solutions was performed by HPLC. In the presence of polymers, the solubility of UC781 
increased for both HPβCD and MβCD solutions (15%), especially in the presence of HPMC. 
Incorporation of HPMC resulted in greater solubility enhancement of UC781 for both HPβCD 
and MβCD over the other three polymers. The solubility enhancement effect on complexed 
UC781 is dependent on the presence of different polymers.  A significant increase of HPβCD 
complexed UC781 solubility was obtained to a value of 33.71 μg/ml in the presence of 0.8 % 
HPMC, 15.8 μg/ml for 0.6%PVP K-30, 24.10 μg/ml for 1% PVP K-90  and 12.77 μg/ml for 1% 
PVA in 15% HPβCD, but only 8.28 μg/ml for 0.3% HEC. For 15% MβCD complexation, 
UC781 solubility was obtained to 185.9 μg/ml for 0.6% HPMC, 138 μg/ml for 1.0% PVP K-30, 
123 μg/ml for 0.8% PVP K-90, 184 μg/ml for 0.8 % PVA  and 181 μg/ml for 3% HEC.  The 
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order of UC781 solubility enhancement effect of different polymers is HPMC> PVP K90 > 
HEC, PVP K30 and PVA in 15% HPβCD solution, and HPMC, HEC, and PVA > PVP K90 and 
PVP K30 in 15% MβCD solution.   
 
 
 
 
 
 
 
Figure 4-7.  Polymer effect on UC781 solubility in a 15% HPβCD solution 
 
 
 
 
 
 
 
 
 
 
Figure 4-8.  Polymer effect on UC781 solubility in a 15% MβCD solution 
There are several possible explainations for the enhanced complexation efficiency 
observed in the presence of water-soluble polymers. Some polymers are known to be able to 
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interact with cycldoextrins via hydrophobic moieties in their polymer chains (Beheshti et 
al.,2007; Harada et al.,2005; Werner et al.,2004). Additionally, polymers were reported to inhibit 
the crystallization of water insoluble drugs (Khougaz and Clas,1999; Raghavan et al.,2001; Yeoh 
et al.,1994) into a super saturated state and to enhance the dissolution of drug into the aqueous 
phase. Therefore, βCD inclusion complexes can be impacted by their interaction with water-
soluble polymers forming ternary complexes containing the drug molecule, βCD, and the 
polymer (Loftsson and Brewster,1996; Patel and Vavia,2006). At low concentrations, polymers 
increase the aqueous solubility of the compound. They also enhance the complexation ability of 
CDs as shown through an increase in the complexation constants of the drug-cyclodextrin 
complexes by forming a ternary complex of polymer: drug: cyclodextrins. Finally, low 
concentrations of polymers can enhance complexation of drug with cyclodextrins in solution 
(Chowdary and Srinivas,2006; Kristinsson et al.,1996; Sigurðoardóttir and Loftsson,1995; 
Valero et al.,2003).   
Baseline aqueous solubility of UC781 in the presence of all polymers tested was lower 
than the HPLC limit of detection (<3×10-5 mg/ml), indicating a very limited aqueous solubility 
enhancement effect of polymers on UC781. Therefore, the impact of polymers on the solubility 
of UC781 would not contribute to their complexation enhancement effect.  The ternary complex 
of polymer: UC781: cyclodextrins may be formed as to in aqueous phase to enhance the UC781: 
cyclodextrins complexation. It has been shown that  the polymer partly or totally coats the 
inclusion complex, interacting with both the drug and the βCD molecule through hydrogen 
bonding in the ternary complex (Valero et al.,2003).  
In these studies, different polymers showed different impacts on UC781 solubility in both 
HPβCD and MβCD solution. In both cyclodextrin systems, HPMC showed potent solubility 
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enhancement activity, indicating that it is a promising excipient to be considered in formulation 
to enhance the complex formation of UC781 and cyclodextrins.  
4.3.4 HIV Reverse Transcriptase Inhibition Assay for UC781: Cyclodextrins Complexes 
An in vitro HIV reverse transcriptase inhibition assay was used to study the anti-HIV 
activity of pure UC781 (dissolved in DMSO) as compared to the complex form of UC781 with 
HPβCD and MβCD.  In these studies, the UC781 concentration in the complex was varied (5 and 
10 μg/ml) with fixed amount of HPβCD (15% w/v) and MβCD (15% w/v). PBS (pH 7.2 ) was 
used as a control. A serial dilution of UC781 and its complex was tested to obtain the dilution 
effect for UC781 complexes.  
Results showed that both HPβCD and MβCD have no baseline RT inhibition activity 
themselves (Figure 4-9). Inhibition of RT by the UC781 complexes with HPβCD or MβCD 
follows a similar pattern with the pure UC781 (with DMSO <1% as co-solvent) (Figure 4-10  
and Figure 4-11). HPβCD and MβCD themselves did not show any RT inhibition at either 10% 
or 15% in PBS compared with control. The relative IC50 of UC781 is approximately 10 nM in 
the in vitro assay.  No statistical difference in IC50 of UC781 was observed between UC781 and 
UC781: HPβCD complex or UC781:MβCD complex (p>0.05). (Figure 4-12).  
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Figure 4-9.  RT inhibition activity for HPβCD and MβCD  
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Figure 4-10. RT inhibition assay of UC781 complexed with 15% HPβCD  
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Figure 4-11. RT inhibition assay of UC781 complexed with 15% MβCD 
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Figure 4-12. Comparison of IC50 of complexed vs. uncomplexed UC781 in vitro assay 
No statistically significant differences in IC50 were found when comparing non-
complexed UC781 with complexed UC781. However, complexation could result in competition 
for UC781 between CD and RT in the experimental setup. This would lead to a reduced effective 
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concentration of UC781 around RT, leading to a shift in IC50. Some evidence for this phenomena 
may be seen in the MβCD data.  HPβCD complex did not show this tendency. This can be 
explained by its weaker complexation ability with UC781 compared with MβCD. Thus, HPβCD 
may not interfere with the interaction between UC781 and RT.  
It must be emphasized that MβCD will not enter the cell and only plays a role as a carrier 
to bring UC781 into cells. Therefore, MβCD will not affect the interaction between UC781 and 
RT inside HIV infected cells.  
4.4 CONCLUSIONS 
This study shows that UC781 can interact with βCD, HPβCD, or MβCD forming an 
inclusion complex in aqueous phase.  The formation of an inclusion complex is dependent on 
cyclodextrin, different preparation methods, pH variance, and incorporation of polymers.  
Autoclave method is the most efficient method for the preparation of UC781complex. 
Autoclave method is designed to provide a temperature controlled method for optimization of the 
complexation of UC781 with cyclodextrins due to the enthalpy driven process. In addition, the 
autoclave method may result in increased interaction between UC781 and βCD molecules. 
Compared to the other methods in experiments, the autoclave method provides a quick and 
efficient method to form UC781: cyclodextrins complexes.  
pH variance can directly change the ionization degree of UC781 and enhance its 
solubility in water.  Due to the high pKa value (pKa=9.14), UC781 can only be highly ionized at 
high pH leading to a higher solubility in aqueous phase. However, this pH is not applicable for 
the development of a vaginal formulation at pH 4.2. 
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In these studies, HPMC is the most potent solubility enhancer for UC781 in both 15% 
HPβCD and MβCD solution. In the presence of 0.8% HPMC and 15% MβCD, UC781 solubility 
can be increased to 33 μg/ml (4.2 times); with 0.6% HPMC and 15% HPβCD, UC781 solubility 
can be increased to 185 μg/ml (3.7 times). HPMC was also applied to protect cultured cells and 
human cervical epithelium against the toxicity of βCD as presented in Chapter 5.  
MβCD showed the strongest complexation ability with UC781 in comparison with the 
other two β-cyclodextrins used in this experiment. Solubility of this complexed form is 
approximately 50 μg/ml in 15% w/v MβCD while only to 0.5 μg/ml for 1.5% βCD and 7.7 
μg/ml for 15% HPβCD with the autoclave method. The RT inhibition activity of complexed 
UC781 was effectively maintained. MβCD showed better complexation ability with UC781. 
Further toxicity studies are necessary for the development of a formulation containing  MβCD. 
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5.0  DEVELOPMENT OF VAGINAL GEL AND FILM 
FORMULATIONS FOR UC781 AND ITS β-CYCLODEXTRIN 
COMPLEXES AS  TOPICAL VAGINAL MICROBICIDE PRODUCTS  
5.1 INTRODUCTION  
Vaginal drug administration has a long history dating back to the Middle Ages (Neves et 
al.,2008). This route of administration has long been employed for postmenopausal delivery of 
hormones such as estradiol (Van Laarhoven et al.,2002).  Although the vagina can be used for 
both systematic and local drug delivery, the majority of vaginal products are intenede for local 
pharmacological activity. Compared with classical oral routes of administration, vaginal delivery 
is still not the preferred route for drug delivery. However, anatomical considerations for the 
transmission of HIV and other sexually transmitted diseases (STDs) require vaginal drug 
delivery for effective prevention of infection.  
In these studies, UC781 was complexed with HPβCD or MβCD to enhance its aqueous 
solubility. The state of active agents in a formulation may change the physiological properties of 
the absorption site and affect drug efficacy by changing drug absorption and disposition 
(Bardelmeijer et al.,2002; Malingre et al.,2001). These changes may reduce the bioactivity of 
active agents in microbicide products and lead to an increase in toxicity. Therefore, the anti-HIV 
activity and toxicity of complexed UC781 should be evaluated.   
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Three formulations were developed as potential microbicide products for complexed 
UC781. These formulations include a methylcellulose/carbopol (MC) gel, hydroxyethycellulose  
(HEC) gel, and polyvinyl alcohol (PVA) film.  The MC-based gel is based on the gel currently 
being evaluated clinically for delivery of UC781 in a suspended form. The HEC gel is based on 
the universal placebo designed for vaginal microbicide clinical trials (Tien et al.,2005). The PVA 
film provides a novel delivery system for UC781. PVA film systems are available on the market 
for vaginal cleansing and contraception. In these studies, these three formulations were 
developed as vaginal drug delivery systems for the evaluation of both complexed and non-
complexed UC781. 
The objective of this chapter is to evaluate the impact of complexation of UC781 with 
HPβCD or MβCD on the physical properties, toxicity profile, and the anti-HIV activity of the 
developed vaginal formulations.   
Toxicity is an important concern in the successful development of a safe and effective 
microbicide product. Therefore, the toxicity of HPβCD or MβCD in the presence and absence of 
water-soluble polymers was investigated in a cell-based model (HeLa and A431) as well as in an 
excised human cervical epithelium model. In addition, the toxicity of each developed formulated 
product was assessed in the human cervical epithelium model. To assure that complexation did 
not result in any loss in product effectiveness, the inhibition of RT activity and HIV replication 
by UC781 was investigated. The anti-HIV activity of complexed UC781 in PVA film was also 
evaluated using a TZM-bl cell model.   
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5.2 MATERIALS AND METHODS 
5.2.1 Materials  
UC781 for these studies was provided by Biosyn Co. Ltd. (Huntington, PA). βCD (MW: 
1134), MβCD (MW: approx. 1320; mean degree of substitution: 1.7-1.9),  HPβCD (MW: 
approx. 1380;  mean degree of substitution: 0.8) were purchased from Sigma Aldrich (St. Louis, 
MO). All other reagents used were of reagent grade and all solvents were of HPLC grade. Milli-
Q water was used to prepare buffer solutions and other aqueous solutions. HeLa, A431, and 
TZM-bl cells were obtained from  ATCC.  
5.2.2 Characterization and Evaluation of Physicochemical Properties of UC781 
Complexes Containing Formulations  
5.2.2.1 Preparation of UC781: HPβCD and UC781: MβCD Complexes 
The UC781: HPβCD complex solution was prepared using the following steps: 1) UC781 
was mixed with HPβCD at either a 1:250 or 1:500 (w/w) ratio, and then dispersed into 5ml Milli-
Q water; 2) The suspension was autoclaved at  120oC (250°F) for 15 min, and then formulated 
into a   HEC gel, MC gel, or PVA film after cooling down to room temperature. The UC781: 
MβCD complex was prepared following the same procedure.  
5.2.2.2 Formulation of Complexed UC781 in a Hydroxyethycellulose (HEC) Gel 
Formulation of the hydroxyethycellulose (HEC) gel was prepared based on the recipe of 
the universal placebo used in microbicide clinical trials (Tien et al.,2005).  Briefly, HEC gel was 
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prepared by dissolving 0.1% (w/w) sorbic acid, 0.85% (w/w) sodium chloride, and 0.35% (w/w) 
1 N sodium hydroxide (Spectrum Chemicals & Laboratory Products, Gardena, CA) in 96.0% of 
water. Next, 2.7% (w/w) hydroxyethylcellulose 250HX (Hercules Incorporated, Wilmington, 
DE) was slowly incorporated using an overhead motorized stirrer (RW20 Stirrer, IKA, Divitech 
Equipment Co., Cincinnati, OH). UC781 was dissolved into 2 ml of ethanol and then 
incorporated to 100 ml of gel, under constant stirring, to obtain a 0.01% UC781 containing gel. 
For complex containing gels, pre-prepared UC781: HPβCD or UC781: MβCD complex solution 
was incorporated into the gel under constant stirring to form UC781 complex containing gel. 
HEC gels containing no UC781 or its complex were used as control. The final pH was 
determined and adjusted if necessary to 4.4 ± 0.2 (pH values in normal vagina) using 1 N 
hydrochloric acid. Control gels containing no UC781 or βCD were also prepared. 
5.2.2.3 Formulation of Complexed UC781 in a Methylcellulose/Carbopol (MC) Gel 
Methylcellulose/Carbopol (MC) gel was prepared by dissolving 0.3% of Carbopol 974P 
(Carbopol ®, Noveon, Inc., Cleveland, OH) in water using an overhead motorized stirrer. UC781 
was first dissolved into 2 ML of ethanol and then mixed into the Carbopol® solution. 
Methylparaben, propylparaben and 1.0% methylcellulose 4000 cps (Spectrum Chemicals & 
Laboratory Products, Gardena, CA) were mixed with glycerin, and then dispersed in the 
Carbopol® solution to obtain a 0.01% UC781 containing gels. For preparation of complex 
containing gel, pre-prepared UC781: HPβCD or UC781: MβCD solution was then incorporated 
into the gel under constant stirring to obtain UC781 complex containing gel. The final pH was 
adjusted to 5.2 ± 0.2  with 1 N sodium hydroxide (Spectrum Chemicals & Laboratory Products, 
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Gardena, CA) due to the optimal gellation pH for Carbopol®. Control gels containing no UC781 
or βCD were also prepared.  
5.2.2.4 Formulation of Complexed UC781 in a PVA Film 
A PVA based fast dissolving film formulation was prepared by dissolving 3% PVA (cold 
water-soluble, molecule weight 30-70KD) (Sigma), 0.06% hydroxypropyl methylcellulose 6 
mPa.s (Sigma), and glycerin (Spectrum) in water. 100 μg of UC781 was dissolved into 0.5 ml of 
ethanol and then mixed into 2.5 ml of PVA film solution, which had been previously transferred 
to a single well of an 8-well rectangular plate (Nalge Nunc International Inc. Rochester, New 
York). This process was repeated for each of the eight wells. Plates were then placed into an 
Isotemp® vacuum oven model 285A (Fisher Scientific, Hampton, NH) at 32oC and -25 mHg for 
at least 48 h to remove moisture.  
For the preparation of UC781 complex containing film, the complexed form of UC781 
with HPβCD or MβCD, containing 100 μg of UC781, was prepared following the same method 
described for the HEC gel and MC gel formulations. A total of 0.5ml of ethanol was added to the 
complex containing films to be consistent with procedures used for non-complexed containing 
films. Control films containing no UC781 or βCD were also prepared. 
5.2.2.5 Preparation of Vaginal Fluid Simulant (VFS)  
Vaginal fluid simulant (VFS)  was prepared as described by Owen and Katz (Owen and 
Katz,1999), using 3.51 g sodium chloride (Fisher Scientific, Hampton, NH), 1.4 g potassium 
hydroxide (Spectrum Chemicals & Laboratory Products, Gardena, CA), 0.222 g calcium 
hydroxide, 18 mg albumin bovine fraction V, 2.0 g lactic acid , 160 mg glycerol , 0.4 g urea 
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(Spectrum Chemicals & Laboratory Products, Gardena, CA ), 1.0 g acetic acid glacial (Fisher 
Scientific, Hampton, NH ), 5.0 g glucose (Spectrum Chemicals & Laboratory Products, Gardena, 
CA), and ultra-pure Milli-Q water (Millipore, Billerica, MA) to make 1000 ml of fluid. The pH 
of the vaginal fluid simulant was adjusted with 10% hydrochloric acid (FisherScientific, 
Hampton, NH) to pH 4.2 ± 0.1. 
5.2.2.6 Evaluation of Physicochemical Properties of Formulations 
The osmolality and viscosity of the MC gel and HEC gel, as well as the disintegration 
time of PVA film were evaluated for all formulations. All measurements were conducted in 
triplicate. Osmolality was determined using a Vapor Pressure 5520 Osmometer (Wescor, Inc., 
Logan, UT) calibrated with Opti-mole 290 and 1000 mmol/kg osmolality standards.  
Evaluation of viscosity was conducted using the CP51 spindle on a cone/plate Brookfield 
Model DVIII+ viscometer (Brookfield Eng. Lab., Inc., Middleboro, MA) at 25oC and 37oC. Data 
were collected using Rheocalc software (Brookfield Eng. Lab. Inc., Middleboro, MA). Viscosity 
was measured using a program in which shear rate was increased from 0.2 to 30.0 s-1 and 
subsequently decreased to 0.2 s-1. In order to compare data across samples, viscosity values 
acquired at 30.0 s-1 were used for analysis.  
Disintegration times of PVA film were determined using a shaking method at room 
temperature. One PVA film was placed into 3 ml of Milli-Q water on multi-purpose rotator 
(Barnstead, USA), and shaken at 60 rpm until the film totally dissolved. Dissolving time based 
on visual observation was recorded for analysis.  
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5.2.2.7 Dissolution Testing of UC781 in the MC Gel, HEC Gel, and PVA Film  
The enhancer cell (Distek Inc, North Brunswick, NJ) was used to conduct UC781 
dissolution studies. These studies were conducted to assess UC781 release profiles from the 
formulation. In these studies, one film was inserted into a 100-mesh basket and then placed into 
75 ml of 20 mM VFS (with 0.1% of sodium lauryl sulfate) at 37 oC ± 0.5  oC with continuous 
stirring at 50 rpm. Aliquots of 0.5ml buffer was taken at predetermined time points. These 
aliquots were then filtered using a 0.45 μm filter for HPLC analysis. For the evaluation of  MC 
or HEC gels, 1g was loaded into an ointment cell flask, and the same procedure designed above 
was conducted using VFS (with 1.0% of sodium lauryl sulfate) as the dissolution media.  
5.2.2.8 Kinetic Analysis of Dissolution Data  
The release behavior of UC781 and its complexes from gel and film formulations was 
analyzed using the exponential equation, known as the power law shown as Equation 5-1 
(Korsmeyer et al.,1983; Siepmann and Peppas,2001)  
       kt
M
M nt =
∞
    5-1 
Here, Mt and M∞ are the absolute cumulative amount of drug released at time t and 
infinite time respectively; k is a kinetic constant reflecting formulation characteristics; and n is 
an exponent characterizing the mechanism of drug release.  When n <0.5, the drug is released 
with a quasi-Fickian diffusion mechanism, When n=0.5, the drug is released with a Fickian 
diffusion mechanism representing the special case of the power law, for 0.5<n<1, an anomalous 
transport drug release occurs and when n≥1, a non-Fickian Case II or zero order release kinetics 
is observed (Ritger and Peppas,1987; Siepmann and Peppas,2001).  Dissolution data were fitted 
using SigmaPlot 10.0 software.  
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Mean dissolution time (MDT) was also considered to compare the drug release rate from 
the different formulation (Figure 5-1). MDT was estimated using the following equation 5-2:                              
              
W
ABC
dtW
dtWt
MDT
0 t
0 t
∞∞
=⋅=
∫
∫
5-2 
Here, ABC (area between curves) is the shaded area in Figure 5-1, Wt is the cumulative 
amount of drug released at any time interval, and W∞ is the actual quantity of drug released from 
formulation, which is available from the experiment. ABC was estimated using the trapezoidal 
rule in this study.    
 
 
 
 
 
 
 
 
Figure 5-1.  Graphical presentation of the parameters used to estimate the mean dissolution 
time (MDT) 
 
Cumulative amount of UC781 released from formulations (μg) vs. drug release time (min) was 
plotted to illustrate the estimation of MDT using Equation 5-2. The black area represents the area 
between curves (ABC) used in the evaluation of MDT, which is calculated using the trapezoidal 
rule.  
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5.2.3 Preformulation Evaluation of In Vitro Toxicity of Cyclodextrins  
5.2.3.1 Toxicity Evaluation of Cyclodextins in Hela and A431 Cell Models 
The viability of HeLa cells (human epithelial cells from cervical cancer) and A431 cells 
(human epithelial cells from squamous carcinoma) was measured by quantification of the 
mitochondrial dehydrogenase activity by reducing the tetrazolium salt 1-(4,5-dimethylthiazol-2-
yl)-3,5-diphenylformazan (MTT) (Coligan et al.,2007). HeLa cells or A431 cells were cultured 
in a 96 well-plate to a density of 1×105 cells in 100 μl of media in each well Cells were 
incubated with HPβCD or MβCD in Dulbecco's Modification of Eagle's Medium (DMEM) 
either in the presence or absence of several water-soluble polymers which are commonly used 
in vaginal formulations (0.5% and 1% HPMC, PVA, HEC, and PVP K30) at 37 °C with 5% 
CO2 at saturated humidity. After the incubation period, cells were washed with DMEM, 
followed by incubation with 100 μl DMEM containing 20 μl (5mg/ml) MTT solution for an 
additional 4 h at 37°C with 5% CO2 at saturated humidity. After incubation, 120 μl of stop 
solution was added into each culture well. After extraction of formazan crystals by isopropanol, 
optical density of the extracted solution was measured at 595 nm. A Tukey's multiple 
comparison test (GraphPad software, version 4) was used to determine significant differences in 
MTT levels. 
5.2.3.2 Toxicity Evaluation of Cyclodextrins in an Excised Human Cervical Tissue Model 
Viability of the human cervical tissue was quantified by MTT after direct exposure to 
HPβCD or MβCD in the presence or absence of polymers.  
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HPβCD or MβCD was dissolved into 1ml DMEM containing either 0.5% or 1.0% of 
each of the tested polymers (HPMC, HEC, PVA, and PVP K30) to obtain a final cyclodextrin 
concentration from 1% to 20%.  Briefly, human cervical explants (3-mm diameter) were exposed 
directly to 200 μl of solution containing various concentrations of HPβCD or MβCD.  DMEM 
was used as control in these experiments.  After a 2 h exposure, explants were washed two times 
with fresh DMEM. Tissues were immediately incubated in DMEM containing MTT (500 µg/ml) 
for an additional 3 h at 37°C. Tissue viability was determined by dividing the optical density of 
the formazan product in isopropanol (595 nm) by the weight of the explants. The impact of each 
test sample on tissue viability was determined by comparing the viability of the treated explants 
to the DMEM treated tissue control. All samples were prepared in triplicate.  Extra tissues 
treated with the same treatment were also fixed for histological study. A Tukey's multiple 
comparison test (GraphPad software, version 4) was used to determine significant differences in 
MTT levels. 
5.2.4 Preformulation  Evaluation of  Ex Vivo Toxicity of  Cyclodextrins and 
Uc781:Cyclodextrins Complexes Containing  Formulations  
5.2.4.1 Toxicity Evaluation of HPβCD or MβCD Containing Formulations in an Excised 
Human Tissue Model 
Viability of human cervical tissue for the three formulations containing HPβCD or 
MβCD were evaluated using an MTT assay. The toxicity of the formulations was quantified by 
the reduction of the tetrazolium salt 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT). 
In these experiments, film products were dissolved into 1ml DMEM cell culture media to obtain 
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an equivalent concentration of cyclodextrin used in the gels.  Briefly, human cervical explants 
(3-mm diameter) were exposed directly to 200 μl HEC gel, MC gel, or PVA film solution 
containing HPβCD or MβCD at concentrations of 5%, 10%, and 20%. DMEM was used as a 
control.  The MTT assay was conducted as described in section 5.2.2.2. All samples were tested 
in triplicate. 
5.2.4.2 Toxicity Evaluation of UC781:Cyclodextrins Complexes Containing  Formulations 
in an Excised Human Tissue Model 
Viability of the human cervical tissue for the three formulations was evaluated using the 
Multiple Exposure Device (MED) developed in our lab. This toxicity evaluation differs from the 
MTT described in section 5.2.4.1, in that the tissues are polarized. Formulation toxicity was 
quantified by MTT assay.  In these experiments, film products were dissolved into 1ml DMEM 
cell culture media to obtain an equivalent concentration of cyclodextrin used in the gels.  Briefly, 
Human cervical explants (6-mm diameter) were exposed directly to 200 μl HEC gel, MC gel, or 
PVA film solution containing UC781:HPβCD complex or UC781:MβCD complex. DMEM was 
used as a control.  The MTT assay was conducted as described in section 5.2.2.2. All samples 
were tested in triplicate. 
5.2.5 In Vitro Bioactivity Studies of UC781: Cyclodextrins Complexes 
5.2.5.1 Effects of UC781:Cyclodextrins Complexes on RNA-dependent DNA Polymerase 
Activity of HIV-1 Reverse Transcriptase 
HIV-1 RT DNA polymerase activity was determined by a fixed time assay. Briefly, 
HPβCD or MβCD were dissolved in 10mM pH 7.2 PBS buffer to obtain a 15% w/w solution. 
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UC781 was added into 1ml of a 15% HPβCD or a 15% MβCD solution to prepare a 5μg/ml, or 
10μg/ml UC781 complex solution. The solution was then autoclaved at 250 °F for 15 min 
followed by a shaking in a Labquake shaker (Barnstead Thermolyne, USA) at 50 rpm overnight 
at room temperature to form the UC781:HPβCD and UC781:MβCD complexes containing  
5μg/ml or 10μg/ml UC781. Non-complexed UC781 was dissolved using DMSO and quickly 
dispersed into 10mM PBS buffer as positive control (DMSO amount equal to 1% or less). PBS 
buffer was used as the negative control. The remaining procedure details are as described 
previously in section 4.2.2.5. All samples were tested in triplicate. 
5.2.5.2 Effects of UC781:cyclodextrins Complexes Containing Formulations on RNA-
dependent DNA Polymerase Activity of HIV-1 Reverse Transcriptase  
UC781:HPβCD or UC781: MβCD complexes containing formulations were dissolved 
into PBS before experiments. These solutions were used for RT inhibition analysis as described 
in Section 5.2.5.1. The remaining procedure details are as described previously in Section 4.2.2.5. 
All samples were tested in triplicate. 
5.2.5.3 Effect of UC781: Cyclodextrins Complexes Containing Film Formulations on The 
Replication of HIV in TZM-bl Cell Model.  
PVA film containing non-complexed UC781 (100 μg/film) and complexed UC781 
(100μg/ film) were dissolved into PBS for HIV inhibition testing. For UC781: HPβCD complex 
containing PVA films, the complexes were prepared with UC781:HPβCD at a 1:250 ratio and 
UC781:HPβCD at a 1:500 mass ratio.  UC781:MβCD complex films were prepared following  
the same procedure.  
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A TZM-bl cell-based assay (TZM-bl cell is a genetically engineered HeLa cell line that 
express CD4, CXCR4 and CCR5 and contains Tat-inducible Luc and β-Gal reporter genes) for 
evaluation of HIV infection has been described in detail as previously reported(Derdeyn et 
al.,2000). The assay was briefly described as follows: TZM-bl cells were seeded into 96-well 
Packard ViewPlate at a density of 5×103 cells/well. 50 μl film solution was added into each well 
and then mixed with 40 μg/ml diethylaminoethyl-dextran (DEAE-Dextran) solution 50 μl 
containing HIV-1Bal or HIV-1LAV. Another 150 μl DMEM were added after two hours incubation 
at 37 °C. All cells were then cultured for 48 hthen carefully rinsed with blank Hank's Buffered 
Salt Solution (HBSS) to remove virus and residual film solution. TZM-bl cells were then lysed 
using 100 μl Bright-Glo reagent (Promega Corporation, Madison, WI), and the mixture was 
shaken for two min. The light intensity of each cell lysate was measured by DTX 800/880 Series 
Multimode Detectors (Beckman Coulter, Inc. Fullerton, CA). Samples were treated and 
measured in triplicate. The percentage of HIV-1 inhibition was expressed as mean ± SD.  
5.2.6 Histology Studies on Excised Human Cervical Tissue 
Human cervical tissue was fixed following exposure to test products using the following 
procedure for toxicity evaluation. Tissues were put in a cartridge with a foam insert and placed in 
Clark's solution of acetic acid and ethanol (1 part to 3 parts) for 12 hr. After this time, Clark’s 
solution was replaced with 100% EtOH. The 100% EtOH was changed every hour for three 
hours following which the cartridge was removed from the EtOH and placed into 100% xylene, 
which was changed every 30 min for a total of one hour. Tissues were put in xylene overnight at 
-20°C prior to embedding in wax. Once embedded, tissues were cut in 5μM sections using a 
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microtome (Microm HM320, Brodersen, USA), and then stained with hematoxylin and eosin 
(H&E), and evaluated microscpically for gross morphological changes to the tissue. 
5.2.7 Statistical Analysis 
Data for physicochemical analysis (osmolality and viscosity) and disintegration time of 
PVA film were expressed as the mean ± SD. Tissue viability in percentage was expressed as 
mean ± SD. IC50 values determined for UC781 in each formulation were expressed as mean ± 
SD.  IC50 was calculated with GraphPad software 4. Data were analyzed with one-way ANOVA 
using Tukey’s multiple comparison tests (GraphPad software 4). Obtained p < 0.05 were 
considered to be statistically significant. 
5.3 RESULTS AND DISCUSSION 
5.3.1 Characterization and Evaluation of Physicochemical Properties of 
UC781:Cyclodextrins Complexes Containing Formulations  
5.3.1.1 Osmolality Evaluation of MC and HEC Gels 
Osmolality is an important parameter for the characterization of semisolid formulations. 
The osmolality (mmol/kg) results of MC gel and HEC gel are listed in Table 5-1. Figure 5-2 
(HEC gel) showed that the osmolality increased with the incorporation of either HPβCD or 
MβCD complexed UC781.  Osmolality results for the HEC gel without complex were 319 
mmol/kg. Only a slight change of osmolality was observed in UC781 containing HEC gel (323 
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mmol/kg). The incorporation of cyclodextrin complexed UC781 into the HEC gel resulted in a 
statistically significant increase in osmolality as compared to placebo. The osmolality increased 
to 358 mmol/kg (UC781: HPβCD =1:250) and 361 mmol/kg (UC781: HPβCD = 1:500) for 
UC781:HPβCD complex containing gels; 357 mmol/kg (UC781: MβCD =1:250) and 392 
mmol/kg (UC781: MβCD = 1:500) for UC781 :MβCD complex containing gels.    
 
 
 
 
 
 
 
Figure 5-2.  Effect of UC781 Complex on Osmolality (HEC gel) 
 
Table 5-1. Impact of UC781 complex on osmolality change of HEC and MC gel 
 Placebo Gel UC781 UC781 HPβCD 
complex  (1:250) 
UC781 HPβCD 
 complex  1:500) 
UC781 MβCD 
 complex  (1:250) 
UC781 MβCD 
 Complex   (1:500) 
HEC Gel 319.67±16.26 323.67±11.93 358.67±4.16 361.00±7.94 356.67±1.53 392.00±4.58 
MC Gel 585.67±4.04 573.33±6.66 616.00±4.58 677.00±4.36 667.00±11.79 696.00±6.24 
 
Similar results in osmolality change were obtained in MC gels as shown in Figure 5-3. 
The osmolality value without complex was 585 mmol/kg for MC placebo gel and 573 mmol/kg 
for UC781 containing MC gel. The osmolality increased to 616 mmol/kg (UC781: HPβCD 
=1:250) and 677 mmol/kg (UC781: HPβCD = 1:500) for UC781: HPβCD complex containing 
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MC gels; 667 mmol/kg (UC781: MβCD =1:250) and 696 mmol/kg (UC781: MβCD = 1:500) for 
UC781: MβCD complex containing MC gels.    
 
 
 
 
 
 
 
 
 
 
Figure 5-3.  Effect of UC781 Complex on Osmolality (MC gel) 
In these studies, cyclodextrin complexes with UC781 increased the osmolality of both 
gels. Osmolality changes were statistically significant (p<0.05) for all UC781 complex 
containing products tested compared with its placebo products. Greater amount of cyclodextrin 
in the complex leads to a higher osmolality value for the formulation indicating that cyclodextrin 
changes the osmolality of both MC and HEC gel formulations.   
For gel formulations, osmolality not only reflects the physical characteristics of the gel 
product itself, but also affects the local vaginal environment.  Products with too high osmolality 
value will increase the risk of HIV transmission by changing the barrier properties of vaginal 
epithelium  (Fuchs et al.,2007).  In addition, it was shown that products with high osmolality 
would leak more readily from the vagina than those that are isoosmolar.  Viscosity will also 
affect the application of semisolid formulations. Lower viscosity products can lead to greater 
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leakage of the formulation from the vagina (Owen and Katz,1999). These data show that the 
incorporation of the complexed form of UC781  with HPβCD (2.5% to 5%) or MβCD (2.5% to 
5%) into the formulation  can statistically significantly increase the osmolality of both the MC 
gel and the HEC gel (p < 0.05). This observed increase is related to the amount of βCD in the 
gels.  However, the osmolality of  the complex containg gels are only 19% (HEC gel) or 35% 
(MC gel) of osmolality value for the marketed K-Y® gel product (containing 2% Nonoxynol 9 
(N9)) listed in literature (Fuchs et al.,2007).  
Comparison of these results suggests that the complex containing MC gel and HEC gel 
(even at the 5% level) are comparatively safe without potential for barrier alteration as a result of 
high osmolality.  
5.3.1.2 Viscosity Evaluation of MC and HEC Gels 
The viscosity of each gel used was experimentally determined at both 25 °C and 37 °C 
using the methods described in the methods section of the section 5.2.3.6. The viscosity results 
of products are shown in Figure 5-4 (MC gel 25 °C), Figure 5-5 (MC gel 37 °C), Figure 5-6 
(HEC gel 25 °C), and Figure 5-7 (HEC gel 37 °C).  A significant decrease in viscosity was 
observed for all MC products at both 25 °C and 37 °C when complexed UC781 was incorporated 
into the products compared to placebo gels (p<0.05).  For the HEC formulation, viscosity 
significantly decreased only in UC781: MβCD complex containing gels compared to placebo gel 
at 25 °C.  At 37 °C, the viscosity values significantly decreased in the complex containing gels of  
UC781: HPβCD complex (UC781:HPβCD=1:500), UC781:MβCD complex 
(UC781:MβCD=1:250), and UC781:MβCD complex (UC781:MβCD=1:500) compared to 
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placebo gel. This suggests that the viscosity may be both cyclodextrin and temperature 
dependent.  
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Figure 5-4.  Effect of UC781 Complex on viscosity change in MC gel at 25 °C 
*: p<0.05; **: p<0.01 
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Figure 5-5.  Effect of UC781 Complex on viscosity change in MC gel at 37 °C 
*: p<0.05; **: p<0.01 
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Figure 5-6.  Effect of UC781 Complex on viscosity change in HEC gel at 25 °C 
*: p<0.05; **: p<0.01 
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Figure 5-7.  Effect of UC781 Complex on viscosity change in HEC gel at 37 °C 
*: p<0.05; **: p<0.01 
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For vaginal microbicide products, viscosity plays an important role for product 
application and distribution over the vaginal mucosa. The viscosity of marked vaginal products is 
quite varied (Garga et al.,2001). The impact of HPβCD or MβCD on the gel viscosity was 
evaluated in our study. All HEC and MC gels showed a decrease in viscosity upon addition of 
complexed UC781 with HPβCD or MβCD into the formulation. With the incorporation of 
complexed form of UC781 with HPβCD (2.5% to 5%) and MβCD (2.5% to 5%) into the MC gel 
or the HEC gel, the viscosity of the gels greatly decreased as the β-cyclodextrin amount 
increased in complex. This result coincided with that observed in several previously published 
studies (Beheshti et al.,2007; Boulmedarat et al.,2003). This viscosity decrease indicates the 
interaction between the complex and the polymer chains of the viscosity increasing agents used 
in the formulation. This interaction could affect the binding force (hydrogen bonding) or 
decouple the hydrophobic interactions between polymer molecules. In addition, cyclodextrins 
inclusion complexes are known to interact with water-soluble polymers forming ternary 
complexes consisting of the drug molecule, cyclodextrins, and the polymer chain (Hsiue et 
al.,1998; Kim et al.,2002; Kristinsson et al.,1996; Loftsson and Brewster,1996; Patel and 
Vavia,2006). In the ternary complex, the polymer partly or totally coats the inclusion complex, 
interacting with both the drug and the βCD molecule through hydrogen bonding (Valero et 
al.,2003). This inclusion can reduce the interaction between polymer chains and therefore, the 
polymer chains are wholly disentangled and well aligned in the direction of   flow, resulting in a 
lower viscosity.  
The viscosity decrease provides both advantages and disadvantages for formulation 
development. The lower viscosity microbicide product can be more easily applied in the vagina, 
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but may lead to more leakage and thus decrease the dosing level. The ideal viscosity for a 
microbicide product still needs to be further investigated  
5.3.1.3 Disintegration Evaluation of PVA Film 
Disintegration test results for PVA films are shown in Figure 5-8. The disintegration time 
was shortened significantly with the incorporation of UC781 complexes compared to placebo 
film (p<0.05), decreasing from 34 min for placebo film to 14 min for UC781:MβCD complex 
containing films. This decrease in disintegration time is in accordance with the mass ratio 
increase in complex, indicating that cyclodextrin enhances the disintegration of the PVA film 
during the disintegration process. Notable, the data indicate that MβCD has a more significant 
impact on the disintegration time of PVA films than HPβCD.  
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Figure 5-8.  Disintegration time of PVA film 
*: p<0.05; **: p<0.01 
Disintegration is the first step toward dissolution of a solid dosage form. A complete 
disintegration is defined as that state in which any residue of the unit remaining on the screen of 
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the test apparatus is a soft mass having no palpably firm core (USP,2000). The official 
disintegration test for vaginal preparations requires a large volume of disintegrating fluid (1L of 
water). In our study, 3 ml of water were used. This was sufficient volume to keep test PVA film 
immersed, but provided a low volume that more closely represents the physical environment of 
the vagina (Owen and Katz,1999). The disintegration process was accelerated significantly when 
the complexed form of UC781 was incorporated into the film for both HPβCD and MβCD. This 
can be explained by the interaction between cyclodextrin and the PVA chains, leading to a 
weaker interaction between polymer chains.  
Our studies suggest  that the disintegration time of PVA films could be improved by the 
incorporation of βCD into films. βCD can enhance the disintegration of PVA film through 
reducing the interaction among PVA molecules. This effect of βCD on PVA film will help to 
improve the release of UC781 from the film due to the hydrophobic properties of UC781 itself. 
However, additional studies are required to fully characterize the mechanism for the enhanced 
disintegration of PVA film containing CD.  
5.3.1.4 Dissolution Evaluation of UC781 Release from MC Gel, HEC Gel and PVA Film 
The purpose of complexation of UC781 with cyclodextrins is to enhance the solubility of 
UC781 and obtain a rapid release of UC781 from the formulation in order to provide more 
immediate protection from sexual HIV transmission. Studies were conducted to investigate the 
impact of cyclodextrin on the viscosity, osmolality, and disintegration of PVA film. The results 
indicate that complexation of UC781 with HPβCD or MβCD may improve the dissolution of 
UC781. The dissolution of UC781 from three different formulations was investigated in vaginal 
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fluid simulant (VFS) at 37 °C. VFS was used to mimic the physical environment of  the vagina. 
Released UC781 in VFS was expressed as a percentage of loaded UC781 as mean ± SD.  
Incorporation of the complexed form of UC781 in all three formulations showed greatly 
enhancement on the release of UC781. All formulations containing non-complexed UC781 
showed a relatively slower initial release of the drug during initial stages of dissolution testing 
than that of complexed UC781 containing formulations.  
For MC and HEC gel formulations, UC781 was only found in the dissolution medium 
after the first 3 min for non-complexed UC781 containing MC gel (Figure 5-9 and Figure 5-10) 
and after 5 min for HEC gel (Figure 5-11 and Figure 5-12) in non-complexed UC781 gels. 
Conversely, over 8% of UC781 was released within 3 min (p<0.05) from all HPβCD or MβCD 
complexed UC781 containing formulations. For PVA film formulations, more than 20% of 
UC781 was released from complex containing films compared to around 10% of UC781 released 
from non-complexed UC781 containing  film within 3 min (p<0.05) as shown in Figure 5-13 and 
Figure 5-14.  
In all non-complexed UC781 containing formulations (gels and film), no more than 40% 
of UC781 was released over a 60 min time frame. Conversery, about 80% of UC781 was 
released in all complex containing formulations in this same period.  
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Figure 5-9.  Effect of UC781:HPβCD complex on UC781 release from MC gel 
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Figure 5-10. Effect of UC781:MβCD complex on UC781 release from MC gel 
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Figure 5-11. Effect of UC781:HPβCD complex on UC781 release from HEC gel 
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Figure 5-12. Effect of UC781:MβCD complex on UC781 release from HEC gel 
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Figure 5-13. Effect of UC781:HPβCD complex on UC781 release from PVA Film 
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Figure 5-14. Effect of UC781: MβCD complex on UC781 release from PVA Film 
Accumulated drug release at 10 min (Table 5-2) and 60 min (Table 5-3) was selected for 
comparison. From our studies, the complexation of UC781 can significantly improve the release 
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of UC781 at 10 min (p<0.05, t-test) and 60 min (p<0.05, t-test) in MC gel, HEC gel, and PVA 
films in MC gel. The data suggested that the complexation of UC781 could greatly enhance both 
extent and speed of drug release. These attributes would provide great advantage for microbicide 
products. This would result in a rapid drug release and more immediate protection against HIV 
transmission.  
Table 5-2. Accumulated UC781 release in 10 min (percentage %) 
 MC gel HEC gel PVA film 
0.01% UC781 11.18±0.85 10.13±0.40 14.45±3.79 
0.01% UC781 HPBCD complex ( 1:250) 18.93±2.60*  14.45±0.87* 34.28±10.12** 
0.01% UC781 HPBCD complex ( 1:500) 35.45±12.24 ** 35.45±12.24** 39.13±4.73* 
0.01% UC781 MBCD complex (1:250) 30.73±6.19 ** 18.63±4.04* 35.08±11.07** 
0.01% UC781 MBCD complex (1:500) 47.88±3.16 ** 34.03±3.88** 38.88±8.90* 
*: p<0.05; **: p<0.01 
 
 
Table 5-3. Accumulated UC781 release in 60 min (percentage %) 
 MC gel HEC gel PVA film 
0.01% UC781 34.68±9.44 35.50±3.89 44.57±3.11 
0.01% UC781 HPBCD complex ( 1:250) 37.50±3.08 57.05±1.06** 72.12±9.41** 
0.01% UC781 HPBCD complex ( 1:500) 73.60±2.49** 73.60±2.49** 76.17±2.92** 
0.01% UC781 MBCD complex (1:250) 81.10±20.24** 83.28±4.62** 74.15±11.08** 
0.01% UC781 MBCD complex (1:500) 82.05±8.91** 105.31±11.18** 87.37±0.73** 
*: p<0.05; **: p<0.01 
The power law was used to analyze the UC781 release pattern according to Equation 5-1. 
The n value decreased in all three formulations with the increase in CD concentration in the 
complex. This indicates a change of UC781 release pattern caused by complexation. The 
parameters for fitting are shown in Table 5-4. 
Table 5-4. Calculated K and n following Power law 
 UC781 UC781 :HPβCD complex  (1:250) 
UC781 :HPβCD 
complex  (1:500) 
UC781 :MβCD 
complex  (1:250) 
UC781 :MβCD 
complex  (1:500) 
 K n K n K n K n K n 
Film 3.84 0.58 13.06 0.41 15.71 0.38 13.79 0.41 13.98 0.46 
MC gel 1.51 0.76 11.42 0.47 8.24 0.36 11.57 0.51 16.51 0.42 
HEC gel 0.85 0.91 2.70 0.76 11.42 0.47 7.15 0.64 8.74 0.63 
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The k values reflect the drug dissolution rate from the formulation into the dissolution 
system. The larger the k value, the quicker the drug dissolution from the formulation. In all 
formulations, the k values for complexed UC781 containing formulations are much higher than 
those obtained for non-complexed UC781 formulations. In addition, the k value increase follows 
a dose dependent relationship with respect to cyclodextrin concentration in the complex.  
The release of UC781 from all gels and film formulations containing non-complexed 
UC781 displayed an anomalous pattern (n values are between 0.5 and 1.0), most likely due to the 
relative contributions of drug diffusion, polymer relaxation, and matrix erosion. The release 
pattern of non-complexed UC781 from MC gel (n=0.91), HEC gel (n=0.76), and PVA film 
(n=0.58) indicate differences in mechanism of drug release for the three different formulations. 
The higher n value (non-Fickian release) obtained for the MC gel suggests that drug release is 
controlled by matrix erosion and drug dissolution in this formulation.  For the PVA films, the 
range of n values is in the neighborhood of the exponent 0.5, which is the theoretical value for a 
diffusion controlled pattern (Fickian release).  The lower n value obtained for the PVA film 
group compared to those of MC and HEC gels indicates that UC781 is released faster from the 
film formulation than from gel formulations.  
For the formulations containing complexed UC781, n values decreased greatly in 
comparison to those of non-complexed UC781 containing formulations. These results suggest 
that UC781 release is predominately controlled by its enhanced dissolution due to the increased 
water enhancement of complexed UC781 with either HPβCD or MβCD. 
Mean dissolution time (MDT) of UC781 and its complexes was also evaluated and are 
shown in Table 5-5 and Figure 5-15. The complexed form of UC781 in all three formulations 
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greatly decreases the MDT of UC781 and follows a dose dependent relationship based on the 
amount of  HPβCD or  MβCD in the formulation (p<0.05, t-test, one tail). 
Table 5-5. MDT (min) of complexed UC781 in different formulations  
 UC781 UC781 :HPβCD complex  (1:250) 
UC781 :HPβCD 
complex  (1:500) 
UC781 :MβCD 
complex  (1:250) 
UC781 :MβCD 
complex  (1:500) 
Film 26.09±3.45 19.46±3.88* 18.47±2.11* 18.05±2.43* 16.84±2.49** 
MC gel 26.80±3.02 20.93±1.63* 17.02±1.10** 23.36±7.36* 14.94±3.50** 
HEC gel 28.43±0.95 23.35±1.11* 22.72±3.25* 19.52±2.29** 21.77±1.89** 
*: p<0.05; **: p<0.01 
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Figure 5-15. MDT of complex UC781 in different formulations 
MDT data also show that the complexed UC781 is more readily dissolved than non-
complexed UC781 in all three tested formulations. This decrease in MDT is related to the βCD 
amount in UC781 complex. Greater amounts of βCD in the UC781 complex resulted in shorter 
MDT values. With respect to the PVA film dosage from containing HPβCD or MβCD 
complexed with UC781, this data shows that the film is fast dissolving with rapid release of 
UC781.  
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In our studies, the complexation of UC781 with HPβCD or MβCD not only increases the 
solubility of UC781 in the aqueous phase, but also changes the release behavior of UC781 from 
the formulations. The drug release rate and pattern were changed due to the incorporation of 
cyclodextrins complexed with UC781. The complexation of UC781 is an effective technique for 
the design of  quick dissolving dosage forms with rapid drug release.  
5.3.2 Preformulation evaluation of in vitro toxicity of cyclodextrins 
5.3.2.1 Toxicity Evaluation of Cyclodextrins in HeLa and A431 Cell Models 
The toxicity data obtained from studies in which HeLa cells or A431 cells were exposed 
to HPβCD or MβCD (1% to 20%) for 30 min, 1 h, or 2 h is shown in Figure 5-16 (HPβCD in 
HeLa cell), Figure 5-17 (MβCD in HeLa cell) and Figure 5-18 (HPβCD in A431 cell) and 
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Figure 5-19 (MβCD in A431 cell). The data shows that cell viability decreases with both 
increased βCD concentration and exposure time.  An 80% viability represents the damage 
threshold to evaluate the cytotoxic effect of HPβCD and MβCD according to other previous 
cytotoxicity studies (Kim et al.,2004) (Wang et al.,2004) (Maniratanachote et al.,2005).  Using 
this threshold for toxicity, a 2 h exposure to 1% HPβCD (Figure 5-16) is comparatively safe. 
However, a 2 h exposure to 1% for MβCD is toxic (Figure 5-17).   
In the A431 cell model, the safe concentration was found to be is 2.5% for HPβCD 
(Figure 5-18) and less than 1% MβCD 
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Figure 5-19) for 2 hour exposure.  
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Figure 5-16. Cytotoxicity of HPβCD on HeLa cell 
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Figure 5-17. Cytotoxicity of MβCD on HeLa cell 
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Figure 5-18. Cytotoxicity of HPβCD on A431 cell 
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Figure 5-19. Cytotoxicity of MβCD on A431 cell 
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The impact of the presence of water-soluble polymers on toxicity following exposure to 
cyclodextrin for 2 h was evaluated in both the HeLa cell and the A431 cell model. These data 
show that all polymers evaluated in both the HeLa and A431 cell-based model reduced the 
toxicity of both HPβCD and MβCD.  
The reduction in toxicity for water-soluble polymers as shown in the HeLa cell model is 
shown in Figure 5-20 (HPMC), Figure 5-21 (HEC), Figure 5-22 (PVA), and Figure 5-23 (PVP 
K30).  The concentration of HPβCD can be increased to 5% while maintaining 80% cell viability 
when the exposure included the presence of either 0.5% or 1.0% of all four polymers used in 
experiments. In the absence of polymers, the HPβCD concentration must be 1% or less to 
maintain an 80% cell viability level.  Moreover, recall that in the absence of polymers, the toxic 
concentration for MβCD was found to be less than 1%.  Incorporation of water-soluble polymers 
with MβCD resulted in 80% cell viability being maintained even at the 1% level. Comparing 
individual polymers evaluated, It is observed that HPMC, HEC, and PVA can maintain cell 
viability of HeLa cells more effectively than PVP K-30 in the HPβCD treated groups. This 
indicates that HPMC, HEC, and PVA are safer components than PVP K30 in the formulations 
containing HPβCD.  
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Figure 5-20. HPMC protection effect on cyclodextrin toxicity in HeLa cells in 2 hour exposure 
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Figure 5-21. HEC protection effect on cyclodextrin toxicity in HeLa cells in 2 hour exposure 
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Figure 5-22. PVA protection effect on cyclodextrin toxicity in HeLa cells in 2 hour exposure 
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Figure 5-23. PVP K30 protection effect on cyclodextrin toxicity in HeLa cells in 2 hour exposure 
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In the A431 cells, similar results were observed as shown in Figure 5-24 (HPMC), Figure 
5-25 (HEC), Figure 5-26 (PVA), and Figure 5-27 (PVP K30).  Incorporation of water-soluble 
polymers leads to greater protection in the A431 cell model as compared to the HeLa cell model. 
The safe concentration of HPβCD (that which maintains 80% cell viability) was increased to 10 
% in the presence of 1% of HPMC, HEC, PVP K-30 or PVA. Moreover, 2.5% of MβCD was 
shown to be safe in the A431 cell model in the presence of 1% water-soluble polymer.  These 
results suggested that A431 cells are less susceptible to the toxic effect of either HPβCD or 
MβCD than the HeLa cells.  
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Figure 5-24. HPMC protection effect on cyclodextrins toxicity in A431 cells in 2 hour exposure 
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Figure 5-25. HEC protection effect on cyclodextrin toxicity in A431 cells in 2 hour exposure 
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Figure 5-26. PVA protection effect on cyclodextrin toxicity in A431 cells in 2 hour exposure 
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Figure 5-27. PVP K-30 protection effect on cyclodextrin toxicity in A431 cells in 2 hour exposure 
 Due to the polymeric matrix of most dosage forms, the impact of polymers in the 
formulations on active agents should be evaluated for their efficacy or toxicity. In our studies, a 
microbicide product was developed for UC781complexed with either HPβCD or MβCD for the 
prevention of HIV transmission; the toxicity of HPβCD or MβCD was a factor of concern in the 
formulation development. Using cell models, the impact of water-soluble polymers on HPβCD 
and MβCD was evaluated using an MTT assay. From these data, the water-soluble polymers 
were shown to provide protective effect from cyclodextrin toxicity. Therefore, incorporation of 
any of the four polymers evaluated into a formulated product for the delivery of cyclodextrins 
complexed UC781 will result in a formulation with a more acceptable toxicity profile.   
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5.3.2.2 Toxicity Evaluation of Cyclodextrins on Excised Human Cervical Tissue in The 
Presence of Water-Soluble Polymers 
The protective effect of water-soluble polymers on cyclodextrins was shown in a cell-
based model as described in section 5.3.1.1. However, the cell model utilized are only a first step 
toward toxicity assessment, since they provide only a simple system for toxicity evaluation. 
Further studies are necessary for toxicity evaluation of HPβCD and MβCD.  To this end, studies 
were conducted in a human cervical epithelial model.  This model provides a more comfort 
mechanism to evaluate toxicity in a more complex model, which is more physiologically relevant 
to the development of microbicide products.  
Figure 5-28 to Figure 5-30 represent the data obtained for the toxicity evaluations in the 
excised human cervical tissue model.  In these studies, excised human cervical tissue was 
exposed to either HPβCD or MβCD in the presence or absence of 1% water-soluble polymers in 
DMEM culture media for 2 hours. A DMEM exposure was used as a control. These results 
showed that toxicity is dependent on the cyclodextrin concentration used in the experiment. 
Water-soluble polymers included can effectively protect from the toxicity of HPβCD or MβCD 
at all concentrations used in experiment. Tissue viability was improved in the presence of 
polymers as compared to viability obtained in the absence of polymers. Importantly, in studies 
incorporation of 1% HPMC with the CD, no tissue toxicity was found at the 10% level of 
HPβCD exposure (Figure 5-29) or at 5% level of MβCD (Figure 5-30) exposure comparable to 
tissue viability obtained for the DMEM control group (containing no polymers) (p>0.05, 
unpaired t-test, one tail).  These results indicated that HPMC could be safely used in microbicide 
products containing βCD based drug delivery systems.  
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Figure 5-28. HPβCD and MβCD toxicity on Human Cervical Tissue in 2 horu exposure 
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Figure 5-29. Polymers protection effect on HPβCD toxicity on Human Cervical Tissue in 2 hour 
exposure 
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Figure 5-30. Polymers protection effect on MβCD toxicity on Human Cervical Tissue in 2 hour 
exposure 
Our data suggested that water-soluble polymers can greatly protect cells and excised 
human cervical tissue against HPβCD and MβCD.  These polymers may reduce the toxicity of 
CDs through their interaction with CD. HPMC is the most potent of all water-soluble polymers 
tested in these experiments in their ability to provide protection from toxicity.   
Inactive excipients are always required to formulate drug substances into drug products. 
In our studies, all four water-soluble polymers were shown to effectively protect from the 
potential toxicity of HPβCD or MβCD in both cell and tissue models. Additionally, all four 
polymers are able to enhance the complexation efficiency of UC781 with HPβCD or MβCD. 
Our data show that different excipients may play an important role in the toxicity profile 
of formulations as well as the complexation efficiency of UC781 with HPβCD or MβCD.  With 
the toxicity and complexation information that is provided, optimization of complexed UC781 
containing formulations with regard to toxicity is possible.  However, it is important to assure 
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that the formulation maintains anti-HIV activity. These studies demonstrate that HPMC can be 
included in cyclodextrins complexed UC781 containing formulations to achieve a more 
acceptable toxicity profile and more efficient complexation of UC781.  
5.3.3 Ex vivo Toxicity Evaluations of Cyclodextrin Alone and UC781: Cyclodextrins 
Complexes in The Formulated State 
5.3.3.1 Toxicity Evaluation of HPβCD and MβCD Containing Formulations in an Excised 
Human Tissue Model 
In addition to the physical and chemical properties of formulations, it is important to 
consider the toxicity of formulations to the vaginal epithelium, especially in the prevention of 
sexual transmission of HIV. Any toxicity from formulation may result in alteration of the 
epithelial barrier, which may facilitate pathogen entry. Cyclodextrins are known to modify  
membranes due to their complexation with cholesterol present in membranes (Ilangumaran and 
Hoessli,1998). The toxicity of any formulations on the vaginal epithelium must be evaluated for 
the development of a successful microbicide product.  
Our MTT assay data show that 0.5% of N9 can cause great damage to cervical tissue. 
Different toxicity profiles for cervical tissues were observed for formulations containing either 
HPβCD or MβCD, as shown in Figure 5-31. When formulated in the MC gel, tissue viability 
decreased as a function of HPβCD or MβCD concentration, whereas formulation in the HEC gel 
or PVA film lead to a better toxicity profile in that toxicity was not observed even at levels of 
20% HPβCD or 5% MβCD. MβCD showed significant toxicity when its concentration was 
greater than 10%, regardless of the formulation (p<0.05, t-test, one tail).   
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Figure 5-31. Toxicity of HPβCD and MβCD in differenct formulations 
*: p<0.05; **: p<0.01 
Above figure represents the data for excised human cervical tissue after exposure to 
formulated products containing HPβCD and MβCD. DMEM solution containing 0.5% 
N9was used as positive control. 
 
For the formulations examined, a concentration-dependent and formulation selective 
toxicity was exhibited for HPβCD and MβCD. No toxicity was observed at the level of 5% 
MβCD or  HPβCD in all tested formulations. For HEC gel and PVA film, no tissue damage was 
observed even at the level of 20% HPβCD.   However, 10% or higher levels of MβCD may 
cause damage to epithelial cells. It is interesting that both HPβCD and MβCD showed a dose 
dependent pattern when formulated in MC gels, but not when formulated in HEC gels or PVA 
films.  This suggests that the toxic effect of cyclodextrin is formulation dependent.  
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These results strongly suggested that the toxicity of cyclodextrins in the human cervical 
tissue model could be reduced in formulations compared to cyclodextrins solution. Although 
MβCD was more toxic than HPβCD in both cell and human cervical epithelium models, the 
toxicity of both cyclodextrins was decreased when formulated in MC gel, HEC gel, or PVA film. 
HEC gel and PVA film may provide better protection to cervical epithelium from βCD 
containing drug delivery systems than do MC gels. Thus, HEC gel or PVA film formulations 
should be considered as more suitable microbicide product platforms than MC gels for clinical 
use. 
5.3.3.2 Toxicity Evaluation of UC781: HPβCD and UC781: MβCD Complexes Containing  
Formulations in An Excised Human Tissue Model 
The toxicity of HPβCD or MβCD alone in three different formulations was evaluated in 
section 5.3.3.1.  However, the toxicity profile for formulated products containing either HPβCD 
or MβCD complexed UC781 must also be evaluated since the solubility of UC781 is elevated in 
such formulations.  
 Figure 5-32  represents the data for tissue exposed to MC gel, HEC gel or PVA film 
containing UC781 complexed with either HPβCD or MβCD. No significant difference was 
observed between tissues treated with formulated product and DMEM treated tissues (p>0.05). 
No detectable epithelial damage was found upon exposure to any of the three formulations tested 
that contained complexed UC781with HPβCD or MβCD. This result correlates with the studies 
described in Section 5.3.3.1 that showed no observed toxicity at 5% concentrations of either 
HPβCD or MβCD. These results suggested that 50 mg of HPβCD or MβCD in film dosage 
forms or 5% HPβCD or MβCD in gel dosage forms is safe for vaginal delivery.  
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Figure 5-32. Toxicity of complexed UC781 (0.01% UC781) in MC gel, HEC gel, and PVA film 
 
5.3.4 In Vitro Anti-Hiv Activity of Formulations Containing Complexed UC781  
The anti-HIV activity of complexed and non-complexed UC781 needs to be evaluated in 
a formulated state. As an RT inhibitor, the in vitro bioactivity of UC781 should be investigated at 
both the enzyme level (RT inhibition) and the cell level (TZM-bl cell model).  
5.3.4.1 RT Inhibition Assay of Formulations Containing UC781 Complexes 
HIV reverse transcriptase inhibition results showed a complete RT inhibition for all 
UC781 containing formulations in our test HEC gel (Figure 5-33), MC gel (Figure 5-34), and 
PVA film (Figure 5-35).  It should be noticed that some baseline RT inhitition activity was 
observed for all formulatios, but this activity could be quickly eliminated with product dilution.  
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In the MC and HEC gels, non-complexed UC781 containing formulations potently 
inhibited RT activity. However, this inhibition ability of formulated UC781 is lost quickly after 
dilution to 0.4 μg/ml or lower.  Conversely, all complexed UC781 containing gels retain their RT 
inhibition activity as compared to non-complexed UC781with statistically significant difference 
(p<0.01).   
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Figure 5-33. RT assay of UC781 and its complex in HEC gel 
** p<0.01   
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Figure 5-34. RT assay of UC781 and its complex in MC gel 
**: p<0.01   
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Figure 5-35. RT assay of UC781 and its complex in PVA film 
** p<0.01 
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Similar RT inhibition results were observed for UC781 complex containing PVA film. 
Except for the complex of UC781: HPβCD (UC781: HPβCD = 1:250), all other UC781 complex 
containing PVA films can significantly increase the RT inhibition activity of UC781 as 
compared to noncompelxed UC781 (p <0.01). There was no significant difference in RT 
inhibition between non-complexed UC781 and UC781 complexed with HPβCD (UC781: 
HPβCD =1:250). This may be explained by the low amount of HPβCD amount used for 
complexation with UC781 in this film formulation. Thus, greater amounts of HPβCD are needed 
for effective complexation with UC781 in the formulated state. This tendency is also observed in 
MC and HEC gel formulations.   
The film formulation provided a better vehicle for delivery of non-complexed UC781. 
This is apparent given that, at a 625 times dilution, non-complexed UC781 in PVA film can still 
inhibit 17% RT activity as compared to no inhibition observed for MC and HEC gels at this 
dilution. This difference in results obtained for PVA film formulations and gel formulations may 
be caused by due to water cotent in formulations.  PVA films formulations contain greatly less 
water content (less than < 1%) than that in gel formulations (over than 96% in HEC gel and over 
than 97% in MC gel). For this reason, the non-complexed UC781 is maintained in a highly 
dispersed state in PVA film as opposed to the gel formulations. This may lead to the increase of 
apparent solubility of UC781. Therefore, when UC781 concentrations were diluted to 0.08 μg/ml 
in the non-complexed UC781 containing formulations, gel formulations lost all these RT 
inhibition activity, whereas film formulation maintained 17% RT inhibition activity. These 
results suggested that PVA film formulations can maintain greater UC781 activity than gel 
formulations.  
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As detected IC50 value is a more sensitive index to compare the RT inhibition activity of 
UC781 in non-complexed and complexed form. IC50 values were calculated using GraphPad 
software for all three formulations containing either non-complexed or complexed UC781 as 
shown in Figure 5-36 and Table 5-6. For the MC and HEC gels, the IC50 of UC781 complexed 
with either HPβCD or MβCD is statistically significantly lower than that for non-complexedd 
UC781 (p<0.05). For PVA films, complexed UC781: HPβCD (UC781:HPβCD =1:500) and all 
MβCD compolexed UC781 can significantly decrease the IC50 values as compared to non-
complexed UC781 (p<0.01). However, the complexed UC781:HPβCD (UC781:HPβCD =1:250)   
did not show the ability to improve the IC50 of UC781. This result suggests that the 1:250 mass 
ratio is not sufficient for UC781:HPβCD complexation in film formulation.  
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Figure 5-36.  IC 50 of UC781 in MC gel, HEC gel, and PVA film 
** p<0.01 
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Table 5-6. IC 50 of UC781 in MC gel, HEC gel, and PVA film 
IC50 μM 
 UC781 
UC781:HPβCD 
(1: 250). 
UC781:HPβCD  
(1: 500). 
UC781:MβCD  
(1: 250). 
UC781:MβCD  
(1: 500). 
MC gel 3.72±0.13 0.71±0.04** 0.23±0.02** 0.13±0.03** 0.33±0.02** 
HEC gel 1.94±0.30 0.22±0.05** 0.09±0.01** 0.22±0.05** 0.25±0.05** 
PVA Film 0.25±0.01 0.43±0.08 0.09±0.01** 0.14±0.02** 0.11±0.04** 
** p<0.01 
The impact of formulation on RT inhibition was also observed in non-complexed UC781 
containing formulations. The IC50 values decreased as ranked: PVA film (0.25 μM) < HEC gel 
(1.94μM) < MC gel (3.72 μM) (p<0.01).  Therefore, the PVA film provides a better formulation 
for non-complexed UC781 as a microbicide product by maintaining higher anti-HIV activity. 
This can be explained by efficient solid dispersion formation of non-complexed UC781 in the 
PVA film formulation, which is likely caused by the processing method. In the preparation of 
PVA film, UC781 was dissolved into EtOH and incorporated into the polymeric film solution, 
which may lead to  more efficient solid dispersion of UC781 increasing the solubility of UC781. 
This data can be supported by previous reports on UC781 solid dispersion (Damian et al.,2001; 
Damian et al.,2002).   
In addition to these IC50 results, PVA film formulations  can enhance the dissolution of 
complexed UC781 in VFS. Properties of the PVA film formulation containing complexed 
UC781 offer great benefit toward providing quick and effective protection against HIV infection, 
and greater efficacay as a microbicide product. 
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5.3.4.2 HIV Inhibition Assay of UC781 Complexes Containing Film Formulation in TZM-
bl Cell Model 
In addition to the evaluation of RT inhibition for different formulations containing 
complexed UC781. It is important to assess the in vitro inhibition of HIV replicaion prior to 
further in vivo evaluation. TZM-bl cell models were commonly used for these studies.   
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Figure 5-37. HIV inhibition assay of UC781:βCD complex film formulation in TZM-bl cells line 
model. 
** p<0.01 
 
Figure 5-37 shows results of obtained from the HIV-1 virus inhibition assay for 
complexed (HPβCD or MβCD) and non-complexed forms of UC781 in PVA film. Each film 
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contained 100 μg UC781. Films containing 25 mg or 50 mg of HPβCD or MβCD were used as 
comparison. PVA placebo film was used as a control. In these studies, TZM-bl cells, HIV, and 
UC781 were incubated together for 48 hours to obtain a full contact of all compournts.  
These results showed that UC781 containing films can significantly reduce the infection 
of TZM-bl cells by HIV-1BAL and HIV-1LAI (p<0.01). Films containing only HPβCD exhibit no 
HIV-1 inhibition at concentration of 25 mg/film. But PVA film containing either 50 mg HPβCD 
/film, 25 mg MβCD /film or 50 mg MβCD /film greatly reduce HIV-1 infection (p<0.01).  This 
observe baseline activity can be explained by the ability of CD to depelete cholesterol from viral 
and cell membranes (Doncel,2005; Kozak et al.,2002).   
In our studies, the potency of film containing complexed UC781 was evaluated to be 
compared with non-complexed UC781 containing films. No significant difference was observed 
between non-complexed and complexed forms of UC781 (HPβCD or MβCD), which further 
validates the idea that the complexed form of UC781 maintaines anti-HIV activity in vitro.   
5.3.5 Histologies Study of HPβCD and MβCD on Excised Human Cervical Tissue  
5.3.5.1 Ex Vivo Toxicity Evaluation of HPβCD and MβCD Containing Formulations on 
Excised Human Cervical Tissue  
Figure 5-38 shows the histology obtained from tissues exposed to either HPβCD or 
MβCD incorporated into the three developed formulations at the highest concentration evaluated. 
No gross morphological changes were observed for tissue exposed to 5%, 10%, or 20% of 
HPβCD or MβCD in the formulated state.  
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Figure 5-38. Histological results for excised human tissue exposed to 20% of  HPβCD or MβCD 
formulated in a MC gel, HEC gel,  and PVA film. 
Pre treatment and N9 5% were used at placebo control and positive control for the histologies 
studies of cyclodextrins containing formulations. Pictures of highest concentration of 
cyclodextrins (20%)were shown here for comparison.  
5.3.5.2 Ex Vivo Toxicity Evaluation of UC781:HPβCD or UC781:MβCD Complexes 
Containing Formulations on Excised Human Cervical Tissue  
No toxicity was observed when complexed UC781 was incorporated into the developed 
formulations.  No gross morphological changes were observed for either cyclodextrin evaluated 
(HPβCD or MβCD) at the 1:250 or 1:500 mass ratio (UC781: cyclodextrins) evaluated.   
Pre treatment  
N9 0.5% 
HEC gel HPBCD 20% 
HEC gel MBCD 20% 
MC gel HPBCD 20% 
MC gel MBCD 20% 
Film HPBCD 20% 
Film MBCD 20% 
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5.4 CONCLUSIONS  
This research provides valuable information that can be used  toward the development of 
beta-cyclodextrin based drug delivery systems. For mucosal administration, HPβCD and MβCD 
exhibit a concentration dependent toxic effect. However, this toxicity can be avoided by 
maintaining CD levels below 5% for HPβCD and below 1% for MβCD.  In both cell-based  and 
human cervical epithelial tissue models, water-soluble polymers can be used to reduce the 
toxicity of HPβCD and MβCD. HPMC was found to be the most effecive polymer for reduction 
of HPβCD and MβCD toxicity. Incorporation of this water-soluble polymer results in an increase 
in the amount of either HPβCD or MβCD (20% for HPβCD and 2.5% MβCD) that can be safely 
used. Interestingly, dosage form choice and excipient selection impact toxicity profile for 
HPβCD or MβCD. The HEC gel formulation and PVA film formulation offered better protective 
effects than the MC gel formulation. In both HEC gel formulations and PVA film formulations, 
20% of HPβCD and 5% of MβCD can be used without gross toxicity.  
These studies indicate that UC781 complexed with either HPβCD or MβCD can greatly 
enhance the release of UC781 from formulations by changing the release pattern from non-
Fickian to Fickian release in VFS. Moreover, HPβCD or MβCD complexation increases the 
osmolality and decreases the viscosity of MC and HEC gel formulations. In addition, 
complexation resulted in shortened disintegration time for PVA film formulations due to the 
interaction between cyclodextrin and the polymer chains. These properties will facilitate 
distribution and rapid release of UC781 in the vagina, resulting in better protection against 
sexual HIV transmission. 
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Additionally, UC781 complexed with either HPβCD or MβCD greatly enhanced HIV RT 
inhibition activity as compared to non-complexed UC781 for all formulations. The IC50 values of 
complexed UC781 were greatly reduced as compared to non-complexed UC781. Importantly, 
complexed UC781 in a PVA film formulation can maintain the potency of UC781 and 
effectively reduce in vitro HIV-1 infection to almost zero.  Finally, the toxicity study results of 
formulations indicate that HPβCD and MβCD are safe at 1:500 mass ratios (or 5% w/v) level in 
all three formulation.  
Our studies showed that complexation with HPβCD or MβCD provides a safe and 
effective method for the development of UC781 drug delivery systems capable of overcoming 
UC781’s innately poor water solubility.  The complexed form of UC781 with either HPβCD or 
MβCD in a PVA film formulation provided quick release, potent HIV-1 inhibition, and low 
toxicity, all of which are essential criteria for a successful microbicide product. βCD-based drug 
delivery systems combined with PVA film formulation provides a promising solution for the 
formulation development of water insoluble drugs as effective microbicide products.  
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6.0  GENERAL DISCUSSION AND PERSPECTIVES  
In these studies, β-cyclodextrin complexed with UC781 formulated in a PVA based fast 
dissolving film was developed as a microbicide product. The complexes of UC781 with βCD 
and its derivatives were systemically evaluated and characterized with UV, DSC, FTIR and 
NMR.  These results confirm the formation of UC781: βCD complexes in both the liquid and 
solid state. The thermodynamic profile of the complexation of UC781 with three types of 
cyclodextrins was investigated using an HPLC method. The complexation ability of CDs with 
UC781 was found to follow the sequence of MβCD > βCD > HPβCD. An enthalpy driven 
process was identified for the complexation of UC781 with βCD, HPβCD, or MβCD. The 
enthalpy-entropy compensation was also observed for complexation of UC781 with CD, which 
is attributed to replacement of water molecules by UC781 in the βCD cavity.  
The impact of pH variance, water-soluble polymers, and different preparation methods 
were investigated to optimize the complexation of UC781 with βCD, HPβCD and MβCD. 
Complexation of UC781 with CDs was conducted at pH 7.0, 9.0, or 11.0 to evaluate the impact 
of pH on complexation. pH 11.0 was shown to be the most efficient for complexation. This 
complexation enhancement effect resulted from the solubility increase of UC781 at pH 11.0 due 
to the increased degree of ionization at this pH. However, this condition cannot be applied in a 
vaginal formulation due to the extreme pH value.  Kneading, shaking, autoclave, and 
lyophilization methods were evaluated for the complexation of UC781 with CDs. Comparison of 
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methods showed that the autoclave method is the most efficient method to form the complex of 
UC781 with CDs.  Four water-soluble polymers, HPMC, HEC, PVA, and PVP K30, were 
incorporated during complexation of UC781 with HPβCD or MβCD. Although all polymers used 
in experiment resulted in enhanced complexation, maximal complexation of UC781 was 
obtained in the presence of  HPMC.  
Finally, MC gel, HEC gel, and PVA film formulations were developed and evaluated as 
carriers for complexed UC781 and non-complexed UC781. Complexed UC781 greatly increased 
osmolality and decreased viscosity for MC and HEC gel formulations. Complexed UC781 was 
also found to accelerate the disintegration rate of PVA film formulations. Importantly, 
complexed UC781 with HPβCD or MβCD can greatly enhance the dissolution and relative IC50 
of UC781 in all three formulations tested without observed toxicity as evaluated in an excised 
human cervical epithelial tissue model. These results indicated that complexation of UC781 with 
HPβCD or MβCD provided a quicker and more potent protection from HIV infection han non-
complexed UC781. Moreover, the PVA film formulation was found to be superior to the other 
two gel formulations with respect to tissue toxicity profile, UC781 release, and RT inhibition.  
Although these studies provide proof of concept for utilization of a prototype fast 
dissolving film as a microbicide formulation for delivery of UC781 further evaluations are 
necessary.  Formulation optimization is required to achieve a product with long-term stability, 
which can be manufactured using existing technologies.  In addition, a thorough pharmacokinetic 
and pharmacodynamic evaluation will be required for the developed formulation.  Finally, to 
achieve a more effective microbicide product the use of combination active agents in this dosage 
form should be explored. 
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6.1 FURTHER OPTIMIZATION AND OPTIMIZATION OF CYCLODEXTRIN 
BASED DRUG DELIVERY SYSTEMS  
6.1.1 Consideration of Alternate Cyclodextrin Types and Modification To 
Manuafacturing Methods to Enhance Complexation Effiency of UC781 with 
Cyclodextrins 
A number of potent, small anti-HIV molecules face the challenge of either poor water 
solubility or low permeability (BCS Class II or BCS Class III ), which greatly hinders their 
clinical application. The development of many of these potent molecules is discontinued due to 
the lack of availability of applicable formulations. Therefore, a favorable formulation, which can 
enhance the solubility and permeability of these molecules, may help to bring more compounds 
into the therapeutic area of HIV prevention and treatment. 
In our studies, we evaluated three cyclodextrin types for the formulation of UC781 as a 
microbicide product. βCD based drug delivery systems can greatly enhance the solubility of 
UC781 and accelerate the dissolution of UC781 while maintaining the anti-HIV activity of 
UC781. The membrane modulation effect of βCD may provide additional anti-HIV benefits for 
the microbicide product (Habeck,2001; Liao et al.,2001). It was reported that βCD can block the 
vaginal transmission of cell-associated HIV-1 in the mouse following a topical application 
(Khanna et al.,2002).  
Although cyclodextrin can greatly improve the pharmaceutical profile of drug in 
formulation, it is important to incorporate as little cyclodextrin as possible in a pharmaceutical 
formulation due to the mass limitation in solid formulation, isotonicity of formulations, and its 
own toxicity (Loftsson et al.,1999; Loftsson et al.,2005b; Miller et al.,2007). Cyclodextrins have 
 164 
an affinity for cholesterol and can extract it and other lipid membrane components from cells 
(Christian et al.,1997) leading to cellular toxicity at high concentration. Furthermore, considering 
the mass limitation of vaginal drug administration and the economic requirement for a low cost 
microbicide, complexation efficiency needs to be maximized to reduce the dose for both UC781 
and cyclodextrin in the formulation while still maintaining the anti-HIV activity in vivo.  
6.1.1.1 Use of Chemically Modified Cyclodextrins in UC781 Formulation (Captisol®) 
The low intrinsic solubility (1.8%) of βCD itself greatly limits its application in 
pharmaceutical formulations. Thus, chemically modified cyclodextrins were developed to 
enhance the solubility of βCD.  Functional groups are introduced at the 2-, 3- and 6-hydroxyl 
groups of the glucose residues to improve the solubility of βCD by breaking the 2-OH–3-OH 
hydrogen bonds and preventing crystallization of βCD. Thus, chemically modified cyclodextrins 
are amorphous products and are made up of isomers. Highly hydrophilic βCD derivatives, such 
as 2-hydroxypropyl–β-CD (HPβCD), provide a great increase on solubility as compared to βCD.  
Lipophilic cyclodextrin derivatives, such as the methyl-cyclodextrin (MβCD), are more efficient 
at extracting cholesterol (Christian et al.,1997) resulting in increased cell toxicity (Ulloth et 
al.,2007) leading to the limitation of its use.  
Sulfobutyl ether–βCD (SBE-βCD) (Captisol®) is a new hydrophilic βCD derivative 
developed by CTD Inc. Captisol®, which has been intensively studied for its application in 
pharmaceutical research due to its low toxicity, water solubility, and organic solvent 
compatibility (CTD Inc,; Irie and Uekama,1997; Rajewskix and Stella,1996). Captisol® was 
reported to improve the ocular delivery of the pilocarpine prodrug (Jarho et al.,1996a). It has also 
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been successfully applied in the development of the formulation of Vfend® (voriconazole), a new 
antifungal agent developed  and marketed by Pfizer Inc.  
In future studies, the use of Captisol ® should be considered for UC781 complexation. 
Given the properties of this cyclodextrin derivative, an increased complexation efficiency with 
UC781 may be obtained with Captisol ®.  In addition, a lower toxicity profile may be achieved as 
compared to that found for HPβCD in our previous studies. 
6.1.1.2 Options for Improvement of Complexation Efficiency of UC781 with Cyclodextrins  
Various methods to prepare drug/cyclodextrin complexes have been applied to enhance 
complexation efficiency, including co-precipitation, slurry, kneading, spray-drying and 
lyophilization (Hedges,1998). To obtain the liquid or solution state, cyclodextrin complexes are 
usually prepared by addition of an excess amount of drug to an aqueous cyclodextrin solution 
agitating at the desired temperature until equilibrium is achieved. The suspension is then filtered 
or centrifuged to form clear drug/cyclodextrin complex solution. For complex in the solid state, 
the water or solvent is removed from the drug/cyclodextrin solution by evaporation (e.g. spray-
drying) or sublimation (e.g. lyophilization) (Pralhad and Rajendrakumar,2004). 
In the studies described within this dessertation, the complexation of UC781 with 
cyclodextrin was found to be an enthalpy driven process. In addition, the autoclave method was 
the most efficient manufacturing process with respect to enhancement of the formation of UC781 
complex. Spray-drying is a technique which can remove solvent from the system by evaporation 
at high temperature. It is applied in the preparation of solid dispersation for enhancing the 
solubility of water insoluble molecules (Otsuka et al.,1993; Paradkar et al.,2004). Therefore, the 
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spray-drying method may provide advantage with respect to the complexation efficiency of 
UC781 with cyclodextrins and should be further evaluated.  
In addition to alternate manufacturing methods, other strategies can be used to enhance 
complexation efficiency. Such strategies include: addition of water-soluble polymers to the 
complexation media (Patel and Vavia,2006; Sigurðoardóttir and Loftsson,1995; Valero et 
al.,2003); adjustment of  pH to change drug ionization and salt formation (El-Barghouthi et 
al.,2006; Peeters et al.,2002); addition of cosolvents (Miyake et al.,1999);  or  a combination of  
different methods as shown in Table 6-1.  
Table 6-1. Methods for increasing cyclodextrin complex efficiency 
Methods  Mechanism  
Drug ionization Ionization of a drug enhanced complexation through increase its apparent intrinsic solubility.(Peeters et al.,2002) 
Salt formation Salt formation can enhance apparent intrinsic solubility of a drug.(Mura et al.,2003; Redenti et al.,2001) 
The acid/base 
ternary complexes 
Some organic acids or bases are able to enhance the complexation efficiency by 
forming ternary drug/cyclodextrin/acid or base complexes.(Redenti et al.,2000) 
Polymer  
complexes 
Water-soluble polymers form a ternary complex with drug/cyclodextrin 
complexes increasing the apparent stability constant of the drug/cyclodextrin 
complex. (Faucci and Mura,2001; Loftsson et al.,1994) 
In the studies described in this dissertation, four water-soluble polymers were evaluated 
for their impact on complexation efficiency of UC781 with both HPβCD and MβCD. It is 
possible to expand the number and type of polymers evaluated.  Poloxamer 188 and PEG should 
also be investigated for their potential synergistic effect to enhance the complexation of UC781 
with cyclodextrin and UC781’s solubility (Chaudhari et al.,2007). However, the toxicity of 
Poloxamer-188 and PEG need to be carefully evaluated in cell and tissue models as described 
previously before their incorporation into formulations.     
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6.2 PROPOSED ADDITIONAL ASSESSMENTS OF UC781:CYCLODEXTRINS 
COMPLEXES  BASED DRUG DELIVERY SYSTEMS  
6.2.1 Biorelevant Evaluation of UC781 Release from Formulations 
Rapid drug release is necessary for some microbicide products to enhance the efficiency 
with which they prevent HIV transmission. The main challenge for the evaluation of drug release 
behavior from microbicide products is the limited fluid present in the vaginal cavity. Normally, 
the daily production of vaginal fluid is around 6 g/day (Owen and Katz,1999). This fluid level is 
much less than the media levels (1000 ml media) typically used in USP dissolution testing (The 
United States Pharmacopeia,2000).  
Within the studies conducted, a low volume dissolution model that uses vaginal fluid 
simulant (VFS) was used to evaluate the three developed formulations (75 ml). This model 
provides information on the rate and extent of drug release, as well as information toward the 
establishment of drug release mechanism in a comparatively low volume without the interference 
of organic solvents. It is a more physiologically relevant model for the evaluation of microbicide 
products as compared to the traditional USP method.   
Considering differences between in vitro and in vivo conditions, the results obtained in 
vitro should be carefully considered prior to attempting to extrapolate to define in vivo properties 
of formulations. The dissolution of UC781 from formulations and its penetration through 
cervical tissue is currently being studies in order to predict the in vitro – in vivo relationship of 
formulations for this drug. Development of mathematical models is necessary to achieve more 
relevant predictions regarding in vitro – in vivo relationships of formulations.   
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6.2.2 Stability of Complexed vs. Non-Complexed UC781 in Formulations 
The stability of a formulation or product under typical conditions of use is critical to its 
efficacy, shelf-life and ultimate success. Stability assessment is essential for pharmaceutical 
product evaluation. Therefore, with regard to the formulations developed within this dissertation 
work, it is critical to investigate the stability of the products containing UC781 complexed with 
cyclodextrins.  
There are several reports showing that complexation with cyclodextrin can enhance the 
stability of drugs in formulation (Jarho et al.,1996b; Loftsson and Jarvinen,1999).  Based on 
these reports we anticipate that the complexation of UC781 will result in enhanced stability of 
the drug in the formulation.  Additional studies are needed to establish whether complexation 
results in increased stability of UC781 in product.  
6.2.3 Pharmacokinetic (PK)/Pharmacodynamic (PD) Evaluation of UC781 Complexes 
Containing Film Formulations 
Pharmacokinetic (PK) and pharmcodynamic (PD) studies of drug products are critical to 
evaluate clinical efficacy. PK data for UC781 established using a mouse model was reported 
(Buckheit et al.,1997a).  In these studies a low oral bioavailability was observed for UC781 (31%) 
indicating either poor absorption or quick elimination of UC781 in vivo. Currently, no PK data is 
available for UC781 delivered in a film dosage form in human subjects. Therefore, investigation 
of PK properties for UC781 delivered via this dosage form is required.  
In addition to the PK evaluation, clinically relevant studies on the in vivo PD properties 
of UC781 should be investigated. Animal models, especially small animal models, offer a 
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potential mechanism for studying the ability of a product to provide protection from HIV 
infection. However, a huge challenge in the development of NNRTIs is the lack of useful animal 
models. 
Currently, rhesus macaque SIV (Simian Immunodeficiency Virus) models 
(Stellbrink,2003) and feline FIV (Feline Immunodeficiency Virus) models (Bendinelli et 
al.,1995) have been used as small animal models for HIV infection research. SIV and FIV are 
both similar to HIV-1 with regard to their genomic organization and biologic properties. In vitro 
models of FIV and SIV were used for anti-HIV studies (North et al.,1989; Witvrouw et al.,1999). 
However, FIV and SIV are not susceptible to NNRTIs. Therefore, modified FIVs or SIVs have 
to be developed for NNRTIs research. Reverse Transcriptase Chimeras of hybrids between HIV 
and feline immunodeficiency virus (FHIV) and hybrids between HIV and simian 
immunodeficiency virus (SHIV) were developed for NNRTIs evaluation (Auwerx et al.,2004; 
Hofman et al.,2004). In the monkey model for the evaluation of NNRTI activity, hybrid SIV 
strains in which the entire RT gene was replaced by the HIV-1 RT gene (designated RT-SHIV) 
have already been constructed (Hofman et al.,2004). However, both models have limitations. 
Hybrid FIV-FHIV greatly decreases the catalytic efficacy of RT (Auwerx et al.,2002).  SHIV 
models in macaques may not directly correlate with the pathogenesis of HIV infection in humans. 
 As an alternative, transgenic rat models provide another method to evaluate anti-HIV-1 
activity of fusion inhibitors and NNRTIs (Goffinet et al.,2007; Zhang et al.,2007).  The 
humanized rat model is infectible with a broad range of HIV isolates using human CD4+ and 
CCR5 receptors and amenable to genetic manipulation of the rate recipient with  relatively low 
cost (Goldstein,2008). Importantly, transgenic rats can be also used as a model to study 
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prevention of HIV-1 vaginal transmission (Di Fabio et al.,2003), offering an easyily controllable 
animal model for microbicide research. 
The anti-HIV activity of the developed UC781 formulations should be evaluated in the 
humanized rat model. The PD data obtained will help to elucidate the mechanism of action for 
UC781 when used as a microbicide product in vagina.  This model can also provide information 
toward effective dosing level choice. 
6.2.4 Combination with Other Microbicide Candidates  
Fusion inhibitors, RT inhibitors, and integrase inhibitors may block HIV-1 infection prior 
to irreversible cellular infection. Combined application of RT inhibitors with drug candidates 
with other mechanisms of action may result in synergistic activity. Some reports have shown that 
combination of UC781 with L-870812 (integrase inhibitor) or cellulose acetate 1,2-
benzenedicarboxylate (CAP) results in significant synergistic effect on the inhibition of HIV-1 
infection (Liu et al.,2005a; Terrazas-Aranda et al.,2008). Some advantages may be achieved by 
combining UC781 with other active drug candidates.  We anticipate that the combination of 
UC781 with either fusion inhibitors or integrase inhibitors may potentially provide a microbicide 
product with increased potency and decreased drug-resistance.  
6.2.5 Other Considerations for Formulation Optimization of UC781  
Currently, more than 50 potential microbicides are being investigated for potential 
vaginal use.  Some of those currently being evaluated in clinical trials are shown in Table 6-2.  
The main challenges to successful microbicide product development are generally recognized as 
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inadequate understanding of HIV transmission, uncertainty regarding which host cells to target, 
complexities of the genital and rectal environments, lack of adequate animal models, and 
inadequate funding. However, the impact of formulation on the effectiveness of a microbicide 
product can be easily underestimated.  In fact, formulation may play a key role for drug 
availability from a microbicide product and furthermore can result in varied effectiveness or 
toxicity profile for anti-HIV agents.  Our studies have demonstrated the feasibility of the use of a 
film formulation for delivery of complexed UC781. Additional studies on this formulation are 
required before its introduction to the clinic.  
Table 6-2. Microbicide candidates in ongoing clinical trials 
(Modified from Alliance for Microbicide Development 2008, www.microbicide.org ) 
Phase Candidate Name  Sponsor* Sites by Country 
III PRO 2000/5 gel Indevus, MRC, DFID (Funder) 
South Africa, Tanzania, Uganda, 
Zambia 
II B Tenofovir gel  
CAPRISA, USAID, 
LIFElab, Gilead, FHI, 
CONRAD 
South Africa 
II/IIB PRO 2000/5 gel (P) and BufferGel®  
NIAID, Indevus, 
ReProtect 
Malawi, South Africa,  United 
States, Zambia, Zimbabwe 
Dapivirine (TMC120) gel IPM Belgium 
Ethanol in  
Emollient Gel NIAID Kenya 
HEC/CS/N-9† CONRAD/USAID USA 
Tenofovir/PMPA gel CONRAD, IPM/USAID Dominican Republic, United States 
Tenofovir gel NIAID United States 
UC781 gel NIAID, CONRAD United States 
UC781 gel UCLA, NIAID, CONRAD United States 
UC781 gel CDC, Thailand Ministry of Health, CONRAD Thailand 
UC781 CONRAD United States 
UC781 CONRAD, CDC, Emory University United States 
I 
VivaGel™  
(SPL7013 gel) 
DAIDS/NIAID, NICHD, 
Starpharma Puerto Rico, United States 
N/A Placebo ring IPM Kenya, South Africa, Tanzania 
 
Most excipients in pharmaceutical dosage forms are considered to be inactive ingredients. 
However, these excipients may have baseline toxicity or activity or they may interfere with the 
active or other excipients in the formulation.  This may result in pharmacological profile changes. 
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In the development of a microbicide, the toxicity of excipients in the formulation as well as any 
potential impact imparted by the excipients on product bioactivity should be considered.  
In the studies presented, a formulation dependent toxicity profile was observed for 
HPβCD and MβCD. Of the developed formulations the HEC gel and PVA film formulations 
showed greater protective effect with regard to toxicity of HPβCD and MβCD to human cervical 
epithelial tissue than did MC gel formulations.  This result may be due to the excipents present in 
the different formulations. In the studies conducted, the major reason for observed differences in 
toxicity may result from the type of polymer present in the formulation as well as its 
concentration. 
 In addition, the impact of the polymer type used in the formulation on HIV infection 
should also be considered. Cellulose sulfate (CS), a polyanionic compound derived from cotton, 
has been proposed as a topical microbicide product to reduce the sexual transmission of HIV. It 
was reported as effective (Bourne et al.,1999; Keller et al.,2005) and safe (Smita et al.,2006; Van 
Damme et al.,2000)  in vivo. However, recently it was found to enhance HIV infection under 
some circumstance (low concentration at < 10 μg/ml) (Tao et al.,2008).  Developing a better 
understanding of the role of the excipients present in this product may help to explain the failure 
of the CS product in Phase III clinical trials.   
The barrier function of the vagina should not be significantly affected after the 
application of a microbicide product for effective  prevention of HIV transmission. Nonoxynol-9 
is an example of the attempted use of a contraceptive product to prevent HIV transmission which 
resulted in failure (Richardson,2002). A vaginal formulation should not affect the integrity of 
vaginal epithelium nor should it negatively impact the normal vaginal flora. The normal flora of 
the vagina consists predominantly of lactobacilli species. A significant change in vaginal 
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lactobacilli, integrity of the vaginal epithelium, or alteration of the permeability of vaginal 
tissues may lead to the increased risk of HIV transmission . Therefore, the impact of microbicide 
products on vaginal lactobacilli, integrity of the vagina, and permeability of the vagina must be 
evaluated.  
Semen viral load is an important risk factor for the vaginal HIV infection.  It was 
reported that the mean viral load in semen is 3.9 log 10 RNA copies/ml (Medeiros et al.,2004). 
HIV RNA can be detected from treated patients with undetectable blood plasma  HIV-1 RNA 
levels in HIV positive patients (Marcelin et al.,2008).  In addition, human semen contains a 
peptide component- semen-derived amyloid fibrils, which can enhance HIV infection from 500 
to 1000 times (Munch et al.,2007). Therefore, the activity of microbicide products should be 
evaluated in the presence of semen to provide information for appropriate dosing levels required 
in formulations.  
The physicochemical properties of a formulation will play an important role in the 
interaction of the formulation with the vaginal/rectal tract. This ultimately will affect the 
pharmacological profile of the drug. Osmolality and viscosity are two common parameters 
evaluated for liquid and semisolid formulations. The osmolality of normal biofluid is around 
∼290 mOsm/kg. Products with extremely high osmolality values may potentially enhance HIV 
infection (Fuchs et al.,2007).  However, no optimal osmolality value or viscosity has been set for 
microbicide products. The findings from these studies show that the components in a formulation 
can greatly change the osmolality of products. This may correspond to a reduction of the anti-
HIV activity of the drug formulation. Further studies should be conducted to identify the 
appropriate range for osmolality with respect to safety for use in vaginal products.  
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In addition, high osmolality or low viscosity will lead to the leakage of microbicide 
products resulting in decreased patient acceptability. Incorporation of bioadhesive materials into 
formulations should be considered to overcome this problem. Bioadhesive materials when used 
in formulations maintain the formulation at the vaginal mucosal surface. In the studies described 
for UC781, HPMC, which is a bioadhesive material, provided an optimal choice for use in the 
formulation in that it imparts bioadhesiveness as well as complexation enhancement and 
reduction of toxic effects of CDs. Different types of HPMC should be evaluated for use in the 
PVA film formulation to assure that bioadhesion is optimized. It should also be noted that 
bioadhesive materials may hinder the drug release from formulations. For this reason, it is 
imperative that in vitro drug release testing be conducteded simultaneously to optimize the 
formulation. 
In a summary, a promising prototype film formulation for the delivery of complexed 
UC781 was developed in these studies.  Future studies are still necessary before this dosage form 
can be introduced into the clinic.  Briefly, further formulation optimization, evaluation of the 
stability of complexed UC781, assessment of drug release from the product, and PK/PD 
characterization should be conducted prior to clinical evaluation of this new dosage form. Our 
studies have contributed to gain better insight into the development of βCD based drug delivery 
systems for water insoluble anti-HIV drug candidates into a successful microbicide product.   
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APPENDIX A 
COMPLEXATION OF EFFECT OF CYCLODEXTRINS 
Cyclodextrins (CDs) have aroused considerable attention in pharmaceutical application 
since the 1950’s, due to their ability to form complexes with poorly water-soluble drugs and drug 
candidates, resulting in an increase in their apparent water solubility which can improve the 
pharmaceutical profile of these water insoluble drugs via complexation. Appendix A intends to 
give a general background for the principles and mechanism of cyclodextrin complexation. 
Table A-1 Selected symbols used in Appendix 
K equilibrium constant 
Kc Complexation constant or stability constant (equilibrium constant for a drug-cyclodextrin interaction) 
Kd dissociation constant 
K1:1 complexation constant for the interaction of one drug molecule with one cyclodextrin molecule 
Kn:m complexation constant associated with the interaction of n drug molecules with m cyclodextrin 
molecules 
So intrinsic drug solubility 
St total drug in solution (complexed form + uncomplexed form) 
CDt total cyclodextrin in solution (complexed and uncomplexed) 
Cp the solubility of the precipitated complex 
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A.1 PHASE SOLUBILITY 
 
Conceptually, the complexation process of drug and cyclodextrin can be considered as a 
reversible chemical reaction at equilibrium. The stability or complexation constant (Kc or Kn:m) 
or its inverse, the dissociation constant (Kd) are crucial since these values provide an index of 
change of physicochemical properties for the whole complexation.  
There is a equiblium exist in the complexation process,                             
               CDDrugmCDnDrug mn
K or K m:nc ⋅⎯⎯⎯ →←+ 6-1 
The complexation constant/equilibrium constant (Kn:m) can be defined as: 
                 
]CD[]Drug[
]CDDrug[K mn
mn
m:n ⋅
⋅= 6-2 
Therefore, the dissociation constant can be expressed as  
                 
K
1
]CDDrug[
]CD[]Drug[K
m:nmn
mn
d =⋅
⋅= 6-3 
The complexation with cyclodextrins results in change in the physicochemical properties 
of guest molecules, such as apparent solubility, UV and IR profile, florescence properties, NMR 
chemical shifts, and DSC properties, and HPLC retention time (Chadha et al.,2004; Loftsson and 
Brewster,1996). 
The solubility change may be the most convenient method to provide information on 
complexation process. Thus, the complexation of guest molecule can be addressed in solubility 
method – phase-solubility relationships. 
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Phase-Solubility Analysis 
Phase-solubility analysis is a traditional isothermal approach to investigate the 
complexation phenomenon based on the solubility change in guest molecules in aqueous solution. 
Phase-solubility analysis can provide stability constant information as well as stoichiometry of 
the equilibrium with a simple diagram analysis, even only involves simple technology to form 
the complex.  
The process of phase-solubility can be described as follows: Briefly, an excess amount of 
guest molecules is added to a CD solution at different concentrations to form a suspension. The 
suspension is then agitated at constant temperature until it reaches equilibrium. After removing 
the extra undissolved guest molecules using filtration, the total concentration of guest molecules 
in solution is then determined with an appropriate analytical technique. The phase-solubility 
diagram is then plotted as CD concentration [CDt] vs. the apparent concentration of guest 
molecules [S t].   
Phase–solubility analysis was developed by Higuchi and Connors(Higuchi and 
Connors,1965). Based on the shape of the generated phase–solubility relationships, several types 
of behaviors can be identified. Phase–solubility diagrams can be classified into two major types: 
A and B as shown in Figure A 1 (Challa et al.,2005).  
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Figure A 1  Diagram of phase- solubility with A and B-type (AP, AL, AN and BS, Bi). 
A and B type of phase-solubility diagrams were shown in above Figure. A type 
phase-solubility diagram reflects the soluble complex formed in system leading to 
an increase in drug concentration. B type phase-solubility diagram can be 
explained with the formation of insoluble complex in system.  
A-type phase-solubility 
A-type phase-solubility systems are most commonly scene in the complexation of 
cyclodextrin. In A-type phase-solubility systems, the apparent solubility of the substrate 
increases as a function of CD concentration. Three subtypes of phase-solubility diagrams are 
defined: an AL profile is defined as a linear relationship of drug solubility vs. CD concentration 
(Senel et al.,1992), AP system indicates a positive direction from linearity (Ventura et al.,2005) 
and AN relationship suggests a negative deviation from linearity (Szafran and Pawlaczyk,1999).  
AL-type relationship is often assumed to be one-to-one relationship of complexation 
between guest molecule and cyclodextrin molecule in the system. However, a higher order 
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complexation may be formed with respect to the drug (i.e. Drug • CD, Drug2 • CD, Drug3 • CD, 
etc). AP type profiles show the curvng pattern suggesting that the formation of higher order 
complexes with respect to the CD at high CD concentrations (i.e. Drug • CD, Drug • CD2, 
Drug • CD3, etc). CD is more effective for complexation at higher concentrations. The 
stoichiometry of the formed complexes can be obtained by using best-fit function. Thus, a best 
fit to different functions indicats the formation of different stoichiometric complex. For example, 
a quadratic function suggests the formation of a one-to-two (D • CD2) complex; one best fit to a 
cubic function suggests a one-to-three complex (D • CD3); and so forth. AN type profiles indicate 
that the CD is less effective on complexation with drugs at higher concentrations. This 
phenomenon may caused by complex self-aggregation or self-association at high concentration 
and bulk changes imparted to the solvent by CD at various concentrations. Chemically modified 
cyclodextrins such as HPβCD can cause great change in volume as well as viscosity of its 
solution at 20% and above.  
Although, Ap and AN relationships show curving  profiles of phase-solubility diagram, 
the linear part of the phase-solubility can still be used to estimate the complexation constant for 
one-to-one complex formation. Generally, a polynomial function is used for complexation 
constant estimation using the following Equations for mass balance:  
      S]S[ 0= 6-4 
       ]CDS[mS]S[ nm0t ⋅+= 6-5 
        ]CDS[n]CD[]CD[ nmt ⋅+= 6-6 
Here, S0 is intrinsic solubility of drug, S is free drug concentration, St is soluble drug 
concentration, CD is free cyclodextrin concentration, CDt is total concentration of CD, and Sm 
CDn is complex in solution. With Equation (4)-(6), [Dt] can be expressed as  
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                         S]CD[
SK1
SKm
]S[ 0tm
0n:m
m
0n:m
t +⋅+
⋅⋅= 6-7 
Thus, with a plot of [St] vs. [CDt], the slope and y-intercept can be easily obtained. 
Therefore, from equation (7), the intercept from y-axis represents the S0, and slope can be 
defined as  
                          
SK1
SKm
Slope m
0n:m
m
0n:m
⋅+
⋅⋅= 6-8 
When a one-to-one complex form (a drug interacts with one CD) happens in 
complexation system, m=n=1, the K1:1 can given by  
                           
)slope1(S
slopeK
0
1:1 −= 6-9 
Similar procedure can be applied to one-to-two complex form (a drug interacts with two 
CD). The K1:1 and K1:2 can be expressed as following: 
                             
]CD[]S[
]CDS[K 1:1 ⋅
⋅= 6-10 
      
]CD[]S[
]CDS[K 2
2
2:1 ⋅
⋅= 6-11 
The mass balance equations are adjusted as  
      S]S[ 0= 6-12 
   ]CDS[  ]CDS[S]S[ 20t ⋅+⋅+= 6-13 
       ]CDS[2  ]CDS[]CD[]CD[ 2t ⋅+⋅+= 6-14 
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                   S]CD[
]CD[SKK2SK1
]CD[SKKSK
]S[ 0t
02:11:101:1
02:11:101:1
t +⋅⋅+⋅+
⋅⋅+⋅= 6-15 
                         ]CD[SKK]CD[SKS]S[ 202:11:101:10t ⋅⋅+⋅+= 6-16 
Thus, the parameters of S0, K1:1, and K1:2 can be easily calculated using a fitting curve 
from the phase-solubility diagram.  
For one-to-three or higher order complex form, this equation can be derived in a similar 
way:  
     ]CD[SKKK]CD[SKK]CD[SKS]S[ 303:12:11:1
2
02:11:101:10t ⋅⋅⋅+⋅⋅+⋅+= 6-17 
B-type phase-solubility 
The property of B-type phase-solubility is the formation of complexes with limited water 
solubility. Type B phase–solubility profiles are more easily observed in the complexation of 
naturally occurring CDs, especially βCD due to its limited the water solubility (1.8%) (Piel et 
al.,2006). The temperature impact on some chemically modified βCD can also lead to B-type 
phase-solubility diagram (Ventura et al.,2005). B-type diagrams can be classified into two 
subclasses: BS and Bi systems.  
For the BS-type phase-solubility, the following balance is assumed to occur in system as 
shown in Equation 18.  
solid
C
Dissolved
K
dissolved
S
Solid CDDrugCDDrugCDDrugDrug
p ⋅⎯→←⋅⎯→←+⎯→← 0    6-18 
Where S0 is intrinsic solubiligy of drug; K is the complexation constant; and Cp is the 
solubility of the precipitated complex (Cp). The solubility of complex observed in the systems is 
associated with the solubility of the precipitated complex. 
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With the βCD concentration increasing, the balance shifts to middle with increasing 
soluble complex forms, which increase the total solubility of the substrate. When the critical 
concentration of soluble complex is reached, the balance shifts to right to form insoluble 
complex leading to the plateau phase in phase-solubility diagram, which maintains the drug 
concentration St unchanged.  After the drug is totally transferred into soluble from solid state, the 
extra CD added into the system will enhance precipitation, which results in the decrease of St in 
the system. The complex constant K can also be obtained from the initial ascending portion of a 
BS-type phase-solubility with the same techniques used to assess AL-type systems with the use of 
Equation (7) 
In the Bi-type systems, the complex is also in insoluble form, which leads to the no 
ascension part in the phase-solubility diagram.  The stoichiometry of complexes formed from BS-
type solubility can be obtained by analyzing the precipitated complex to get the stoichiometric 
relationships between drug and CD using job’s plot.   
Another benefit brought from phase-solubility method is to estimate the intrinsic drug 
solubility So from the y-intercept of the phase–solubility relationship.  The results from this 
technique should be carefully treated when drug’s intrinsic solubility is extremely low. It may 
cause underestimation of observed intrinsic solubility (Loftsson et al.,2005a). This will result in 
an overestimation of the Kc or K1:1 value, especially for those highly lipophilic molecules. 
As a traditional approach to determine the complexation of cylcodextin, phase-solubility 
analysis provides a simple and quick method to assess and evaluate the complexation phenomena 
of cyclodextrin with guest molecules.  
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